Title 2 U.S. Code of Federal Regulations Part 200 (Uniform Guidance) Reports for the Year Ended June 30, 2022

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

TABLE OF CONTENTS

| | Page |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| INDEPENDENT AUDITOR'S REPORT | 1–2 |
| CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2022 AND 2021: | |
| Consolidated Balance Sheets | 3 |
| Consolidated Statements of Operations and Changes in Net Assets | 4–5 |
| Consolidated Statements of Cash Flows | 6 |
| Notes to Consolidated Financial Statements | 7–31 |
| SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWAFOR THE YEAR ENDED JUNE 30, 2022 | ARDS 32–43 |
| NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2022 | 44 |
| REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS | 45–46 |
| REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON THE SCHEDULE OF EXPENDITURES OF FEDERAL REQUIRED BY THE UNIFORM GUIDA | ANCE 47–49 |
| SCHEDULE OF FINDINGS AND QUESTIONED COSTS | 50-51 |



INDEPENDENT AUDITOR'S REPORT

To the Board of Trustees Children's Hospital Medical Center and Affiliates: Cincinnati, Ohio

Deloitte & Touche LLP

50 W 5th Street Suite 200 Cincinnati, OH 45202-3789 USA

Tel: +513 784 7100 Fax: +513 784 7204 www.deloitte.com

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of Children's Hospital Medical Center and Affiliates (the "Company"), which comprise the consolidated balance sheets as of June 30, 2022 and 2021, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2022 and 2021, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards* (Government Auditing Standards), issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions,

misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated September 30, 2022 on our consideration of the Company's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company's internal control over financial reporting and compliance.

September 30, 2022

Deloite ? Touche LLP

Consolidated Balance Sheets June 30, 2022 and 2021 (dollars in thousands)

| | 2022 | 2021 |
|---------------------------------------------------------|-------------|-------------|
| CURRENT ASSETS: Cash and cash equivalents | \$ 293,360 | \$ 274,863 |
| Marketable securities | 1,259,210 | 1,352,918 |
| Cash, cash equivalents and marketable securities | 1,552,570 | 1,627,781 |
| Patient receivables, net | 511,704 | 506,944 |
| Other receivables | 141,986 | 140,916 |
| Inventories and prepaid expenses | 80,350 | 74,042 |
| Total current assets | 2,286,610 | 2,349,683 |
| ASSETS LIMITED AS TO USE - Funds in trust | 32,275 | 31,250 |
| PROPERTY AND EQUIPMENT, net of accumulated depreciation | 1,432,608 | 1,403,713 |
| GOODWILL | 7,296 | 8,154 |
| OPERATING LEASE RIGHT-OF-USE ASSETS | 17,345 | 16,485 |
| PENSION BENEFIT ASSET | 281,043 | 171,709 |
| OTHER LONG-TERM ASSETS | 72,387 | 48,651 |
| INTEREST IN NET ASSETS OF SUPPORTING ORGANIZATIONS | 4,462,791 | 4,545,670 |
| Total assets | \$8,592,355 | \$8,575,315 |
| CURRENT LIABILITIES: | | |
| Accounts payable and accrued expenses | \$ 466,433 | \$ 410,481 |
| Current portion of long-term debt and lease obligations | 17,986 | 28,815 |
| Commercial paper | 100,000 | 100,000 |
| Bonds payable subject to remarketing, net | 86,302 | 91,640 |
| Total current liabilities | 670,721 | 630,936 |
| SELF-INSURANCE RESERVES | 25,274 | 22,184 |
| LONG-TERM DEBT: | | |
| Tax-exempt bonds payable | 327,916 | 340,776 |
| Taxable bonds payable | 596,176 | 595,946 |
| Finance lease obligations | 48,544 | 51,647 |
| Operating lease obligations | 14,949 | 14,242 |
| OTHER LONG-TERM LIABILITIES | 19,487 | 54,976 |
| Total liabilities | 1,703,067 | 1,710,707 |
| COMMITMENTS AND CONTINGENCIES (Note 11) | - | - |
| NET ASSETS: | | |
| Without donor restrictions | 2,212,893 | 2,100,516 |
| With donor restrictions | 4,676,395 | 4,764,092 |
| Total net assets | 6,889,288 | 6,864,608 |
| Total liabilities and net assets | \$8,592,355 | \$8,575,315 |

See accompanying notes to consolidated financial statements.

Consolidated Statements of Operations and Changes in Net Assets For the Years Ended June 30, 2022 and 2021 (dollars in thousands)

| | 2022 | 2021 |
|---------------------------------------------------------------------|-------------|-------------|
| OPERATING REVENUES, GAINS AND OTHER SUPPORT: | | |
| Net patient service revenue | \$2,369,523 | \$2,226,690 |
| Net assets released from restriction used for operations- | | |
| Grant revenue | 218,688 | 202,492 |
| Other restricted net assets used to support operations | 129,721 | 109,627 |
| Other revenue | 193,115 | 207,082 |
| Total operating revenues, gains and other support | 2,911,047 | 2,745,891 |
| OPERATING EXPENSES: | | |
| Salaries | 1,374,087 | 1,258,656 |
| Employee benefits | 372,037 | 347,711 |
| Supplies, drugs and other | 525,548 | 469,344 |
| Purchased services | 287,721 | 252,208 |
| Depreciation | 151,729 | 138,638 |
| Utilities | 20,079 | 18,401 |
| Interest | 30,926 | 23,249 |
| Total operating expenses | 2,762,127 | 2,508,207 |
| Operating income | 148,920 | 237,684 |
| NONOPERATING (LOSSES) GAINS: | | |
| Net investment (loss) return | (84,045) | 85,743 |
| Net benefit gain other than service cost | 26,485 | 1,682 |
| Net nonoperating (losses) gains | (57,560) | 87,425 |
| Revenue and gains in excess of expenses and losses | 91,360 | 325,109 |
| OTHER CHANGES IN NET ASSETS WITHOUT DONOR RESTRICTIONS: | | |
| Receipts from supporting organizations | 4,229 | 3,757 |
| Net assets released from restrictions used for purchase of property | | |
| and equipment | 16,626 | 4,031 |
| Transfers to supporting organizations | (82,346) | (37,181) |
| Pension and post-retirement health liability adjustment | 82,508 | 149,032 |
| Increase in net assets without donor restrictions | \$ 112,377 | \$ 444,748 |

(Continued on next page)

Consolidated Statements of Operations and Changes in Net Assets For the Years Ended June 30, 2022 and 2021 (dollars in thousands)

| | 2022 | 2021 |
|----------------------------------------------------------------------------------------------------------------|-------------|-------------|
| NET ASSETS WITH DONOR RESTRICTIONS: Contributions and investment income- | | |
| Grant receipts | \$ 220,629 | \$ 202,702 |
| Gifts and contributions of financial assets and other income | 139,588 | 140,273 |
| | 360,217 | 342,975 |
| Net assets released from restriction- | | |
| Grant expenditures | (218,688) | (202,492) |
| Net assets with donor restrictions used to support operations | (129,721) | (109,627) |
| Net assets with donor restrictions used for purchase of property | ` | , , , |
| and equipment | (16,626) | (4,031) |
| | (365,035) | (316,150) |
| (Loss) gain in interest in net assets of supporting organizations (Decrease) increase in net assets with donor | (82,879) | 1,120,619 |
| restrictions | (87,697) | 1,147,444 |
| INCREASE IN NET ASSETS | 24,680 | 1,592,192 |
| NET ASSETS, beginning of year | 6,864,608 | 5,272,416 |
| NET ASSETS, end of year | \$6,889,288 | \$6,864,608 |

See accompanying notes to consolidated financial statements.

Consolidated Statements of Cash Flows For the Years Ended June 30, 2022 and 2021 (dollars in thousands)

| | 2022 | 2021 |
|--------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-----------------------|
| CASH FLOWS FROM OPERATING ACTIVITIES: | | |
| Increase in net assets | \$ 24,680 | \$ 1,592,192 |
| Adjustments to reconcile increase in net assets to net cash provided by operating activities- | | |
| Depreciation and amortization | 151,095 | 135,955 |
| Loss on disposal of property and equipment | 2,077 | 1,563 |
| Proceeds from sale of donated securities | 773 | 2,176 |
| Receipts from supporting organizations | (4,229) | (3,757) |
| Contributions of financial assets to supporting organizations Contributions of financial assets restricted for purchase of property and | 82,346 | 37,181 |
| equipment | (16,626) | (4,031) |
| Loss (gain) in interest in net assets of supporting organizations | 82,879 | (1,120,619) |
| Unrealized and realized losses (gains) on marketable securities, net | 129,121 | (50,232) |
| Gain on interest rate swap | (7,377) | (3,066) |
| Increase in receivables | (5,830) | (95,869) |
| Increase in inventories and prepaid expenses and other assets Increase in pension benefit asset | (25,623) (109,334) | (23,161) (250,640) |
| Increase in accounts payable and accrued expenses, net | 65,286 | 71,877 |
| Decrease in operating lease obligations | (2,736) | (2,097) |
| (Decrease) increase in self-insurance reserves and other long-term liabilities | (29,443) | 8,443 |
| Net cash provided by operating activities | 337,059 | 295,915 |
| rvet easii provided by operating activities | 331,037 | 273,713 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | |
| Expenditures for property and equipment | (187,563) | (220,455) |
| Acquisition of pediatric primary care practices | (277) | (8,583) |
| Purchases of marketable securities | (1,263,928) | (1,484,503) |
| Sales and maturities of marketable securities | 1,227,728 | 1,208,023 |
| Cash withdrawn from funds in trust | 5,750 | 1,391 |
| Cash invested in funds in trust | (5,828) | (8,526) |
| Net cash used in investing activities | (224,118) | (512,653) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | |
| Issuance of bonds and notes payable | - | 200,000 |
| Repayment of bonds, notes payable, and finance lease obligations | (32,006) | (30,214) |
| Contributions restricted for purchase of property and equipment | 16,626 | 4,031 |
| Receipts from supporting organizations | 4,229 | 3,757 |
| Contributions to supporting organizations Net cash (used in) provided by financing activities | (82,346) | (37,181) |
| | (93,497) | 140,393 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 19,444 | (76,345) |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, beginning of year | 282,902 | 359,247 |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, end of year | \$ 302,346 | \$ 282,902 |
| SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES: | | |
| Capital expenditures in accounts payable and accrued expenses | \$ 20,548 | \$ 29,882 |
| Acquisition of property through finance leases | \$ 3,337 | \$ 5,793 |
| | • | • |
| Acquisition of property through operating leases | \$ 3,673 | \$ 3,906 |

6

See accompanying notes to consolidated financial statements.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(1) <u>Accounting Policies</u> –

(a) <u>Basis of Consolidation</u> – Children's Hospital Medical Center (Cincinnati Children's), River City Insurance Limited (River City), CHMC Community Health Services Network (CHSN), HealthVine LLC (HealthVine) and other entities with the purpose to hold land for future use, which are under common management, are included in the accompanying consolidated financial statements and are collectively referred to as Cincinnati Children's. Intercompany transactions and balances have been eliminated.

Cincinnati Children's is an Ohio not-for-profit corporation providing pediatric healthcare services, education, and research. River City is a captive insurance company and a wholly owned subsidiary of Cincinnati Children's. CHSN is a wholly owned subsidiary of Cincinnati Children's whose purpose is to manage primary care practices in a community setting. Other land holding entities are wholly owned subsidiaries of Cincinnati Children's whose purpose is to hold land for future use.

(b) <u>Supporting Organizations</u> – The Children's Hospital (TCH) and Convalescent Hospital Fund for Children (CHFC) are both Ohio not-for-profit corporations that provide financial support to Cincinnati Children's. The TCH and CHFC purpose clauses both specify the support of Cincinnati Children's as the organization's sole purpose. Additionally, certain endowment funds of these supporting organizations are restricted by the donors for specific operating purposes of Cincinnati Children's. As such, the assets of TCH and CHFC are recorded in Cincinnati Children's consolidated financial statements as Interest in Net Assets of Supporting Organizations and as Net Assets with Donor Restrictions. Changes in the fair value of Interest in Net Assets of Supporting Organizations are recorded as a Gain (Loss) in Interest in Net Assets of Supporting Organizations in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

The majority of receipts are from TCH and CHFC donor-restricted endowment funds or are other receipts that are designated by the supporting organizations' Boards of Trustees for specific operating purposes. The receipts are reflected in Gifts and contributions of financial assets and other income with donor restrictions in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Upon spending, such funds are reflected in Other restricted net assets used to support operations in the Consolidated Statements of Operations and Changes in Net Assets.

Other receipts from TCH are designated by the supporting organization's Board of Trustees to provide general support. The receipts are reflected in Receipts from supporting organizations without donor restrictions in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

(c) <u>Support Received from Supporting Organizations</u> – TCH and CHFC provide annual support to Cincinnati Children's through transfers of dividend and interest earnings on investments, net of investment management fees, administrative expenses, and donor-required income reinvestments.

The supporting organizations' respective Boards of Trustees may also make certain pledges of principal without donor restriction in support of key projects or initiatives at Cincinnati Children's. In January 2020, CHFC's Board of Trustees made a gift in the amount of \$36,000 to support the construction of a new facility at the College Hill Campus and programmatic support of Cincinnati Children's *Pursuing our Potential in Mental Health* initiative. The agreement has certain criteria that represent donor-imposed conditions that must be overcome before Cincinnati Children's is entitled to the assets promised. Contributions of \$6,651 and \$1,855 were made for the years ended June 30, 2022 and June 30, 2021, respectively. The receipts are reflected in Gifts and contributions of financial assets and other income with donor restrictions and in Net assets used for purchase of property and equipment in the Consolidated Statements of Operations and Changes in Net Assets.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The following table details transfers between Cincinnati Children's and Supporting Organizations in the Consolidated Statements of Operations and Changes in Net Assets:

| | 2022 | 2021 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|------------------------------------|
| Transfers of net assets with donor restrictions included in | | |
| Gifts and contributions of financial assets and other | | |
| income: | | |
| Cincinnati Children's from TCH | \$102,823 | \$103,074 |
| Cincinnati Children's from CHFC | 11,887 | 6,280 |
| Total | \$114,710 | \$109,354 |
| Transfers of net assets without donor restrictions included in Receipts from (Transfers to) supporting organizations: Cincinnati Children's from TCH Cincinnati Children's to TCH (1) Total | \$ 4,229 (82,346) \$(78,117) | \$ 3,757 (37,181) \$(33,424) |
| Total | \$(/8,11/) | \$(33,424) |

- (1) The purpose of this transfer is to establish funds designated to support divisional activities and strategic priorities.
- (d) <u>Revenue Recognition</u> The following revenue streams are subject to the revenue recognition guidance in Accounting Standards Codification No. 606 (ASC 606) "Revenue from Contracts with Customers":

| | 2022 | 2021 |
|-----------------------------|-------------|-------------|
| Net patient service revenue | \$2,369,523 | \$2,226,690 |
| Other revenue | 193,115 | 207,082 |
| | \$2,562,638 | \$2,433,772 |

Net Patient Service Revenue

Cincinnati Children's net patient service revenue generally relates to contracts with patients in which the performance obligations are to provide health care services to patients. As patients simultaneously receive and consume the benefits of health care provided by Cincinnati Children's, the performance obligations meet the criteria to be satisfied over time. Net patient service revenue is recorded as services are provided. Payment for such services is due between thirty to forty-five days from payer receipt of claim. Consideration for patient service revenue is variable. Agreements with payers typically provide for payments at amounts less than established charges.

Effective January 1, 2021, Cincinnati Children's signed an agreement with an Ohio Medicaid managed care company in which performance obligations are to stand-ready to provide care for approximately 130,000 children. The performance obligation to stand-ready is satisfied over time. Cincinnati Children's is reimbursed under a variable capitation methodology for hospital services. All physician and home care services are reimbursed based on provider fee schedules. The hospital services are reimbursed through a variable capitation payment which represents the amount remaining after payment has been made for (a) Cincinnati Children's physician services, (b) Cincinnati Children's home care services, (c) services provided to members by facilities outside the Cincinnati Children's network, and (d) an actuarially determined accrual for incurred but not reported claims (see Note 1h). Under delegation agreements, Cincinnati Children's receives fixed payments to perform the required medical management, care management and care coordination functions. Medicaid managed care organizations retain risk for payments to providers. The amount of net patient service revenue recorded under this arrangement in fiscal year 2022 and 2021 was \$174,467 and \$103,836, respectively.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

Laws and regulations concerning government programs, including Medicaid and Medicare, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from related programs. There can be no assurance that regulatory authorities will not challenge Cincinnati Children's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon Cincinnati Children's. In addition, the contracts Cincinnati Children's has with third party payers also provide for retroactive audit and review of claims. At June 30, 2022, Cincinnati Children's has settled all Medicaid cost reports through 2016 and all Medicare cost reports through 2020.

Settlements with third party payers for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of estimated transaction price for providing patient care. These settlements are based on the terms of the payment agreement with the payer, correspondence from the payer, and Cincinnati Children's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Estimated settlements are adjusted in future periods as adjustments become known based on new information or as years are settled and no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in transaction price were not material in fiscal years 2022 and 2021.

Generally, patients who are covered by third party payers are responsible for related deductibles and coinsurance, which vary in amount. Cincinnati Children's also provides services to uninsured patients and offers those uninsured patients a discount, either by policy or law, from standard charges. Cincinnati Children's estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by established contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of change.

Consistent with Cincinnati Children's mission, care is provided to patients regardless of their ability to pay. Therefore, Cincinnati Children's has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances. The implicit price concessions included in estimating the transaction price represent the difference between the amounts billed to patients and the amounts Cincinnati Children's expects to collect based on its collection history with those patients.

Patients who meet Cincinnati Children's criteria for charity care are provided care without charge or at amounts less than established rates. Amounts determined to qualify as charity care are not reported as net patient service revenue.

Because the majority of its performance obligations relate to contracts with a duration of less than one year, Cincinnati Children's has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the fiscal year. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the fiscal year. The performance obligations for these contracts are generally completed when patients are discharged, which generally occurs shortly after the end of the fiscal year.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

In both fiscal years 2022 and 2021, substantially all of net patient service revenue is derived from third-party payment programs (Medicaid, insurance companies and various managed care agreements). Cincinnati Children's classifies its patients by payer. The following table disaggregates Cincinnati Children's net patient service revenue by payer categories for the fiscal year ended June 30, 2022 and 2021:

| | | 2022 | | 2021 |
|----------------------------------|-----|-------------|-----|-------------|
| Commercial insurers | 1% | \$ 23,695 | 1% | \$ 22,266 |
| Managed care | 62% | 1,469,104 | 63% | 1,402,815 |
| Government (HMO and third party) | 31% | 734,552 | 28% | 623,473 |
| International | 3% | 71,086 | 4% | 89,068 |
| Specialty contracts ¹ | 2% | 47,390 | 3% | 66,801 |
| Self-pay | 1% | 23,696 | 1% | 22,267 |
| | | \$2,369,523 | | \$2,226,690 |

The following details the percentage of accounts receivable by payer category as of June 30, 2022 and 2021:

| | 2022 | 2021 |
|----------------------------------|------|------|
| Commercial insurers | 1% | 2% |
| Managed care | 56% | 63% |
| Government (HMO and third party) | 23% | 20% |
| International | 11% | 7% |
| Specialty contracts ¹ | 6% | 7% |
| Self-pay | 3% | 1% |

Other Revenue

Cincinnati Children's other revenue generally relates to contracts with external organizations in which the performance obligations are to provide research services or other various fee-for-service arrangements outside the scope of healthcare services. Relief funds received as a result of the Coronavirus Aid, Relief, and Economic Security (CARES) Act are also included in other revenue. See Note 1(s) for further discussion on the COVID-19 Pandemic.

Revenue from industry contracts and certain government contracts is earned based on performance obligations to provide research services to the external organizations. License and royalty revenue relates to contracts with other organizations in which our performance obligations are to provide intellectual property to the organization. Revenue is also earned for various other contracted fee-for-service arrangements where services are performed for external organizations outside the scope of healthcare services for Cincinnati Children's patients. Performance obligations for industry and government contracts, license and royalty contracts, and various other fee-for-service arrangements are satisfied over time. Consideration is fixed based on contracted price, and there is no significant variable consideration related to these agreements.

(e) <u>Graduate Medical Education</u> – Cincinnati Children's receives Federal graduate medical education funding. Other revenue of \$11,762 and \$11,188 was recognized for the years ended June 30, 2022 and 2021, respectively.

¹ Specialty contracts are single case agreements or contracts for specialty services, such as transplants.

10

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(f) <u>Tax Exempt Status</u> – Cincinnati Children's, CHSN and HealthVine are recognized by the Internal Revenue Service as exempt from federal income taxes under Section 501(a) of the Internal Revenue Code as charitable organizations qualifying under Section 501(c)(3). River City is a captive insurance company and has no income tax obligations. Other land holding entities with the purpose to hold land for future use are limited liability corporations whose income is taxable to Cincinnati Children's. The income tax provisions recorded in the accompanying consolidated financial statements are immaterial for the years ended June 30, 2022 and 2021.

Cincinnati Children's accounts for income taxes in accordance with Accounting Standards Codification Topic (ASC) 740 "Income Taxes". It is Cincinnati Children's policy to classify the expense related to interest and penalties, if any, to be paid on underpayments of income taxes within other expenses. There were no material penalties or interest recognized in fiscal years 2022 and 2021. Cincinnati Children's paid \$5,227 in income taxes for unrelated business income during the year ended June 30, 2022.

Fiscal years 2019 through 2022 are subject to examination by both the Federal and State tax jurisdictions.

- (g) <u>Cash Equivalents</u> Cash equivalents consist primarily of money market investments (including money market mutual funds) and demand deposits. Money market investments have maturities of 90 days or less at the time of purchase. Cash is held primarily in two financial institutions.
- (h) <u>Inventories and Prepaid Expenses</u> Inventories consist primarily of medical supplies and pharmaceuticals and are valued on an average cost method.

As part of Cincinnati Children's variable capitation agreement, reimbursement is reduced by an actuarially determined estimate for incurred but not reported claims. Cincinnati Children's recorded incurred but not reported claims of approximately \$23,507 and \$21,107 for the years ended June 30, 2022 and 2021, respectively. The estimate is recorded as an increase in prepaid expenses and an increase in accounts payable and accrued expenses.

(i) Marketable Securities – Cincinnati Children's accounts for its investments under ASC 958-320 "Not-for-Profit Entities – Investments – Debt Securities" and ASC 958-321 "Not-for-Profit Entities – Investments – Equity Securities." Cincinnati Children's carries its marketable securities at fair value with unrealized gains and losses included in net investment return (loss) in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

At both June 30, 2022 and 2021, 19% of Cincinnati Children's marketable securities were invested in U.S. Treasury securities.

(j) <u>Property and Equipment</u> – Property and equipment are stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, ranging from three to forty years, as follows:

Land Improvements

Buildings and Building Improvements

Equipment

3-25 years
5-40 years
3-25 years

Cincinnati Children's evaluates long-lived assets under the provisions of ASC 360 "Property Plant and Equipment." During fiscal years 2022 and 2021, Cincinnati Children's did not incur any losses related to impairment of property and equipment.

(k) Goodwill - Goodwill is the excess of the purchase price over the fair value of the net assets of an entity acquired. Cincinnati Children's acquired the assets of a pediatric primary care practice, resulting in

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

goodwill of \$8,583 in fiscal year 2021, and elected to apply the accounting alternatives available for not-for-profit entities. During the year ended June 30, 2022, no amounts were recorded to goodwill. Goodwill is amortized over a 10-year period and tested for impairment when a triggering event occurs. During fiscal year 2022 and 2021, \$858 and \$429 of amortization expense and no impairment losses were recognized, respectively.

(l) <u>Leases</u> – Cincinnati Children's leases property and equipment under finance and operating leases. Cincinnati Children's determines if an arrangement is a lease at inception. Right-of-use assets and lease obligations are recognized for leases with terms greater than 12 months based on the net present value of the future minimum lease payments over the lease term at commencement date. When readily determinable, Cincinnati Children's uses the interest rate implicit in the lease to determine the present value of future minimum lease payments. However, most of Cincinnati Children's leases do not have a readily determinable implicit interest rate. For these leases, Cincinnati Children's uses a collateralized incremental borrowing rate based on the period and cash payment stream comparable with that of each lease. The right-of-use asset and lease obligations include a value for options to extend a lease if it is reasonably certain that the option will be exercised.

The current portion of operating lease obligations is included in the current portion of long-term debt and lease obligations and the non-current portion is separately stated as operating lease obligations on the consolidated balance sheets. The related right-of-use assets are included in operating lease right-of-use assets on the consolidated balance sheets. Operating lease expense is recognized on a straight-line basis over the lease term and is included in purchased services in the consolidated statements of operations and changes in net assets.

The current portion of finance lease obligations is included in current portion of long-term debt and lease obligations and the non-current portion is separately broken out as finance lease obligations on the consolidated balance sheets. The related finance lease right-of-use assets are included in property and equipment, net on the consolidated balance sheets. Finance lease right-of-use assets are amortized using the straight-line method over the shorter period of the lease term or the estimated useful life of the property or equipment. Such amortization expense is included in depreciation in the consolidated statements of operations and changes in net assets.

(m) Costs of Borrowing – Interest incurred on borrowed funds, net of interest earned on restricted bond funds, during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets. In fiscal years 2022 and 2021, Cincinnati Children's capitalized \$4,329 and \$11,013 of interest related to construction in progress, respectively. Total cash paid for interest was approximately \$35,339 and \$33,655 in fiscal years 2022 and 2021, respectively.

Deferred bond issuance costs and issuance premiums are amortized using the effective interest method over the period the related obligation is outstanding.

- (n) Interest Rate Swap Agreement Cincinnati Children's has an interest rate swap agreement to manage interest rate risk associated with the variable rate 2018Z and 2018AA bonds. The swap agreement is measured at fair value and recognized in the Consolidated Balance Sheets within other long-term liabilities. Cincinnati Children's recognizes gains and losses from the changes in fair value of the interest rate swap agreement as non-operating gains and losses within net investment return on the Consolidated Statements of Operations and Changes in Net Assets.
- (o) Net Asset Classifications Cincinnati Children's reports its financial position and activities according to the following net asset classifications:

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

<u>Net assets without donor restrictions</u> – Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objective of the organization are classified as net assets without donor restrictions. These net assets may be used at the discretion of management of Cincinnati Children's.

Net assets with donor restrictions – Net assets subject to stipulations imposed by donors or supporting organizations are classified as net assets with donor restrictions. Some restrictions are temporary in nature; those restrictions will be met by fulfilling a certain purpose or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the principal be maintained in perpetuity.

Net assets with donor restrictions are comprised of the following:

| | 2022 | 2021 |
|---------------------------------------------------------------------------------------------------------------------|-----------|-----------|
| Subject to expenditure for specified purpose: | | |
| Clinical | \$ 40,735 | \$ 40,342 |
| Research | 96,634 | 93,558 |
| Education | 16,736 | 16,493 |
| General Administration and Other | 35,921 | 44,831 |
| | 190,026 | 195,224 |
| Subject to expenditure for specified purpose, held at supporting organizations: | | |
| Research | 14,525 | 15,507 |
| Education | 1,075 | 1,144 |
| General Administration and Other | 4,326 | 4,604 |
| | 19,926 | 21,255 |
| Subject to expenditure based on Board discretion of the | | |
| supporting organization, held at supporting organizations | 2,179,232 | 2,202,814 |
| | 2,179,232 | 2,202,814 |
| Investment in perpetuity, the income from which is expendable for specified purpose, held at Cincinnati Children's: | | |
| Clinical | 1,161 | 917 |
| Research | 18,120 | 17,929 |
| Education | 1,307 | 1,352 |
| General Administration and Other | 2,990 | 3,000 |
| | 23,578 | 23,198 |

(Continued on next page)

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

Investment in perpetuity, the income from which is expendable for specified purpose, held at supporting organizations:

| Clinical | 53,484 | 46,872 |
|-------------------------------------------------------------------------|-------------|-------------|
| Research | 2,044,408 | 2,099,458 |
| Education | 88,275 | 91,815 |
| General Administration and Other | 75,176 | 81,498 |
| | 2,261,343 | 2,319,643 |
| Subject to appropriation and expenditure when a specified event occurs: | | |
| Upon death of insured party | 2,290 | 1,958 |
| | 2,290 | 1,958 |
| Total net assets with donor restrictions | \$4,676,395 | \$4,764,092 |

- (p) Revenue and Gains in Excess of Expenses and Losses The Consolidated Statements of Operations and Changes in Net Assets subtotals operating revenues, gains and other support, operating expenses and nonoperating gains as Revenue and gains in excess of expenses and losses. Other changes in net assets without donor restrictions are receipts from and transfers to supporting organizations, pension and post-retirement health liability adjustments, and net assets released from restrictions used for purchase of property and equipment, which are excluded from Revenue and gains in excess of expenses and losses.
- (q) <u>Use of Estimates</u> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
- (r) New Accounting Pronouncements In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other (Topic 350): Internal-Use Software. This standard aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for fiscal years beginning after December 15, 2020. Cincinnati Children's adopted ASU 2018-15 effective July 1, 2021. Adopting this standard had no material impact on the consolidated financial statements.

In September 2020, the FASB issued ASU 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets.* This ASU changes the presentation and disclosure requirements for not-for-profit entities to increase transparency about contributed nonfinancial assets. The ASU is effective for annual periods beginning after June 15, 2021, and interim periods within annual periods beginning after June 15, 2022, with early adoption permitted. Cincinnati Children's adopted this standard effective July 1, 2021 and has determined that the impact on the consolidated financial statements is not material.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(s) The Coronavirus Aid, Relief, and Economic Security ("CARES") Act – The CARES Act was passed by Congress on March 27, 2020 to aid organization and individuals with the economic impacts of COVID-19. Cincinnati Children's received \$22,191 and \$50,000 in relief funds from the Department of Health and Human Services in fiscal years 2022 and 2021, respectively. Relief funds are recorded as other revenue in the Operating revenues, gains and other support section of the Consolidated Statements of Operations and Changes in Net Assets for the years ended June 30, 2022 and 2021.

In addition to the distribution of relief funds, the CARES Act also included electable payroll tax credits and deferrals. Cincinnati Children's elected to delay payment of the employer portion of the Social Security payroll taxes on wages paid from March 27, 2020 through December 31, 2020 in the amount of \$45,656. Half of the total deferred amount was paid in December 2021 and the remaining portion is due by December 31, 2022. At June 30, 2022, deferred payroll taxes of \$22,828 are included in Accounts payable and accrued expenses on the Consolidated Balance Sheets. At June 30, 2021, deferred payroll taxes of \$22,828 were included in Other Long-Term Liabilities, and \$22,828 were included in Accounts payable and accrued expenses on the Consolidated Balance Sheets.

(2) Liquidity and Availability –

Financial assets available for general expenditure within one year of the balance sheet date consist of the following:

| 2022 | 2021 |
|-------------|---------------------------------------------------------|
| | |
| \$ 293,360 | \$ 274,863 |
| 1,259,210 | 1,352,918 |
| 511,704 | 506,944 |
| 141,986 | 140,916 |
| 2,206,260 | 2,275,641 |
| 100,000 | 100,000 |
| \$2,106,260 | \$2,175,641 |
| | 1,259,210 511,704 141,986 2,206,260 100,000 |

Cincinnati Children's has cash and cash equivalents, marketable securities (more fully described in Note 4), patient receivables and certain other receivables which are liquid and available for general expenditure within one year in the normal course of operations. Accordingly, these assets have been included in the quantitative information above. During fiscal 2021, the Board of Trustees designated \$100,000 from net assets without donor restrictions to be used to support Cincinnati Children's community pillar of the *Pursuing Our Potential Together* strategic plan. Cincinnati Children's has other assets limited to use for professional liability, self-insurance health care and debt service, as well as perpetual endowments with donor restrictions. These assets limited to use, which are more fully described in Notes 4 and 6, are not available for general expenditure within the next year and are not reflected in the amounts above.

Cincinnati Children's has \$186,302 in outstanding obligations for which liquid funds must be available for payment in the event of a failed remarketing. Cincinnati Children's maintains certain balances in cash and investments and has access to a \$100,000 line of credit, as discussed in more detail in Note 9.

Additionally, Cincinnati Children's is required to maintain certain liquidity ratios as outlined in bond covenants. As of June 30, 2022 and 2021, Cincinnati Children's was in compliance with all such covenants.

Cincinnati Children's forecasts its future cash flows and monitors liquidity on an ongoing basis.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(3) Reconciliation of Cash, Cash Equivalents, and Restricted Cash –

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statement of Cash Flows for the fiscal years ending June 30, 2022 and 2021:

| | 2022 | 2021 |
|----------------------------------------------------------------------------------------|-----------|-----------|
| Cash and cash equivalents | \$293,360 | \$274,863 |
| Restricted cash included in other long-term assets | 8,986 | 8,039 |
| Total cash, cash equivalents, and restricted cash shown in the statement of cash flows | \$302,346 | \$282,902 |

(4) Fair Value Measurements –

Cincinnati Children's accounts for its assets and liabilities under ASC 820 "Fair Value Measurements." As defined in ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three broad levels, which are described below:

Level 1: Quoted Prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date for assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. These include quoted prices for identical or similar assets or liabilities in markets that are not active, that is, markets in which there are a few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers, or in which little information is released publicly and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Unobservable inputs, developed using Cincinnati Children's estimates and assumptions, which reflect those that the market participants would use. Such inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Determining where an asset or liability falls within the hierarchy depends on the lowest level input that is significant to the fair value measurement as a whole. In determining fair value, Cincinnati Children's utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in the assessment of fair value.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The table below includes the major categorization for financial instruments on the basis of the nature and risk of the investments at June 30, 2022.

| | Level 1 | Level 2 | Level 3 | Total |
|-----------------------------------------------------------------------------------------|-----------|-----------|---------|-------------|
| Marketable Securities: | | | | |
| U.S. Government and agency securities | \$ - | \$328,313 | \$ - | \$ 328,313 |
| Foreign bonds | - | 53,936 | - | 53,936 |
| Municipal bonds | - | 16,595 | - | 16,595 |
| Common stock | 227,167 | - | - | 227,167 |
| Corporate obligations | - | 438,485 | - | 438,485 |
| Bond mutual funds | 24,782 | - | - | 24,782 |
| Total marketable securities measured in the fair value hierarchy | 251,949 | 837,329 | - | 1,089,278 |
| Full discretion fixed income ² | - | _ | _ | 169,932 |
| • | 251,949 | 837,329 | | 1,259,210 |
| Assets Limited As To Use: | | | | |
| Money market mutual funds | 9,144 | _ | _ | 9,144 |
| Common stock | 23,131 | - | _ | 23,131 |
| • | 32,275 | | _ | 32,275 |
| Deferred Compensation Plans (included in Other Receivables and Other Long-term Assets): | | | | |
| Common stock | 7,779 | - | - | 7,779 |
| Mutual funds: | | | | |
| Money market | 1,122 | - | - | 1,122 |
| Equity | 663 | - | - | 663 |
| International equity | 325 | - | - | 325 |
| Bond | 732 | - | - | 732 |
| Lifecycle | 3,773 | - | - | 3,773 |
| Variable annuities | - | 73 | - | 73 |
| Guaranteed insurance contract | - | - | 763 | 763 |
| | 14,394 | 73 | 763 | 15,230 |
| Derivative Investments (included in Other-Long-term Assets): | | | | |
| Interest rate swap agreement | - | 4,421 | - | 4,421 |
| Total investments at fair value | \$298,618 | \$841,823 | \$763 | \$1,311,136 |

_

² Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheet.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The table below includes the major categorization for financial instruments on the basis of the nature and risk of the investments at June 30, 2021.

| | Level 1 | Level 2 | Level 3 | Total |
|-----------------------------------------------------------------------------------------------|-----------|-----------|---------|-------------|
| Marketable Securities: | | | | |
| U.S. Government and agency securities | \$ - | \$370,368 | \$ - | \$ 370,368 |
| Foreign bonds | - | 46,067 | - | 46,067 |
| Municipal bonds | - | 9,347 | - | 9,347 |
| Common stock | 239,044 | - | - | 239,044 |
| Corporate obligations | - | 471,451 | - | 471,451 |
| Bond mutual funds | 25,086 | - | - | 25,086 |
| Total marketable securities measured in the fair value hierarchy | 264,130 | 897,233 | - | 1,161,363 |
| Full discretion fixed income ³ | - | - | - | 191,555 |
| - | 264,130 | 897,233 | | 1,352,918 |
| Assets Limited As To Use: | | | | |
| Money market mutual funds | 9,088 | _ | _ | 9,088 |
| Common stock | 22,162 | _ | _ | 22,162 |
| - | 31,250 | | | 31,250 |
| Deferred Compensation Plans (included in Other Receivables and Other Long-term Assets): | | | | |
| Common stock | 8,116 | _ | _ | 8,116 |
| Mutual funds: | 0,110 | | | 0,110 |
| Money market | 1,203 | _ | _ | 1,203 |
| Equity | 950 | _ | _ | 950 |
| International equity | 587 | _ | _ | 587 |
| Bond | 972 | _ | _ | 972 |
| Lifecycle | 3,384 | _ | _ | 3,384 |
| Variable annuities | - | 208 | _ | 208 |
| Guaranteed insurance contract | - | - | 469 | 469 |
| _ | 15,212 | 208 | 469 | 15,889 |
| Derivative Investments (included in Other-Long-term Liabilities): | | | | |
| Interest rate swap agreement | - | (2,956) | - | (2,956) |
| Total investments at fair value | \$310,592 | \$894,485 | \$469 | \$1,397,101 |
| | | | | |

The valuation methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although management believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in different fair value measurement at the reporting date.

The carrying amount and fair value of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value.

Cincinnati Children's uses quoted market prices in active markets to determine the fair value of common stock and mutual funds; such items are classified as Level 1 in the fair value hierarchy.

_

³ Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheet.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

Cincinnati Children's primarily bases fair value for investments in fixed income securities, including U.S. government securities, municipal bonds and corporate obligations on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate). Consideration is also given to the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy.

Cincinnati Children's interest rate swap agreement (Note 14) is a derivative instrument valued using the income approach, which uses market inputs to discount future cash flows to a single present amount based on market expectations.

Cincinnati Children's investment in Full Discretion Fixed Income is an investment in a limited liability company whose investment objective is to invest in marketable and non-marketable securities with issue and industry diversification. As set forth in the LLC agreement, the LLC will dissolve on May 22, 2047, but may dissolve earlier under certain conditions. Any Investing Member may elect to withdraw, in whole or in part from the LLC if the Member notifies of intent to withdraw sixty calendar days in advance. The Full Discretion Fixed Income is measured at fair value using the net asset value per share practical expedient.

The guaranteed insurance contract is recorded based on discounted cash flows, which is an approximation of fair value, and is classified as Level 3 based on time restrictions for redemption.

Activity and transfers into and out of Level 3 and the reasons for those transfers are as follows:

| <u>2022</u> | Guaranteed Insurance Contracts |
|-------------|---------------------------------------|
| Purchases | \$335 |
| Issues | - |
| <u>2021</u> | Guaranteed Insurance Contracts |
| Purchases | \$132 |
| Issues | - |

Cincinnati Children's policy is to recognize transfers in and out as of the actual date of the event or change in circumstances that caused the transfer. For the years ended June 30, 2022 and 2021, there were no material transfers in or out of Levels 1, 2 or 3.

(5) Losses on the Provision of Uncompensated Care –

In accordance with its mission and purpose, Cincinnati Children's maintains a policy of providing medically necessary services to pediatric patients within its primary service area regardless of ability to pay. This primary service area has been defined to include the four counties in Ohio, three counties in Kentucky and one county in Indiana that geographically surround Cincinnati. Under certain circumstances, Cincinnati Children's accepts patients from outside the primary service area regardless of their ability to pay. Cincinnati Children's defines uncompensated care as services rendered to patients whose families' annual income or net worth falls below certain minimum standards. As such, losses absorbed by Cincinnati Children's in rendering services to patients who are covered under governmental programs which are designed to aid low-income families (primarily the Medicaid program) are considered uncompensated care.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The following information summarizes uncompensated care provided during the years ended June 30, 2022 and 2021:

| CHARGES | 2022 | 2021 |
|--------------------------------------------------------------------|---------------|-------------|
| Charges under Medicaid and other entitlement programs | \$2,320,168 | \$1,982,947 |
| Charity care not eligible for Medicaid assistance, at established | | |
| charges | 23,405 | 24,580 |
| Other uncollectible self-pay, at established charges | 20,295 | 19,442 |
| Total Medicaid, charity care and other uncollectible self-pay | | _ |
| charges | \$2,363,868 | \$2,026,969 |
| COSTS/LOSSES | | |
| Estimated costs to provide uncompensated care | \$(1,015,752) | \$(851,532) |
| Reimbursement from Medicaid programs | 714,615 | 611,230 |
| Losses on the provision of uncompensated care | (301,137) | (240,302) |
| Funds received from HCAP and tax levy | 34,068 | 31,463 |
| Losses on provision of uncompensated care net of HCAP and tax levy | \$ (267,069) | \$(208,839) |

The 2022 and 2021 cost amounts reflected in the tables above are calculated using cost to charge ratios calculated from preliminary cost reports because the current year cost report is not yet available. Management does not believe the use of preliminary data would have a material impact on the amounts calculated above.

(6) Funds in Trust –

Cincinnati Children's has certain funds, which are invested and held in trust for various specified purposes. Funds are carried at fair value with unrealized gains and losses included in net investment return in the accompanying Consolidated Statements of Operations and Changes in Net Assets. The amounts of such funds, at carrying value, and the specified purposes for which such funds may be used, are set forth below:

T---- 20

| | June 30, | | |
|-----------------------------------------------------------------------------------------------------------|------------------------|------------------------|--|
| | 2022 | 2021 | |
| Self-insurance Funds- | | _ | |
| Professional liability | \$ 159 | \$ 159 | |
| Employee health and workers' compensation | 140 | 140 | |
| Bond interest and principal escrow funds | 8,687 | 7,740 | |
| Endowment funds held in perpetual trust | 23,289 | 23,211 | |
| | \$32,275 | \$31,250 | |
| Professional liability Employee health and workers' compensation Bond interest and principal escrow funds | 140 8,687 23,289 | 140 7,740 23,211 | |

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(7) <u>Property and Equipment</u> –

Property and equipment consists of the following:

| | June 30, | | |
|-------------------------------------|--------------|-------------|--|
| | 2022 | 2021 | |
| Land | \$ 42,208 | \$ 42,158 | |
| Land improvements | 38,135 | 31,645 | |
| Buildings and building improvements | 2,009,554 | 1,610,173 | |
| Equipment | 765,716 | 693,081 | |
| Construction in progress | 87,544 416,6 | | |
| | 2,943,157 | 2,793,701 | |
| Accumulated depreciation | (1,510,549) | (1,389,988) | |
| Property and equipment, net | \$1,432,608 | \$1,403,713 | |

(8) <u>Professional Liability</u> –

Cincinnati Children's insurance program includes a self-insured retention for losses arising out of healthcare professional liability claims. The current self-insured retention for asserted claims is \$10,000 (\$25,000 in aggregate). Cincinnati Children's regularly purchases excess healthcare professional liability insurance on a claims made basis at varying levels.

The actuarial present value of expected costs (including incurred, but not reported claims) for the healthcare professional liability program of \$25,274 and \$22,184 for 2022 and 2021, respectively, has been accrued in the accompanying Consolidated Balance Sheets. Accrued healthcare professional liability losses have been discounted at a rate of 4% at June 30, 2022 and 2021. The costs of Cincinnati Children's healthcare professional liability program, including premiums paid for excess re-insurance, legal fees, settlements, judgments, and other administrative costs are included in Supplies, Drugs and Other in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Accrued losses funding levels are actuarially determined based on management's estimation of potential outstanding loss liabilities, payout patterns, and various other assumptions, and then adjusted to reflect its best estimate of the present value of expected costs for the healthcare professional liability claims. Healthcare professional liability expense was \$12,278 and \$5,359 for fiscal years 2022 and 2021, respectively.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(9) <u>Debt</u> –

Debt at June 30, 2022 and 2021 is summarized as follows:

| , | 2022 | 2021 |
|-----------------------------------------------------------------------------------------------------------|-----------|-----------|
| Series 2018BB commercial paper, variable interest (1.50% | | |
| to 1.56% at June 30, 2022), taxable | \$100,000 | \$100,000 |
| Bonds payable: | | |
| Series 2011, 2.18% due through 2022 | - | 8,480 |
| Series 2014S, 3.0% to 5.0% due through 2034, net of unamortized premium of \$1,987 in 2022 and \$2,662 in | | |
| 2021 | 85,546 | 92,029 |
| Series 2014T, 4.268% due 2044, taxable | 297,899 | 297,804 |
| Series 2016X, 5.00%, due through 2032, net of unamortized | | |
| premium of \$7,923 in 2022 and \$8,744 in 2021 | 59,164 | 59,937 |
| Series 2016Y, 2.853% due 2026, taxable | 99,644 | 99,558 |
| Series 2018Z*, variable interest (0.89% at June 30, 2022), | | |
| due through 2037 | 33,914 | 36,012 |
| Series 2018AA*, variable interest (0.88% at June 30, 2022), | | |
| due through 2037 | 52,387 | 55,627 |
| Series 2019CC, 5.0% due through 2049, net of unamortized | | |
| premium of \$57,927 in 2022 and \$60,360 in 2021 | 192,332 | 194,715 |
| Series 2020DD, 2.82% due 2051, taxable | 198,633 | 198,585 |
| Notes Payable: | | |
| Term Note Payable, 2.20% due 2022 | <u>-</u> | 6,000 |
| Total | 1,119,519 | 1,148,747 |
| Less: | | |
| Current portion of bonds and notes payable | (9,125) | (20,385) |
| Commercial paper notes | (100,000) | (100,000) |
| Bonds payable subject to remarketing, net | (86,302) | (91,640) |
| Bonds payable and notes payable - long-term | \$924,092 | \$936,722 |
| *Denotes variable rate bonds subject to remarketing agreements | | |

^{*}Denotes variable rate bonds subject to remarketing agreements

(a) <u>Bonds Payable</u> – Cincinnati Children's has pledged gross revenues to secure the payment of 2014S, 2014T, 2016X, 2016Y, 2018Z, 2018AA, 2019CC, and 2020DD bonds. Cincinnati Children's is bound by certain financial covenants included in the bond indentures, direct placement agreements, and related agreements, including a requirement to maintain a minimum Debt Service Coverage Ratio.

The 2018Z and 2018AA tax-exempt bonds are subject to mandatory tender purchase seven days after notice from bondholders and may be remarketed. If the bonds are not remarketed, Cincinnati Children's must repay the bonds. The 2018Z and 2018AA bonds are classified as current liabilities in bonds payable subject to remarketing, net in the accompanying Consolidated Balance Sheets. The interest rates on the 2018Z and 2018AA variable rate bonds are reset weekly by a rate-setting agent.

(b) Commercial Paper – The Series 2018BB taxable commercial paper was issued in the original aggregate principal amount of \$100,000 and outstanding at any one time in a principal amount not to exceed \$100,000. The Notes shall mature no later than May 15, 2048. The commercial paper notes have a maximum maturity period of 270 days and are resold at maturity. In the event the notes have not been resold, Cincinnati Children's must repay the notes. The 2018BB commercial paper is classified as current liabilities in the accompanying Consolidated Balance Sheets. The interest rates on the 2018BB commercial paper are reset with each remarketing by a rate-setting agent.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(c) <u>Future Debt Maturities</u> – The following is a schedule of future debt maturities, excluding discounts/premiums and deferred issuance costs:

| 2023 | \$ 195,895 |
|------------|-------------|
| 2024 | 9,060 |
| 2025 | 9,510 |
| 2026 | 9,750 |
| 2027 | 109,800 |
| Thereafter | 724,035 |
| | \$1,058,050 |
| | |

(d) <u>Line of Credit</u> – In June 2020, Cincinnati Children's entered into a 1-year agreement for a line of credit of \$100,000. The line of credit agreement was amended in June 2021 to extend the maturity date to June 2024. The line of credit bears interest at the greater of the Daily Reset LIBOR Rate or 0.50%, plus 50 basis points. In the event LIBOR is no longer available, the line of credit bears interest at the daily SOFR rate, plus an adjustment spread. There were no draws on the line of credit during fiscal year 2022 or 2021.

(10) Employee Benefit Plans –

Cincinnati Children's maintains non-contributory retirement plans covering substantially all employees. Among these plans is a defined benefit plan where benefits are based on a formula which reflects years of service and salary levels. Cincinnati Children's funding policy for its defined benefit plan meets the funding standards established by the Employee Retirement Income Security Act of 1974 (ERISA).

Cincinnati Children's investment strategy with respect to pension assets is designed to achieve a moderate level of overall portfolio risk in keeping with desired risk objective, which is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. Cincinnati Children's adopted an Investment Policy that adjusts allocations between return-seeking assets and liability-hedging assets based on the funded status of the Plan and prevailing yields. As the funded ratio improves, allocations to liability-hedging assets increase accordingly.

Cincinnati Children's seeks to maintain diversified portfolios and has adopted allocation targets within the return-seeking and liability hedging portfolios as follows:

| Return-Seeking Allocation: | Min - Target -Max |
|---------------------------------------------|-------------------|
| Global Equity | 60% - 70% - 80% |
| Private Equity | 5% - 10% - 15% |
| Private Real Estate | 5% - 10% - 15% |
| Multi-Asset Credit | 5% - 10% - 15% |
| Opportunity Allocation | 0% - 0% - 10% |
| Liability-Hedging Allocation: | |
| Long Credit | 50% - 75% - 100% |
| STRIPS (Long Duration Treasury Instruments) | 0% - 25% - 50% |

In order to maintain the portfolio's actual asset allocation in line with the target allocations specified above, rebalancing will occur periodically. As of June 30, 2022, Cincinnati Children's has made \$126,400 in funding commitments in eleven investment partnerships of which \$106,700 has been funded. Additionally, Cincinnati Children's has made \$82,500 in funding commitments in ten real estate investment partnerships of which \$78,000 has been funded. It is anticipated that these commitments will be funded from liquid investments of the plan.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

Cincinnati Children's defined benefit plan investment allocation at the actuarial measurement date of June 30, 2022 and 2021 by asset category is as follows:

| | 2022 | 2021 |
|-----------------------------|--------|--------|
| Cash and cash equivalents | 1.3% | 1.7% |
| Corporate bonds | 12.9% | 13.6% |
| Government bonds | 1.9% | 1.8% |
| Investment Partnerships: | | |
| Equity | 5.3% | 4.0% |
| Bond | - | 0.8% |
| Real estate | 2.7% | 2.4% |
| Commingled Investment Funds | | |
| Equity | 12.9% | 18.7% |
| Bond | 43.3% | 40.0% |
| Government | 19.0% | 17.0% |
| Real estate | 0.7% | 0.0% |
| | 100.0% | 100.0% |

At June 30, 2022, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 4 for further discussion on the fair value hierarchy and fair value principles):

| | Level 1 | Level 2 | Level 3 | Total |
|--------------------------------------------------------|----------|-----------|---------|-------------|
| Cash and cash equivalents | \$18,057 | \$ - | \$ - | \$ 18,057 |
| Corporate bonds | - | 184,093 | - | 184,093 |
| Government bonds | | 27,241 | | 27,241 |
| Total assets in the fair value hierarchy | 18,057 | 211,334 | | 229,391 |
| Investments measured at net asset value ⁴ : | | | | |
| Investment Partnerships: | | | | |
| Equity | - | - | - | 76,191 |
| Real estate | - | - | - | 38,100 |
| Commingled Investment Funds: | | | | |
| Equity | - | - | - | 183,853 |
| Bond | - | - | - | 617,843 |
| Government | - | - | - | 270,194 |
| Real estate | | | | 10,000 |
| Total assets at fair value | \$18,057 | \$211,334 | \$ - | \$1,425,572 |

24

⁴ Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Change in Plan Assets disclosure.

Consolidated Financial Statements
For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

At June 30, 2021, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 4 for further discussion on the fair value hierarchy and fair value principles):

| | Level 1 | Level 2 | Level 3 | Total |
|--------------------------------------------------------|----------|-----------|---------|-------------|
| Cash and cash equivalents | \$29,579 | \$ - | \$ - | \$ 29,579 |
| Corporate bonds | - | 239,259 | _ | 239,259 |
| Government bonds | <u> </u> | 31,870 | _ | 31,870 |
| Total assets in the fair value hierarchy | 29,579 | 271,129 | _ | 300,708 |
| Investments measured at net asset value ⁵ : | | | | |
| Investment Partnerships: | | | | |
| Equity | - | - | - | 70,552 |
| Bond | - | - | - | 14,348 |
| Real Estate | - | - | - | 42,696 |
| Commingled Investment Funds: | | | | |
| Equity | - | - | _ | 327,271 |
| Bond | - | - | _ | 702,807 |
| Government | <u>-</u> | <u>-</u> | _ | 297,274 |
| Total assets at fair value | \$29,579 | \$271,129 | \$ - | \$1,755,656 |

The fair values of Level 1 investments are based on quoted prices in active markets. The fair value for investments in fixed income securities, including U.S. government securities and corporate obligations, is based on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate) and considers the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy. Investments in partnerships – U.S. equities, real estate, and bonds – are valued using the net asset value reported by the managers of the funds and as supported by the unit prices of actual purchase and sale transactions. The investments in investment partnerships generally are associated with liquidation restrictions that may range from 91 days to the life of the fund (up to fifteen years) and may require redemption penalties. Commingled investment funds are private funds for institutional investors valued at net asset value. The commingled funds primarily invest in actively traded equity mutual funds, bond mutual funds, and US Treasury STRIPS with daily liquidity and no lockup period.

There were no transfers between levels in fiscal year 2022 or fiscal year 2021.

The following table reflects the weighted average assumptions utilized to determine benefit obligations:

| | 2022 | 2021 |
|----------------------------------------------------------------|-------|-------|
| Discount rate used to determine actuarial present value of the | | |
| projected benefit obligation | 5.06% | 3.27% |
| Assumed rate of increase in compensation levels | 3.50% | 3.50% |
| Long-term rate of return | 5.50% | 5.50% |

-

⁵ Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Change in Plan Assets disclosure.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The following table sets forth the funded status of the plan and amounts recognized in the accompanying Consolidated Balance Sheets as of June 30, 2022 and 2021, utilizing actuarial measurement dates as of June 30, 2022 and 2021.

| | 2022 | 2021 |
|---------------------------------------------------------------------|-------------|-------------|
| Change in projected benefit obligation: | | |
| Projected benefit obligation at beginning of year | \$1,583,947 | \$1,533,155 |
| Service cost | 74,571 | 71,800 |
| Interest cost | 50,560 | 49,725 |
| Other actuarial (gain) loss | (450,685) | 33,202 |
| Benefits paid | (113,864) | (103,935) |
| Projected benefit obligation at end of year | \$1,144,529 | \$1,583,947 |
| Change in plan assets: | | |
| Fair value of plan assets at beginning of year | \$1,755,656 | \$1,454,224 |
| Actual (loss) return on plan assets | (291,220) | 233,567 |
| Employer contributions | 75,000 | 171,800 |
| Benefits paid | (113,864) | (103,935) |
| Fair value of plan assets at end of year | 1,425,572 | 1,755,656 |
| Funded status | 281,043 | 171,709 |
| Net accrued pension benefit asset in Consolidated Balance Sheets | \$ 281,043 | \$ 171,709 |

For the Retirement Plan, the overall actuarial gain in plan obligation of approximately \$451 million is primarily attributable to an increase in the discount rate between June 30, 2021 and June 30, 2022. The discount rate increase of 179 basis points resulted in a decrease in benefit obligation of approximately \$481 million.

In 2022 and 2021, the mortality tables utilized by actuaries to value the pension liability were updated based on current experience. The impact of the change in mortality assumptions is included in other actuarial (gain) loss in fiscal years 2022 and 2021.

Amounts included in Unrestricted Net Assets but not yet recognized in pension cost consist of:

| | 2022 | 2021 |
|--------------------------|-----------|-----------|
| Net actuarial loss | \$223,244 | \$317,248 |
| Net prior service credit | (65,290) | (77,041) |
| - | \$157,954 | \$240,207 |

The table below reflects the following weighted average assumptions utilized to determine benefit costs were:

| | 2022 | 2021 |
|--------------------------------------------------|-------|-------|
| Discount rate used to determine benefit costs | 3.27% | 3.33% |
| Assumed rate of increase in compensation levels | 3.50% | 3.50% |
| Expected long-term rate of return on plan assets | 5.50% | 5.50% |

The Cincinnati Children's expected long-term rate of return on plan assets is based on the expected average returns based on the portfolio mix of plan assets and is reassessed on an annual basis.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

Net periodic pension cost for 2022 and 2021 related to the defined benefit plan consisted of the following components:

| | 2022 | 2021 |
|--------------------------------------|----------|----------|
| Service cost | \$74,571 | \$71,800 |
| Interest cost | 50,560 | 49,725 |
| Expected return on plan assets | (91,509) | (76,121) |
| Amortization of prior service credit | (11,751) | (11,751) |
| Recognized net actuarial loss | 26,048 | 36,339 |
| Net periodic pension cost | \$47,919 | \$69,992 |

Based on preliminary estimates, we do not expect any required fiscal year 2022 contributions for the qualified defined benefit plan under the current funding regulations.

The accumulated benefit obligation for the pension plan was \$1,099,257 and \$1,504,250 at June 30, 2022 and 2021, respectively.

Cincinnati Children's estimated benefit payments in each of the next five fiscal years and in aggregate for the five fiscal years thereafter are as follows:

| 2023 | \$64,063 |
|-----------|----------|
| 2024 | 64,539 |
| 2025 | 66,792 |
| 2026 | 68,368 |
| 2027 | 70,145 |
| 2028-2032 | 382,220 |

All other retirement plans maintained by Cincinnati Children's are defined contribution plans. Cincinnati Children's contributions to these plans are generally based on ten percent of salaries up to established ERISA limits. Total expense, net of forfeitures, related to these other plans was approximately \$29,650 and \$27,581 in fiscal years 2022 and 2021, respectively.

Cincinnati Children's provides individual nonqualified deferred compensation benefits to key employees with varying terms. Accounts are participant-directed, and the amounts are at a substantial risk of forfeiture and revert back to the Cincinnati Children's if the employee does not meet certain criteria as established by the plan. The amount of deferred compensation income and expense resulting from changes in market value of underlying investments are recognized in fiscal years 2022 and 2021 was \$(1,087) and \$1,358, respectively. The current portion of plan accounts are included in Other receivables with a corresponding liability in Accounts payable and accrued expenses on the Consolidated Balance Sheets. The long-term portion of plan accounts are included in Other long-term assets with a corresponding liability in Other long-term liabilities on the Consolidated Balance Sheets.

The following table displays the nonqualified deferred compensation plans assets and liabilities as of June 30, 2022 and 2021:

| | 2022 | 2021 |
|------------------------------|----------|----------|
| Current portion | \$ 919 | \$ 307 |
| Long-term portion | 14,311 | 15,582 |
| Total assets and liabilities | \$15,230 | \$15,889 |

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(11) Commitments and Contingencies -

- (a) <u>Litigation</u> Cincinnati Children's is engaged from time to time in a variety of litigation and regulatory compliance matters in addition to professional and general liability matters. Management assesses the probable outcome of unresolved litigation and records estimated reserves consistent with ASC No. 450, "Contingencies." After consultation with legal counsel, management believes that all such currently existing matters will be resolved without material adverse impact to the consolidated financial position or results of operations of Cincinnati Children's.
- (b) <u>Laws and Regulations</u> The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations guide the healthcare industry in many domains such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient service, and Medicare and Medicaid fraud and abuse to name a few. Compliance with these laws and regulations, specifically those relating to the Medicare and Medicaid programs, is complex and can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time. Management believes that Cincinnati Children's is in compliance, in all material respects, with fraud and abuse as well as other applicable government laws and regulations. Cincinnati Children's has recorded reserves for routine regulatory compliance issues and believes these reserves are adequate to cover any potential repayment of previously billed and collected revenue from patient service.
- (c) <u>Capital Commitments</u> Cincinnati Children's has entered into agreements with general contractors for several new construction projects, renovations, equipment, and information system technology projects. Approximately \$592,388 has been spent through June 30, 2022 and approximately \$425,960 is expected to be spent in connection with current active projects. The commitments have expected completion dates ranging from fiscal year 2023 through fiscal year 2026.
- (d) <u>Funding Commitments</u> The Board of Trustees of Cincinnati Children's approved revocable commitments for up to \$20,000 in non-recourse loans to Uptown Consortium Inc. Cincinnati Children's has provided \$17,867 of funding in relation to these commitments through June 30, 2022. Management does not anticipate any additional funding. These funds are used to invest in commercial and residential projects in the uptown area. During fiscal year 2022, none of the loans were repaid. Cincinnati Children's expects to receive an additional \$4,328 related to the loans.
- (e) <u>Investment Commitments</u> Cincinnati Children's has made commitments to invest \$30,000 in six limited partnerships that focus on investing in venture capital funds or provide venture capital for companies in the high-growth sectors of the economy, including life sciences, information technology, advanced manufacturing, and healthcare. Cincinnati Children's has made commitments to invest \$12,294 in nine limited liability companies that focus on investing in early-stage venture capital funds regionally and nationally with the goals of making the Cincinnati region the place for entrepreneurs and investors to launch new ideas and driving capital into scalable technology companies in southwest Ohio. Investment values are included in Other Assets in the Consolidated Balance Sheets. Cincinnati Children's occasionally receives distributions from these investments which reduce investment values.

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The following displays the amounts funded and investment values at June 30, 2022 and 2021:

| 2022 | Funded | Value |
|-----------------------------------------------|-----------------|-----------------------|
| Investment in Limited Partnerships | \$21,099 | \$ 10,041 |
| Investments in Limited Liability Corporations | 10,558 | 19,664 |
| Total | \$31,657 | \$29,705 |
| | | |
| | | |
| 2021 | Funded | Value |
| 2021 Investment in Limited Partnerships | Funded \$20,349 | Value \$ 8,075 |
| | | |
| Investment in Limited Partnerships | \$20,349 | \$ 8,075 |

(12) <u>Leases</u> –

Cincinnati Children's leases certain property and equipment. Cincinnati Children's determines if an arrangement is a lease at inception of a contract.

The following table presents expenses recorded related to lease arrangements for the years ended June 30, 2022 and 2021:

| | 2022 | 2021 |
|---------------------------------------|----------|----------|
| Operating lease expense | \$ 3,588 | \$ 2,765 |
| Finance leases: | | |
| Amortization of right-of-use assets | 7,116 | 6,698 |
| Interest on finance lease obligations | 1,856 | 1,955 |
| Short-term and variable lease expense | 5,061 | 4,994 |
| Total lease expense | \$17,621 | \$16,412 |

Other information related to leases for the years ended June 30, 2022 and 2021 is as follows:

Supplemental cash flow information

Cash paid for amounts included in the measurement of lease liabilities:

| | 2022 | 2021 |
|--------------------------------------------------|----------|----------|
| Operating cash flows from operating leases | \$ 2,736 | \$ 2,097 |
| Financing cash flows from finance leases | 6,228 | 5,319 |
| Weighted average remaining lease term (in years) | | |
| | 2022 | 2021 |
| Operating leases | 7.6 | 7.4 |
| Finance leases | 9.7 | 10.5 |
| Weighted average discount rate | | |
| | 2022 | 2021 |
| Operating leases | 3.25% | 3.27% |
| Finance leases | 3.27% | 3.34% |

Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The aggregate future lease payments for operating and finance leases as of June 30, 2022 are as follows:

| | Operating | Finance |
|--------------------------------------------|-----------|----------|
| 2023 | \$ 3,295 | \$ 7,784 |
| 2024 | 3,221 | 7,032 |
| 2025 | 2,856 | 7,032 |
| 2026 | 1,903 | 6,530 |
| 2027 | 1,348 | 5,442 |
| Thereafter | 6,498 | 30,374 |
| Total lease payments | 19,121 | 64,194 |
| Present values: | | |
| Current lease liabilities | 2,767 | 6,094 |
| Long-term lease liabilities | 14,949 | 48,544 |
| Total lease liabilities | \$17,716 | \$54,638 |
| Difference between undiscounted cash flows | | |
| and discounted cash flows | \$ 1,405 | \$ 9,556 |

(13) <u>Functional Expenses</u> – The cost of providing Cincinnati Children's services are summarized on a functional basis in the following tables. Accordingly, certain costs have been allocated among functions. Such allocations are determined by management on an equitable basis. The expenses that are allocated include the following:

| Expense | Method of Allocation |
|-------------------|----------------------|
| Employee benefits | Full Time Equivalent |
| Depreciation | Square footage |
| Utilities | Square footage |

The following presents expenses by both their nature and function for the year ended June 30, 2022:

| | Clinical | Research | Education | Fundraising | Management and General | TOTAL |
|-----------------------------------|-------------|-----------|-----------|-------------|------------------------|-------------|
| Salaries | \$ 898,559 | \$196,539 | \$62,454 | \$4,215 | \$212,320 | \$1,374,087 |
| Employee benefits Supplies, drugs | 214,293 | 48,365 | 17,114 | 1,116 | 91,149 | 372,037 |
| and other | 402,177 | 39,650 | 3,269 | 491 | 79,961 | 525,548 |
| Purchased services | 90,525 | 49,585 | 2,441 | 917 | 144,253 | 287,721 |
| Depreciation | 92,100 | 29,284 | 152 | 303 | 29,890 | 151,729 |
| Utilities | 12,188 | 3,875 | 20 | 40 | 3,956 | 20,079 |
| Interest | | | | | 30,926 | 30,926 |
| | \$1,709,842 | \$367,298 | \$85,450 | \$7,082 | \$592,455 | \$2,762,127 |

Consolidated Financial Statements
For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The following presents expenses by both their nature and function for the year ended June 30, 2021:

| | Clinical | Research | Education | Fundraising | Management and General | TOTAL |
|---------------------------|-------------|-----------|-----------|-------------|------------------------|-------------|
| Salaries | \$ 814,088 | \$186,686 | \$57,395 | \$4,159 | \$196,328 | \$1,258,656 |
| Employee benefits | 204,106 | 51,114 | 11,822 | 1,043 | 79,626 | 347,711 |
| Supplies, drugs and other | 367,962 | 38,150 | 1,936 | 427 | 60,869 | 469,344 |
| Purchased services | 86,164 | 42,605 | 2,258 | 720 | 120,461 | 252,208 |
| Depreciation | 82,628 | 28,282 | 139 | 416 | 27,173 | 138,638 |
| Utilities | 10,967 | 3,754 | 18 | 55 | 3,607 | 18,401 |
| Interest | _ | _ | - | _ | 23,249 | 23,249 |
| | \$1,565,915 | \$350,591 | \$73,568 | \$6,820 | \$511,313 | \$2,508,207 |

(14) Interest Rate Swap Agreement –

In August 2019, Cincinnati Children's entered into a 10-year interest rate swap agreement in which Cincinnati Children's and the counterparty agree to exchange the difference between fixed rate and variable rate interest amounts calculated by reference to specified notational principal amounts during the agreement period. The objective is to manage interest rate risk associated with the variable rate 2018Z and 2018AA bonds. Parties to interest rate swap agreements are subject to market risk for changes in interest rates and risk of credit loss in the event of nonperformance by the counterparty.

The following table summarizes the general terms of Cincinnati Children's fixed payment swap agreement as of June 30, 2022:

| | | | Interest | | Notational |
|------------------|-------------|------------------|-----------|---------------------------------------|--------------|
| Effective | Expiration | Counterparty | Rate Paid | Interest Rate Received | Amount |
| August 2019 | August 2029 | Fifth Third Bank | 1.38% | USD-SIFMA Municipal Swap | \$86,770,000 |
| | | | | Index, 0.91% at June 30 th | |

As of June 30, 2022, the swap fair value of \$4,421 was recorded in other long-term assets in the accompanying consolidated balance sheet. As of June 30, 2021, the swap market value of \$(2,956) was recorded in other long-term liabilities in the accompanying consolidated balance sheet.

(15) Subsequent Events –

During August 2022, Cincinnati Children's entered into a private placement bond forward refunding agreement with a bank whereby Cincinnati Children's will refund and retire the outstanding principal of its Series 2014S bonds of \$66,155 through the issuance of hospital facilities bonds through Hamilton County, Ohio at a fixed rate of 2.934%. The closing of the refunding is expected to occur on May 15, 2024.

Management reviewed subsequent events through September 30, 2022, the date the consolidated financial statements were issued, noting no changes are required to the consolidated financial statements or footnotes.

| For the Year Ended June 30, 2022 | | | | | | | | | | | |
|----------------------------------|---------|--------------------------------------------------------------------------------|----------------------------------------------|----------------------------------------|---------------------------------------|----------------------|--------------------------------|--------------------------|---------|-----------|-----------|
| Gov Agency | Divisio | n Gov Branch | Award Title | Pass-Through Grantor | Subrecipient Name | Identifying Numb | er Federal Grant Numbe | er ALN | Sub Exp | Fed Exp | Total Exp |
| Department of Defense | DOD | Military Medical Research and Development | Surviving and Thriving in the | • | | • | W81XMH1810677 | 12.420 | - | 117,632 | 117,632 |
| | DOD | Military Medical Research and Development | Multicenter Randomized Trial of Everolimus | Children's Hospital Boston | | W81XWH1710532 | W81XWH1710532 | 12.420 | _ | 12.538 | 12,538 |
| | DOD | Military Medical Research and Development | Therapeutic Benefit of Hsp90 Inhibition in | | | | W81XWH1710666 | 12.420 | _ | 12,064 | 12,064 |
| | | | | | | 5161 | | | | | |
| | DOD | Military Medical Research and Development | Mechanisms of acute pain gener | Henry M. Jackson Foundation | | | W81XWH1720024 | 12.420 | - | 3,872 | 3,872 |
| | DOD | Military Medical Research and Development | The Neurofibromatosis Clinical | University of Alabama-Birmingham | | 000516840-SC004 | W81XWH1720037 W81XWH1810269 | 12.420 | - | 114,651 | 114,651 |
| | DOD | Military Medical Research and Development | A Novel and Rapid System to Cl | | | | | 12.420 | - | 33,185 | 33,185 |
| | DOD | Military Medical Research and Development | Novel Neuroimaging Assessments | | | | W81XWH1810615 | 12.420 | - | 13,029 | 13,029 |
| | DOD | Military Medical Research and Development | Development of Virtual Surgery | | | | W81XWH1910043 | 12.420 | - | 19,801 | 19,801 |
| | DOD | Military Medical Research and Development | A Novel FANCD2-Chromatin Bound | | | | W81XWH1910262 | 12.420 | - | 132,506 | 132,506 |
| | DOD | Military Medical Research and Development | Single cell analyses of NF1 pl | | | | W81XWH1910816 | 12.420 | - | 270,666 | 270,666 |
| | DOD | Military Medical Research and Development | Immune-Schwann cell signaling | | | | W81XWH2010116 | 12.420 | _ | 157.023 | 157.023 |
| | DOD | Military Medical Research and Development | Antioxidant Therapy with N-Ace | | | | W81XWH2010139 | 12.420 | _ | 260.229 | 260,229 |
| | | | | Dhannis Children le Hanniel | | W81XWH2010339 | W81XWH2010339 | 12.420 | | | |
| | DOD | Military Medical Research and Development | Resting State Functional MRI F | Phoenix Children's Hospital | | W81XWH2U1U339 | | | - | 5,444 | 5,444 |
| | DOD | Military Medical Research and Development | Merlin-ASPP2 Tumor Suppressor | | | | W81XWH2010377 | 12.420 | - | 194,318 | 194,318 |
| | DOD | Military Medical Research and Development | Inflammatory vigor in heteroge | | | | W81XWH2010392 | 12.420 | - | 349,449 | 349,449 |
| | DOD | Military Medical Research and Development | Inflammatory vigor in heteroge | | | | W81XWH2010393 | 12.420 | - | 188,257 | 188,257 |
| | DOD | Military Medical Research and Development | Identification of cellular het | | | | W81XWH2010443 | 12.420 | - | 90,587 | 90,587 |
| | DOD | Military Medical Research and Development | The Influence of Social, Educa | Vanderbilt University Medical Center | | VUMC84410 | W81XWH2010475 | 12.420 | - | 52,332 | 52,332 |
| | DOD | Military Medical Research and Development | Mitochondrial ALR protein defi | | University of Cincinnati | | W81XWH2010477 | 12.420 | 106,800 | 459.484 | 566,284 |
| | DOD | Military Medical Research and Development | Rational Targeting Oncogenic K | University of Wisconsin-Madison | , | 0000000812 | W81XWH2010616 | 12.420 | - | 194,967 | 194,967 |
| | DOD | Military Medical Research and Development | The role of mitochondria in bo | Chircinity of Wildonian Madison | Albert Einstein College of Medicine | 000000012 | W81XWH2010689 | 12.420 | 16,734 | 132,164 | 150,851 |
| | | | | | | | W01AW02010009 | 12.420 | | 132,104 | 100,001 |
| | DOD | Military Medical Research and Development | The role of mitochondria in bo | | Baylor College of Medicine. | | | | 1,953 | • | |
| | DOD | Military Medical Research and Development | Evaluating the therapeutic pot | | | | W81XWH2010870 | 12.420 | - | 78,578 | 78,578 |
| | DOD | Military Medical Research and Development | Mechanisms of acute pain gener | Henry M. Jackson Foundation | | 1023994 | W81XWH20C0031 | 12.420 | - | 14,270 | 14,270 |
| | DOD | Military Medical Research and Development | Role of endoplasmic reticulum | | | | W81XWH2110907 | 12.420 | - | 134,738 | 134,738 |
| | DOD | Military Medical Research and Development | Regulation of Translation by N | | | | W81XWH2210196 | 12.420 | - | 2,884 | 2,884 |
| | | | | | | | | tment of Defense Total | 125,487 | 3,044,668 | 3,170,155 |
| | | | | | | | • | | | | |
| Department of Education | DOE | Research in Soecial Education | Stuggish Cognitive Temps - Free ini- | | | | R305A160064 | 84.324 | | 6.580 | 6,580 |
| Department of Education | | • | Sluggish Cognitive Tempo: Examining | | | | | | - | | |
| | DOE | Education Research, Development and Dissemination | Longitudinal Evaluation of Slu | | | | R305A200028 | 84.305 | - | 309,612 | 309,612 |
| | DOE | Research in Special Education | Teaching Academic Success Skil | | | | R324A180053 | 84.324 | - | 263,986 | 263,986 |
| | | | | | | | Departr | nent of Education Total | - | 580,178 | 580,178 |
| | | | | | | | | | | | |
| Department of Justice | DOJ | Crime Victim Assistance | VOCA Mayerson 2021 | | | | 2021-VOCA-133916106 | 16.575 | - | 73,204 | 73,204 |
| | DOJ | Crime Victim Assistance | VOCA Mayerson 2022 | | | | 2022-VOCA-134716904 | 16.575 | _ | 155,229 | 155,229 |
| | DOJ | Edward Byrne Memorial Justice Assistance Grant Program | BJA Police Response Training f | The Arc of The United States INC | | R IA Police Response | BJA Police Response | 16.738 | _ | 44.358 | 44.358 |
| | DOJ | Improv Investigation & Prosec of Child Abuse & Reg & Local Children's Advoca | | THE FIRE OF THE OFFICE CLARES AND | | DUTTI GIOC TEOPOTO | CINCI-OH-PCIT-PI21 | 16.758 | | 24.000 | 24,000 |
| | DCG | Imploy investigation & Plosec of Child Abuse & Reg & Local Children's Advoca | Mayerson NCA MR PCT | | | | | artment of Justice Total | | 296,791 | 296,791 |
| | | | | | | | Бер | arunent of Justice Total | - | 290,791 | 290,791 |
| | | | | | | | | | | | |
| National Science Foundation | NSF | Biological Sciences | NSF/MCB-BSF: Quantitative analysis | | | | 1715822 | 47.074 | - | 9,954 | 9,954 |
| | NSF | Engineering Grants | Plasma treatment for Inactivat | University of Cincinnati | | 013263-002 | 2029268 | 47.041 | - | 98,231 | 98,231 |
| | NSF | Biological Sciences | NSF/MCB-BSF: Modeling the mec | | University of Cincinnati | | 2114950 | 47.074 | 11,697 | 156,277 | 167,974 |
| | NSF | Engineering Grants | Collaborative Research: Unders | | | | 2140441 | 47.041 | - | 9,827 | 9,827 |
| | | | | | | | National Sc | ience Foundation Total | 11,697 | 274,289 | 285,986 |
| | | | | | | | | | | | |
| Department of Energy Total | DOE | | Joint Faculty Agreement No. JF | University of Cincinnati | | | 4000173601 | 81.RD | | 92.605 | 92,605 |
| | | | ,, | | | | | rtment of Energy Total | - | 92,605 | 92,605 |
| | | | | | | | | | | . , | . , |
| | | | | | | | | | | | |
| Dept of Health and Human Serv | ACF | Personal Responsibility Education Program | Evaluation of Using the Connec | Texas A & M | | M2200564 | 90AP2702 | 93.092 | - | 149,320 | 149,320 |
| | ACL | Developmental Disabilities Basic Support and Advocacy Grants | Empowering Families | Ohio Coalition for the Education of Ch | il | Riddle_OCECD | | 93.630 | - | 14,344 | 14,344 |
| | ACL | Developmental Disabilities Basic Support and Advocacy Grants | Accommodations and Adaptations | Florida Develop Disabl Council, Inc | | FDDC #5045EM21 | | 93.630 | - | 132,340 | 132,340 |
| | ACL | Developmental Disabilities Basic Support and Advocacy Grants | Healthy Lifestyles for People with Disabilit | Ohio Developmental Disabilities Coun | cil University of Illinois at Chicago | 17CH03FA21 | 21010HSCDD | 93.630 | 20,000 | 59,339 | 79,339 |
| | ACL | Strengthening Public Health Systems & Services through National Partnerships | | | | | 90IFRE0055-01-00 | 93.433 | - | 70,072 | 70,072 |
| | ACL | University Centers for Excellence in Developmental Disabilities Edu, Res & Svc | Expanding Disabilities Network | University of Cincinnati | | 013610-00002 | 90DDC50047 | 93.632 | - | 48,420 | 48,420 |
| | ACL | University Centers for Excellence in Developmental Disabilities Edu, Res & Svc | AUCD SCOPE renewal 2019_U of W | University of Wyoming | | 1004506-CHMC | 90DDTI0042 | 93.632 | - | 91,224 | 91,224 |
| | ACL | University Centers for Excellence in Developmental Disabilities Edu, Res & Svc | University of Cincinnati University Centers | University of Cincinnati | | 90DDUC0013-01-00 | 90DDUC0013 | 93.632 | - | 588,509 | 588,509 |
| | ACL | Developmental Disabilities Projects of National Significance | Center for Dignity in Healthcare | | AADMD | | 90DNHC0001 | 93.631 | 26,820 | 166,865 | 468,287 |
| | | • | | | Autistic Self Advocacy Network Inc | | | | 25,000 | - | |
| | | | | | Family Voices Inc | | | | 25,000 | _ | |
| | | | | | Kennedy Krieger Institute, Inc. | | | | 80,981 | _ | |
| | | | | | Rutgers, The State University | | | | 18,877 | | |
| | | | | | University of Kentucky Research Fnd | | | | 93.958 | _ | |
| | | | | | Vanderbilt University Medical Center | | | | 30,786 | - | |
| | ACL | Strengthening Public Health Systems & Services through National Partnerships | Enhancing Parenting Skille: Application | University of Oregon | - Underbit Oniversity Medical Center | 239530A | 90DPHF0003-01-00 | 93.433 | 30,766 | 52.667 | 52,667 |
| | ACL | Strengthening Public Health Systems & Services through National Partnerships | | Simolony or olayon | | 2000001 | 90IFDV0003-02-00 | 93.433 | - | 1,472 | 1,472 |
| | | | | | | | | | - | | |
| | AHRQ | Research on Healthcare Costs, Quality and Outcomes | Predicting Pediatric Readmission: Develop | | | | K08HS024735 | 93.226 | - | 113,696 | 113,696 |
| | AHRQ | Research on Healthcare Costs, Quality and Outcomes | Hospital Management of Acute Respiratory | | | | K08HS025138 | 93.226 | - | 105,722 | 105,722 |
| | AHRQ | Research on Healthcare Costs, Quality and Outcomes | The Patient and Parent Perspec | | | | K08HS026763 | 93.226 | - | 146,332 | 146,332 |
| | AHRQ | Research on Healthcare Costs, Quality and Outcomes | AHRQ Mentored Clinical Scienti | | | | K08HS026975 | 93.226 | = | 120,604 | 120,604 |
| | AHRQ | National Research Service Awards_Health Services Research Training | Describing ventilator weaning | Children's Hospital of Philadelphia | | 3201350921 PO 2026 | | 93.225 | - | 243,921 | 243,921 |
| | AHRQ | Research on Healthcare Costs, Quality and Outcomes | Missed Opportunities for Improving Diag | University of Michigan | | 3004658567 | R01HS024953 | 93.226 | - | 1,759 | 1,759 |
| | AHRQ | Research on Healthcare Costs, Quality and Outcomes | Diagnosis and management of pe | Children's Hospital Los Angeles | | 000013257-E | R01HS027619 | 93.226 | - | 22,265 | 22,265 |
| | AHRQ | Research on Healthcare Costs, Quality and Outcomes | CHASM: Children Hospitalization | - | | | R03HS028102 | 93.226 | - | 71,045 | 71,045 |
| | AHRQ | Research on Healthcare Costs, Quality and Outcomes | Ambulatory Pediatric Safety Le | Children's Hospital Boston | | RHS026644B | R18HS026644 | 93.226 | - | 231,919 | 231,919 |
| | AHRQ | Research on Healthcare Costs, Quality and Outcomes | Spread of Safety Interventions | Children's Hospital Boston | | RHS027401A | R18HS027401 | 93.226 | - | 120,974 | 120,974 |
| | CDC | Disabilities Prevention | Improving the Health of People | Ohio State University | | SPC - 1000005432 | NU27DD000032 | 93.184 | - | 37.308 | 37.308 |
| | | | Pediatric Environmental Health | | | | | | - | | |
| | CDC | Health Program for Toxic Substances and Disease Registry | | Univ of Illinois @ Chicago | | 17852-00 | NU61TS000296 | 93.161 | - | 57,397 | 57,397 |
| | CDC | Occupational Safety and Health Program | Enhanced injury surveillance u | | | | R01OH011996 | 93.262 | - | 255,386 | 255,386 |
| | CDC | Occupational Safety and Health Program | Newman UC sub T42 ERC Renewal | University of Cincinnati | | 013704-00008 | T42OH008432-16-00 | 93.262 | - | 15,872 | 15,872 |
| | CDC | Rare Disorders: Research, Surveillance, Health Promotion, and Education | Woodward CDC NSBPR Registry 20 | | | | U01DD001279 | 93.315 | - | 78,792 | 78,792 |
| | CDC | Training and Clinical Skills Improvement Projects | Enhanced Surv for New Vaccine Prevent | | | | U01IP001059 | 93.185 | - | 218,361 | 218,361 |
| | | | | | | | | | | | |

| ФС | Training and Clinical Skills Improvement Projects | COVID-19 Enhanced Surv for New Vaccine Prevent | | University of Cincinnati | | COVID-19 U01IP001059 | 93.185 | 79,204 | 584.973 | 664,177 |
|--------------|---------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------------------------|------------------------------------|------------------|------------------|---------------------|---------------------|
| CDC | Training and Clinical Skills Improvement Projects | US Enhanced Surveillance Netwo | | Omitotoky or Omitomata | | U01IP001155 | 93.185 | - | 841.746 | 841,746 |
| CDC | Training and Clinical Skills Improvement Projects | COVID-19 US Enhanced Surveillance Netwo | | | | COVID-19 U01IP001155 | 93.185 | - | 335,024 | 335,024 |
| CDC | Assistance Programs for Chronic Disease Prevention and Control | SEARCH for Diabetes in Youth Registry | | | | U18DP006134 | 93.945 | - | 5,454 | 5,454 |
| CDC | Birth Defects and Developmental Disabilities - Prevention and Surveillance | Beyond EHDI Benchmarks in Earl | University of South Carolina | | 19-37777 | U19DD001218 | 93.073 | - | 75,944 | 75,944 |
| CDC | Blood Disorder Program: Prevention, Surveillance and Research | Community Counts: Public Health Surv | Hemophilia Foundation of Michigan | | U27DD001155 | U27DD001155 | 93.080 93.137 | - | 36,426 | 36,426 |
| | S Community Programs to Improve Minority Health Grant Program S National Bioterrorism Hospital Preparedness Program | Sickle Cell Clinical Data Plat Eastern Great Lakes Pediatric | American Society of Hematology University Hospital of Cleveland | | ASH_Lannon,C 1U3REP190615-01-00 | 1 SPIMP201190-01-00 U3REP190615 | 93.137 | - | 412,297 190,231 | 412,297 190,231 |
| FDA | Food and Drug Administration_Research | Safety and Efficacy of Inhaled Tissue Plasm | University of Michigan | | SUBK00006758 | R01FD005393 | 93.103 | - | 5,277 | 5,277 |
| FDA | Food and Drug Administration_Research | Quercetin Chemoprevention for | | | | R01FD006353 | 93.103 | - | 531,067 | 531,067 |
| FDA | Food and Drug Administration_Research | Abatacept for the treatment of | | | | R01FD007267 | 93.103 | - | 229,231 | 229,231 |
| FDA | Food and Drug Administration_Research | Sirolimus TSC Epilepsy Prevent | | The University of Alabama at Birmingham The University of Texas Science Center | | R01FD007275 | 93.103 | 6,165 8,147 | 259,054 | 273,366 |
| FDA | Food and Drug Administration_Research | Development of the Pediatric P | Children's Hospital of Philadelphia | The dimensity of rexast describe darker | GRT-00000431 | U01FD007003 | 93.103 | - | 2,189 | 2,189 |
| FDA | Food and Drug Administration_Research | I-ACT for Children, Global Pediatric Clinical | Inst For Adv Clin Trials For Children | | CCHMC-01 | U18FD006297 | 93.103 | - | 47,851 | 47,851 |
| HRSA | Grants for Training in Primary Care Medicine and Dentistry | Dental Faculty Loan Repayment Program | | | | D87HP31252 | 93.884 | - | 158,520 | 158,520 |
| HRSA HRSA | Maternal and Child Health Federal Consolidated Programs Healthy Start Initiative | Region V East Comprehensive Care Netw HRSA Cradle Cincinnati | Hemophilia Foundation of Michigan | | H30MC24047 | H30MC24047 H49MC27823 | 93.110 93.926 | - | 20,724 1.139.667 | 20,724 1.139.667 |
| HRSA | Poison Center Support and Enhancement Grant Program | Cincinnati Drug and Poison Inf | | | | H4BHS15468 | 93.253 | - | 147,318 | 147,318 |
| HRSA | Affordable Care Act (ACA) Family to Family Health Information Centers | Ohio Family to Family Health I | | | | H84MC28443 | 93.504 | - | 80,820 | 80,820 |
| HRSA | Maternal and Child Health Federal Consolidated Programs | Severe Combined Immunodeficien | University of California, San Francisco | | 13048sc | SC1MC31881 | 93.110 | - | 5,569 | 5,569 |
| HRSA HRSA | National Research Service Award in Primary Care Medicine Maternal and Child Health Federal Consolidated Programs | General Pediatrics Research Fe Leadership Education in Neurod | University of Cincinnati | | 013719-0003 | T32HP10027 T73MC00032-30-W | 93.186 93.110 | - | 426,923 592,662 | 426,923 592,662 |
| HRSA | Emergency Medical Services for Children | Pediatric Emergency Care Appli | Oniversity of Circumati | Medical College of Wisconsin | 013718-0003 | U03MC22684 | 93.127 | 55,627 | 465,559 | 611,020 |
| | | | | Washington University | | | | 89,834 | - | |
| HRSA | Maternal and Child Health Federal Consolidated Programs | HRSA Central Region Thalassemi | Ann & Robert H Lurie Children's Hospital | | 901639-CCHMC | U1AMC41738-01-00 | 93.110 | - | 14,447 | 14,447 |
| HRSA | Sickle Cell Treatment Demonstration Program | Sickle Treatment and Outcomes Resear | | Children's Hosp & Clinics of Minnesota | | U1EMC27863 | 93.365 | 19,068 | 450,648 | 687,021 |
| | | | | Five Rivers Health Centers Indiana Hemophilia & Thrombosis Ctr. Inc | | | | 15,766 51.361 | - | |
| | | | | Medical College of Wisconsin | • | | | 30,295 | - | |
| | | | | Sanford Research | | | | 90 | - | |
| | | | | Sickle Cell Disease Assoc of America | | | | 38,852 | - | |
| HRSA | Maternal and Child Health Federal Consolidated Programs | Center for Pediatric Everyday | University Hospital of Cleveland | University of Illinois at Chicago | U1IMC43532-01-00 | U1IMC43532 | 93.110 | 80,941 | 31,155 | 31.155 |
| HRSA | Maternal and Child Health Federal Consolidated Programs | Regional Ped Pand Network (ODH) | Ohio State University | University Hospitals of Cleveland | GR125125 | U7AMC337160101 | 93.110 | 129,057 | 47,848 | 176,905 |
| HRSA | Maternal and Child Health Federal Consolidated Programs | DBPNet ADHD Node | Children's Hospital of Philadelphia | | 3208960819-S1 | UA3MC20218 | 93.110 | - | 3,304 | 3,304 |
| HRSA | Maternal and Child Health Federal Consolidated Programs | Identifying Patient Level Fact | University of Colorado Denver | | FY22.609.011 | UA6MC31101-05-00 | 93.110 | - | 2,181 | 2,181 |
| HRSA | Autism Collaboration, Accountability, Research, Education and Support | DBPNet ADHD Node CHOP SubIN RE | Children's Hospital of Philadelphia | | GRT-00001441 | UT5MC42432-01-00 | 93.877 | - | 8,912 | 8,912 |
| NIH NIH | International Research and Research Training Allergy, Immunology and Transplantation Research | Reducing the Impact of Rheumat Immunological identity redefined by gene | Makerere Institute of Social Research | University of Cincinnati | MakCHS06042022 | D43TW012255 DP1AI131080 | 93.989 93.855 | 3.844 | 2,917 752.840 | 2,917 756.684 |
| NIH | Trans-NIH Research Support | Engineering multi-organs in a | | | | DP2DK128799 | 93.310 | - | 545,882 | 545,882 |
| NIH | Allergy, Immunology and Transplantation Research | Silencer Control of T cell Hom | | | | F30Al157421 | 93.855 | - | 4,968 | 4,968 |
| NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Identification of the genetic | | | | F30DK123841 | 93.847 93.839 | - | 31,468 | 31,468 |
| NIH | Blood Diseases and Resources Research Mental Health Research Grants | Elucidating the role of dynein Contributions of the striatal | | | | F30HL156519 F30MH123056 | 93.242 | - | 18,880 29.694 | 18,880 29,694 |
| NIH | Oral Diseases and Disorders Research | Role of the Ciliary Protein C2 | | | | F31DE030664 | 93.121 | - | 37,177 | 37,177 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Development and Disease of the | | | | F31DK118823 | 93.847 | - | 137 | 137 |
| NIH | Child Health and Human Development Extramural Research | SMPD4: Role of a microcephaly | | | | F31HD104350 | 93.865 | - | 7,322 | 7,322 |
| NIH NIH | Cardiovascular Diseases Research Cardiovascular Diseases Research | Nr2f1a suppresses bulbous arte Prox1 and oscillatory shear st | | | | F31HL147399 F31HL150935 | 93.837 93.837 | - | 27,465 33,339 | 27,465 33.339 |
| NIH | Cardiovascular Diseases Research | Nr2fla promotes atrial mainten | | | | F31HL152600 | 93.837 | - | 39,636 | 39,636 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | The Role of Raptor in Temporal | | | | F31NS115525 | 93.853 | - | 34,517 | 34,517 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Role of dentate granule cell g | | | | F31NS122484 | 93.853 | - | 34,777 | 34,777 |
| NIH NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders Allergy, Immunology and Transplantation Research | The role of macrophages in neo Maternal microchime rism transf | | | | F31NS122494 F32Al145184 | 93.853 93.855 | - | 34,683 32.089 | 34,683 32.089 |
| NIH | Allergy, Immunology and Transplantation Research | Epithelial antigen presentatio | | | | F32Al147591 | 93.855 | - | 83,014 | 83,014 |
| NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Elucidating the mechanisms of | | | | F32AR077396 | 93.846 | - | 6,625 | 6,625 |
| NIH | Blood Diseases and Resources Research | The role of GPR56 in platelet | | | | F32HL149280 | 93.839 | - | 82,032 | 82,032 |
| NIH NIH | Cardiovascular Diseases Research Cardiovascular Diseases Research | Defining the role of DHHC3 in TgfB-dependent regulation of e | | | | F32HL154387 F32HL154505 | 93.837 93.837 | - | 56,782 68.568 | 56,782 68.568 |
| NIH | Cardiovascular Diseases Research | Mechanisms of regulating cardi | | | | F32HL159894 | 93.837 | - | 63,336 | 63,336 |
| NIH | Drug Abuse and Addiction Research Programs | Using Administrative and Clinical Data | | | | K01DA041620 | 93.279 | - | 100,402 | 100,402 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | The Role of DDX41 in Inherited | | | | K01DK121733 | 93.847 | - | 149,920 | 149,920 |
| NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research | Glucocorticoid and circadian c Enteroendocrine Regulation of | | | | K01DK121875 K01DK125341 | 93.847 93.847 | - | 186,096 90,942 | 186,096 90,942 |
| NIH | Cancer Research Manpower | Patient Preferences and Adherence in Ad | | | | K07CA200668 | 93.398 | - | 32,240 | 32,240 |
| NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Monocyte and macrophage polarization | | | | K08AR072075 | 93.846 | - | 197,422 | 197,422 |
| NIH | Cancer Research Manpower | Targeting MBNL1-mediated after | | | | K08CA237753 | 93.398 | - | 249,243 | 249,243 |
| NIH NIH | Biomedical Research and Research Training Cardinyascular Diseases Research | The Role of Olfactomedin 4 in Septic Shock The Role of PPARa in Cardiac Dysfunction | | | | K08GM124298 K08HL133377 | 93.859 93.837 | - | 73,433 150,994 | 73,433 150.994 |
| NIH | Lung Diseases Research | Mechanistic evaluation of a no | | | | K08HL133377 K08HL140178 | 93.837 | - | 160,677 | 150,994 |
| NH | Cardiovascular Diseases Research | A genetic and molecular approa | | | | K08HL143177 | 93.837 | - | 146,642 | 146,642 |
| NIH | Lung Diseases Research | Personalized Model Systems to | | | | K08HL144825 | 93.838 | - | 168,340 | 168,340 |
| NIH | National Center on Sleep Disorders Research | Circadian Clock Dysregulation | | | | K08HL148551 | 93.233 | - | 233,402 | 233,402 |
| NIH NIH | Lung Diseases Research Child Health and Human Development Extramural Research | TGF-Beta Regulates CFTR-Mediat Improving vaccine efficacy by | Come II University | | 215518-3 | K08HL151762 K12HD000850 | 93.838 93.865 | - | 143,532 125,773 | 143,532 125,773 |
| NH | Child Health and Human Development Extramural Research | Rational therapeutic targeting | Comell University | | 215518-2 | K12HD000850 | 93.865 | - | 114,650 | 114,650 |
| NIH | Child Health and Human Development Extramural Research | Mechanisms of increased matem | Comell University | | 215518-8 | K12HD000850 | 93.865 | - | 133,441 | 133,441 |
| NIH | Child Health and Human Development Extramural Research | Child Health Research Career Dev Award | | | | K12HD028827 | 93.865 | - | 408,310 | 408,310 |
| NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Child Health and Human Development Extramural Research | Predicting Severity and Improv Surviving and Thriving in the | | | | K23DK118190 K23HD094855 | 93.847 93.865 | - | 185,009 | 185,009 165,106 |
| NIH | Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research | Surviving and Thriving in the Electrophysiological Biomarker | | | | K23HD094855 K23HD101416 | 93.865 93.865 | - | 165,106 141,203 | 165,106 141,203 |
| NIH | Lung Diseases Research | Using technology-assisted step | | | | K23HL139992 | 93.838 | - | 181,332 | 181,332 |
| NIH | Blood Diseases and Resources Research | Sickle Cell Anemia, Splenic Pa | | Bugando Medical Centre | | K23HL153763 | 93.839 | 3,250 | 179,440 | 182,690 |
| NIH | Mental Health Research Grants | Anomalous Sensorimotor Physiology in Fra | | | | K23MH112936 | 93.242 | - | 119,739 | 119,739 |
| NIH NIH | Mental Health Research Grants Nursing Research | A Family Navigator Interventio Influence of Parent-Nurse Comm | National Institute of Nursing Research | | K23NR017396 | K23MH125138 K23NR017396 | 93.242 93.361 | - | 184,992 36.859 | 184,992 36.859 |
| 1 | | | | | 0141011300 | | | - | 50,000 | 55,055 |

| NIH | Nursing Research | Fertility Status Assessment Am | Emory University | | A567559 | K23NR020037 | 93.361 | - | 2,853 | 2,853 |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------|
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Towards biomarkers of resilien | | | | K23NS117734 | 93.853 | - | 164,960 | 164,960 |
| NIH | Allergy, Immunology and Transplantation Research | Combinatory Effects of Genetic | | | | K99AI158660 | 93.855 | - | 130,083 | 130,083 |
| NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Mitochondrial regulation of ca | | | | K99AR078253 | 93.846 | _ | 79.962 | 79.962 |
| NIH | National Center on Sleep Disorders Research | Improving Outcomes in Pediatri | | | | K99HL144822 | 93.233 | | 65.095 | 65.095 |
| NIH | National Center for Advancing Translational Sciences | Center for Clinical and Transl | University of Cincinnati | | KL2TR001426 | KL2TR001426 | 93.350 | _ | 369.763 | 369.763 |
| NIH | Lung Diseases Research | The RECOVER Post-Acute Sequels | Children's Hospital of Philadelphia | | OT2HL161847 | OT2HL161847 | 93.838 | _ | 143.644 | 143.644 |
| NIH | Allergy, Immunology and Transplantation Research | Molecular Mechanisms of the Dy | Univ of Texas Medical Branch-Galvestor | 1 | 21-85495-01 | P01AI150585 | 93.855 | _ | 164.985 | 164.985 |
| NIH | Child Health and Human Development Extramural Research | Developmental Mechanisms of Trachea | Univ di Texas Medical Bialici-Gawesidi | Columbia University | 2103480-01 | P01HD093363 | 93.865 | 291,556 | 1,033,891 | 1,325,447 |
| | | | | Columbia Oniversity | 447007 0404 5440074 | | 93.865 | 291,556 | | |
| NIH | Child Health and Human Development Extramural Research | Pediatric HIV/AIDS Cohort Stud | Harvard Medical School University of North Carolina | | 117267-0184-5119274 | | 93.855 | - | 28,299 | 28,299 |
| NIH | Allergy, Immunology and Transplantation Research | Conversations that Matter: Inc | University of North Carolina | | 5123535 | P30Al050410 | | | 29,516 | 29,516 |
| NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Cincinnati Rheumatic Diseases Res Center | | Brigham and Women's Hospital | | P30AR070549 | 93.846 | 2,854 | 461,255 | 464,109 |
| NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Pediatric musculOskeletal and | | University of Cincinnati | | P30AR076316 | 93.846 | 3,934 | 613,042 | 616,976 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Digestive Health Center: Bench to Bedside | | | | P30DK078392 | 93.847 | - | 1,218,543 | 1,218,543 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Personalized Cystic Fibrosis T | | | | P30DK117467 | 93.847 | - | 1,335,669 | 1,335,669 |
| NIH | Environmental Health | Elucidating the mechanisim of | University of Cincinnati | | 011429-00080 | P30ES006096 | 93.113 | - | 42,841 | 42,841 |
| NIH | Child Health and Human Development Extramural Research | Xenbase: a Xenopus Model Organ | | University of Calgary | | P41HD064556 | 93.865 | 622,517 | 1,090,705 | 1,713,222 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Critical Translational Studies in Ped Nep | | | | P50DK096418 | 93.847 | | 770,128 | 770,128 |
| NIH | Child Health and Human Development Extramural Research | HEAL Initiative: Antenatal Opi | RTI International | Emory University | 5-312-0217179-65988 | | 93.865 | 28,467 | 196.340 | 224.807 |
| NIH | Cancer Biology Research | The Role of CHAF1B in Maintain | KII III BIII ALDII AI | Emory Oniversity | 3-312-0217178-03800 | R00CA230314 | 93.396 | 20,407 | 267.414 | 267.414 |
| | | | | | | | | - | | |
| NIH | Oral Diseases and Disorders Research | Prolonger progenitor maintenance sculpt | | | | R00DE026239 | 93.121 | - | 209,938 | 209,938 |
| NIH | Cardiovascular Diseases Research | Uncovering compensatory mechan | | | | R00HL135258 | 93.837 | - | 262,464 | 262,464 |
| NIH | Blood Diseases and Resources Research | The racial disparity in platel | | | | R00HL136784 | 93.839 | - | 244,503 | 244,503 |
| NIH | Lung Diseases Research | Early detection of regional BO | | | | R00HL138255 | 93.838 | - | 290,670 | 290,670 |
| NIH | Cardiovascular Diseases Research | Dissecting the role of novel c | | | | R00HL141630 | 93.837 | - | 217,687 | 217,687 |
| NIH | National Center on Sleep Disorders Research | Improving Outcomes in Pediatri | | | | R00HL144822 | 93.233 | _ | 79.616 | 79,616 |
| NIH | Aging Research | Metabolic alterations in age-associated | | University of Cincinnati. | | R01AG053498 | 93.866 | 13.616 | 530.446 | 544,062 |
| NIH | Aging Research | Role of skeletal muscle stem c | | , | | R01AG059605 | 93.866 | | 336.389 | 336,389 |
| NIH | Aging Research | Novel mechanism of intestinal | | | | R01AG063967 | 93.866 | | 839.970 | 839.970 |
| NIH | Aging Research Allergy, Immunology and Transplantation Research | Genetic Linkage in Lupus | | Cinti Foundatn Biomedical Resrch | | R01Al024717 | 93.855 | 148.500 | 164.486 | 312.986 |
| | | | | Cinti Foundath Biomedical Resich | | | | 148,500 | | |
| NIH | Allergy, Immunology and Transplantation Research | Regulation of Gastrointestinal | | | | R01Al045898 | 93.855 | - | 482,019 | 482,019 |
| NIH | Allergy, Immunology and Transplantation Research | Epidemiologic Impact of HPV Va | | Indiana University | | R01Al104709 | 93.855 | 82,255 | 381,218 | 483,152 |
| | | | | Univ. of California | | | | 19,679 | - | |
| NIH | Allergy, Immunology and Transplantation Research | GM-CSF-Induced Metal Sequestra | University of Cincinnati | | 011636-00010 | R01Al106269 | 93.855 | - | 20,574 | 20,574 |
| NIH | Allergy, Immunology and Transplantation Research | L-citrulline and anti-tuberculosis host | | | | R01Al116668 | 93.855 | | 109.816 | 109,816 |
| NIH | Allergy, Immunology and Transplantation Research | Innate mechanisms of regulatio | | | | R01Al123176 | 93.855 | _ | 351.619 | 351,619 |
| NIH | Allergy, Immunology and Transplantation Research | Genetic and Immunological Diss | | | | R01Al124355 | 93.855 | | 201.416 | 201.416 |
| NH | | Functional immune tolerance to non-inheri | | | | | 93.855 | | 244.513 | 244.513 |
| | Allergy, Immunology and Transplantation Research | | | | | R01Al124657 | | - | | |
| NIH | Allergy, Immunology and Transplantation Research | Role and Regulation of TSLP in Childhood | | | | R01Al127392 | 93.855 | - | 874,826 | 874,826 |
| NIH | Allergy, Immunology and Transplantation Research | Role of Aiolos in eosinophilic asthma | | | | R01Al130033 | 93.855 | - | 421,513 | 421,513 |
| NIH | Allergy, Immunology and Transplantation Research | Wimpy antibody isotypes protect against | University of Cincinnati | | 010728-007 | R01Al130103 | 93.855 | - | 10,658 | 10,658 |
| NIH | Allergy, Immunology and Transplantation Research | FORWARD Study-Food Allergy Out | Northwestern University Medical School | | 60057256 CCHMC | R01Al130348 | 93.855 | - | 144,139 | 144,139 |
| NIH | Allergy, Immunology and Transplantation Research | Forward genetic prediction and | Pennsylvania State University | | 5844-CCH-DHHS-269 | R01Al132692 | 93.855 | - | 13,641 | 13,641 |
| NIH | Allergy, Immunology and Transplantation Research | Role of Microbiome in Neonatal | The Regents of the Univ of California | | A18-0659-S001 | R01Al138553 | 93.855 | - | 152,187 | 152,187 |
| NIH | Allergy, Immunology and Transplantation Research | Non-Invasive Diagnosis of Pedi | Duke University | | 248445-A031576 | R01Al139032 | 93.855 | _ | 25 | 25 |
| NIH | Allergy, Immunology and Transplantation Research | Early life factors, gene-envir | Wake Forest University Health Sciences | | 200-45116-100005537 | R01Al139126 | 93 855 | | 61.724 | 61,724 |
| NIH | Allergy, Immunology and Transplantation Research | Translational Regulation of CD | · · · · · · · · · · · · · · · · · · · | | | R01Al139675 | 93.855 | _ | 576.658 | 576,658 |
| NIH | Allergy, Immunology and Transplantation Research | SLC9A3 regulation of esophagea | University of Michigan | | SUBK00011618 | R01Al140133 | 93.855 | | 57,605 | 57,605 |
| | | | | | | | | - | | |
| NIH | Allergy, Immunology and Transplantation Research | Role of TET1 in airway epithel | University of California-Davis | | A20-0494S001 | R01Al141569 | 93.855 | - | 54,059 | 54,059 |
| NIH | Allergy, Immunology and Transplantation Research | Progesterone induced immune mo | | Univ of Pennsylvania | | R01Al145840 | 93.855 | 467,455 | 259,399 | 726,854 |
| NIH | Allergy, Immunology and Transplantation Research | COVID-19 Progesterone induced immune mo | | Univ of Pennsylvania | | COVID-19 R01Al145840-03S1 | 93.855 | 381,720 | 21,246 | 402,966 |
| NIH | Allergy, Immunology and Transplantation Research | Rapid, safe suppression of IgE | University of Cincinnati | | 012329-003 | R01Al145991 | 93.855 | - | 112,149 | 112,149 |
| NIH | Allergy, Immunology and Transplantation Research | Targeting natural killer cells | | Duke University | | R01Al148080 | 93.855 | 97,388 | 599,965 | 697,353 |
| NIH | Allergy, Immunology and Transplantation Research | Roles of FFAR 3-SCFA axis in T | | | | R01Al148138 | 93.855 | | 268,265 | 268,265 |
| NIH | Allergy, Immunology and Transplantation Research | Genomics of Inflammatory Bowel | | Emory University | | R01Al148276 | 93.855 | 2,908 | 1,067,092 | 1,091,504 |
| | 37, 37 | · · | | University of Cincinnati | | | | 21,504 | - | |
| NIH | Biomedical Research and Research Training | Role of Vpu, Tetherin, and Sig | | University of Wisconsin System | | R01Al150475 | 93.859 | 40,314 | 372,994 | 413,308 |
| NH | Allergy, Immunology and Transplantation Research | Viral and Cellular Determinant | | | | R01AI150486 | 93.855 | | 346.921 | 346,921 |
| | | | | | | | | - | | |
| NIH | Allergy, Immunology and Transplantation Research | An experimentally-refined, dyn | 0.11-1.11-1.15 | | OFNEDODODOG477 | R01Al153442 | 93.855 | - | 634,386 | 634,386 |
| NIH | Allergy, Immunology and Transplantation Research | Immunobiology of Influenza Vr | Children's Hospital Boston | | GENFD0002024871 | R01Al154470 | 93.855 | - | 64 | 64 |
| NIH | Allergy, Immunology and Transplantation Research | Proteasome targeting for allor | University of Pennsylvania | | 580121 | R01Al154932 | 93.855 | - | 370,306 | 370,306 |
| NIH | Allergy, Immunology and Transplantation Research | Regulation of TLR signaling, I | Helicanillo of Charles | Univ of Texas Southwestern | 0.42020.00222 | R01Al155426 | 93.855 | 105,080 | 389,485 | 494,565 |
| NIH | Allergy, Immunology and Transplantation Research | Regulation of C. difficile col | University of Cincinnati | | 013939-00002 | R01Al158451 | 93.855 | - | 7,512 | 7,512 |
| NIH | Allergy, Immunology and Transplantation Research | Pay-it-forward gonorrhea testi | University of North Carolina | | 5123479/1R01AI15882 | | 93.855 | - | 49,729 | 49,729 |
| NIH | Allergy, Immunology and Transplantation Research | Leveraging Health Information | Children's National Medical Center | | 30007046 | R01Al163232 | 93.855 | - | 7,416 | 7,416 |
| NIH | Allergy, Immunology and Transplantation Research | Hyperhydration to Improve Kidn | University of Calgary | | R01Al165327 | R01Al165327 | 93.855 | - | 2,611 | 2,611 |
| NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Deciphering mechanisms of myob | | | | R01AR068286 | 93.846 | - | 308,243 | 308,243 |
| NIH | | | | | | | | | | 1.407.409 |
| | Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT | | Children's Hospital Boston | | R01AR070474 | 93.846 | 40.961 | | |
| | | | | Children's Hospital Boston Children's Mercy Hospital | | | | 40,961 169,055 | 750,522 | |
| | | | | Children's Mercy Hospital | | | | 169,055 | 750,522 | |
| | | | | Children's Mercy Hospital Connecticut Children's Medical Center | | | | 169,055 200,316 | 750,522 | |
| | | | | Children's Mercy Hospital Connecticut Children's Medical Center Emory University | | | | 169,055 | 750,522 - - - | |
| | | | | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University | | | | 169,055 200,316 47,650 96,844 | 750,522 - - - | |
| | | | | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University Nationwide Children's Hospital | | | | 169,055 200,316 47,650 96,844 83,845 | 750,522 - - - - - - | |
| | Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT | | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University | s | R01AR070474 | 93.846 | 169,055 200,316 47,650 96,844 | - - - - | |
| NIH | Arthritis, Musculoskeletal and Skin Diseases Research Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT | | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University Nationwide Children's Hospital The Ohio Stale University-Spon Program | s | R01AR070474 | 93.846 93.846 | 169,055 200,316 47,650 96,844 83,845 18,216 | - - - - - - 323,856 | 323,856 |
| NIH NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT | | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University Nationwide Children's Hospital | s | R01AR070474 | 93.846 | 169,055 200,316 47,650 96,844 83,845 | - - - - | 323,856 418,091 |
| | Arthritis, Musculoskeletal and Skin Diseases Research Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT | | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University Nationwide Children's Hospital The Ohio Stale University-Spon Program | s | R01AR070474 | 93.846 93.846 | 169,055 200,316 47,650 96,844 83,845 18,216 | - - - - - - 323,856 | |
| | Arthritis, Musculoskeletal and Skin Diseases Research Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT | Nationwide Children's Hospital | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University Nationwide Children's Hospital The Ohio State University- Spon Program Boston University | s 700165-0519-00 | R01AR070474 | 93.846 93.846 | 169,055 200,316 47,650 96,844 83,845 18,216 - 33,127 | - - - - - - 323,856 | |
| NIH | Arthritis, Musculoskeletal and Skin Diseases Research Arthritis, Musculoskeletal and Skin Diseases Research Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT In vivo role of the fibroblast in muscular dys Transcription Factor Genetics | Nationwide Children's Hospital | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University Nationwide Children's Hospital The Ohio State University- Spon Program Boston University | | R01AR070474 R01AR071301 R01AR073228 | 93.846 93.846 93.846 | 169,055 200,316 47,650 96,844 83,845 18,216 - 33,127 | | 418,091 |
| NIH NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT In vivo role of the fibroblast in muscular dys Transcription Factor Genetics Complement in Human Lupus: Def GSK3 beta study in patients w | Nationwide Children's Hospital Children's Hospital of Philadelehia | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University Nationwide Children's Hospital The Ohio State University- Spon Program Boston University | 700165-0519-00 | R01AR070474 R01AR071301 R01AR073228 R01AR073311 R01AR073379 | 93.846 93.846 93.846 93.846 93.846 | 169,055 200,316 47,650 96,844 83,845 18,216 - 33,127 | 323,856 375,438 9,769 363,956 | 418,091 9,769 363,956 |
| NIH NIH NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT In vivo role of the fibroblast in muscular dys Transcription Factor Genetics Complement in Human Lupus: Def GSK3 beta study in patients w Refining entry criteria and ou | | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University Nationwide Children's Hospital The Ohio State University-Spon Program Boston University New York University School of Medicine | | R01AR070474 R01AR071301 R01AR073228 R01AR073311 R01AR073379 R01AR073079 | 93.846 93.846 93.846 93.846 93.846 93.846 | 169,055 200,316 47,650 96,844 83,845 18,216 - 33,127 9,526 | - - - - 323,856 375,438 - 9,769 363,956 250 | 418,091 9,769 363,956 250 |
| NIH NIH NIH NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT In vivo role of the fibroblast in muscular dys Transcription Factor Genetics Complement in Human Lupus: Def GSK3 beta study in patients wi Refining ently criteria and ou Identifying neural pathophysio | | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University Indiana University Nationwide Children's Hospital The Ohio State University-Spon Pogram Boston University New York University School of Medicine Universitat De Barcolona | 700165-0519-00 | R01AR070474 R01AR071301 R01AR073228 R01AR073311 R01AR073379 R01AR074096 R01AR074795 | 93.846 93.846 93.846 93.846 93.846 93.846 | 169,055 200,316 47,650 96,844 83,845 18,216 - - - - - - - - - - - - - - - - - - - | | 9,769 363,956 250 371,023 |
| NIH NIH NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT In vivo role of the fibroblast in muscular dys Transcription Factor Genetics Complement in Human Lupus: Def GSK3 beta study in patients w Refining entry criteria and ou | | Children's Mercy Hospital Connecticut Children's Medicial Center Emory University Indiana University Nationwite Children's Hospital The Ohio State University. Spon Program Boston University New York University School of Medicine Universitat De Barcelona Children's Hospital of Philadelphia | 700165-0519-00 | R01AR070474 R01AR071301 R01AR073228 R01AR073311 R01AR073379 R01AR073079 | 93.846 93.846 93.846 93.846 93.846 93.846 | 169,055 200,316 47,650 96,844 83,845 18,216 - - - - - - - - - - - - - - - - - - - | - - - - 323,856 375,438 - 9,769 363,956 250 | 418,091 9,769 363,956 250 |
| NIH NIH NIH NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT In vivo role of the fibroblast in muscular dys Transcription Factor Genetics Complement in Human Lupus: Def GSK3 beta study in patients wi Refining ently criteria and ou Identifying neural pathophysio | | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University Indiana University Nationwide Children's Hospital The Ohio State University-Spon Program Boston University New York University School of Medicine Universitat De Barcolona Children's Hospital of Philadelphia Duke University | 700165-0519-00 | R01AR070474 R01AR071301 R01AR073228 R01AR073311 R01AR073379 R01AR074096 R01AR074795 | 93.846 93.846 93.846 93.846 93.846 93.846 | 169,056 200,316 47,650 96,844 83,845 18,216 | | 9,769 363,956 250 371,023 |
| NIH NIH NIH NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT In vivo role of the fibroblast in muscular dys Transcription Factor Genetics Complement in Human Lupus: Def GSK3 beta study in patients wi Refining ently criteria and ou Identifying neural pathophysio | | Children's Mercy Hospital Connecticut Children's Medicial Center Emory University Indiana University Indiana University Indiana University Spon Pogram Boston University New York University School of Medicine Universitat De Barcolona Children's Hospital of Philadelphia Duke University Johns Hoppina University Johns Hoppina University | 700165-0519-00 | R01AR070474 R01AR071301 R01AR073228 R01AR073311 R01AR073379 R01AR074096 R01AR074795 | 93.846 93.846 93.846 93.846 93.846 93.846 | 169,055 200,316 47,650 98,844 83,845 18,216 | | 9,769 363,956 250 371,023 |
| NIH NIH NIH NIH NIH | Arthritis, Musculoskeletal and Skin Diseases Research Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT In vivo role of the fibroblast in muscular dys Transcription Factor Genetics Complement in Human Lupus: Def GSK3 beta study in patients w Refining entry criteria and cu Identifying neural pathophysio Epigenetic Determinants htfue | | Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University Indiana University Nationwide Children's Hospital The Ohio State University-Spon Program Boston University New York University School of Medicine Universitat De Barcolona Children's Hospital of Philadelphia Duke University | 700165-0519-00 | R01AR070474 R01AR071301 R01AR073228 R01AR073311 R01AR073379 R01AR074098 R01AR074795 R01AR075857 | 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 | 169,056 200,316 47,650 96,844 83,845 18,216 | 322,856 375,438 9,769 363,956 250 302,540 543,857 | 9,769 363,956 250 371,023 611,785 |
| NIH NIH NIH NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT In vivo role of the fibroblast in muscular dys Transcription Factor Genetics Complement in Human Lupus: Def GSK3 beta study in patients wi Refining ently criteria and ou Identifying neural pathophysio | | Children's Mercy Hospital Connecticut Children's Medicial Center Emory University Indiana University Indiana University Indiana University Spon Pogram Boston University New York University School of Medicine Universitat De Barcolona Children's Hospital of Philadelphia Duke University Johns Hoppina University Johns Hoppina University | 700165-0519-00 | R01AR070474 R01AR071301 R01AR073228 R01AR073311 R01AR073379 R01AR074096 R01AR074795 | 93.846 93.846 93.846 93.846 93.846 93.846 | 169,055 200,316 47,650 98,844 83,845 18,216 | | 9,769 363,956 250 371,023 |
| NIH NIH NIH NIH NIH | Arthritis, Musculoskeletal and Skin Diseases Research Arthritis, Musculoskeletal and Skin Diseases Research | Multi-site Randomized Clinical Trial of FIT In vivo role of the fibroblast in muscular dys Transcription Factor Genetics Complement in Human Lupus: Def GSK3 beta study in patients w Refining entry criteria and cu Identifying neural pathophysio Epigenetic Determinants htfue | | Children's Mercy Hospital Connecticut Children's Medicial Center Emory University Indiana University Indiana University Indiana University Spon Pogram Boston University New York University School of Medicine Universitat De Barcolona Children's Hospital of Philadelphia Duke University Johns Hoppina University Johns Hoppina University | 700165-0519-00 | R01AR070474 R01AR071301 R01AR073228 R01AR073311 R01AR073379 R01AR074098 R01AR074795 R01AR075857 | 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 | 169,055 200,316 47,650 98,844 83,845 18,216 | 322,856 375,438 9,769 363,956 250 302,540 543,857 | 9,769 363,956 250 371,023 611,785 |

| NIH | Research and Training in Complementary and Alternative Medicine | Systems biology of microbe-med | University of Virginia | | R01AT010253 | R01AT010253 | 93.213 | - | 978 | 978 |
|------------|----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|----------------------------------------|-----------------------------------------|---------------------|----------------------------|------------------|---------|-------------------|-------------------|
| NIH | Cancer Biology Research | Coagulation factors modifiers of the colon | | | | R01CA204058 | 93.396 | - | 5,619 | 5,619 |
| NIH | Cancer Biology Research | Leukemia stem cell polarity and different | | | | R01CA204895 | 93.396 | - | 412,402 | 412,402 |
| NIH | Cancer Treatment Research | Linked regulation of tumor angiogenesis | | | | R01CA207068 | 93.395 | - | 187,394 | 187,394 |
| NIH | Cancer Treatment Research | Mechanism of non-oncogene addiction | | | | R01CA211594 | 93.395 | - | 345,328 | 345,328 |
| NIH | Cancer Treatment Research | Targeting TET1 signaling to treat acute mye | City of Hope | | 60677.2004668.66930 | R01CA211614 | 93.395 | - | 35,552 | 35,552 |
| NIH | Cancer Cause and Prevention Research | Instructive role of MLL fusion proteins in line | The University of Chicago | | AWD064422 (5306708 | R01CA215504 | 93.393 | - | 295,569 | 295,569 |
| NIH | Cancer Biology Research | Mechanisms coupling DEK to oncogenesis | | | | R01CA218072 | 93.396 | - | 302,403 | 302,403 |
| NIH | Cancer Treatment Research | Innovative Pain and Symptom Ma | Univ of California | | 2018-3581 | R01CA222012 | 93.395 | - | 11,762 | 11,762 |
| NIH | Cancer Biology Research | FA pathway activities in norma | | | | R01CA223790 | 93.396 | - | 316,345 | 316,345 |
| NIH | Cancer Cause and Prevention Research | Research Into Visual Endpoints | Vanderbilt University Medical Center | | VUMV67585 | R01CA225005 | 93.393 | - | 18,404 | 18,404 |
| NIH | Cancer Cause and Prevention Research | Unbiased identification of spl | | | | R01CA226802 | 93.393 | - | 630,245 | 630,245 |
| NIH | Cancer Detection and Diagnosis Research | Integrated Informatic and Expe | University of Pennsylvania | | 577035 | R01CA227485 | 93.394 | - | 327,306 | 327,306 |
| NIH | Cancer Cause and Prevention Research | Strenghening epidermal defense | | | | R01CA228113 | 93.393 | - | 444,136 | 444,136 |
| NIH | Cancer Treatment Research | (PQ10) Role of Gut Microbiota | The University of Texas Southwestern | | PO: 000001910A GM | DR01CA231303 | 93.395 | - | 93,576 | 93,576 |
| NIH | Cancer Biology Research | The role of transcription elon | | | | R01CA234038 | 93.396 | - | 450,922 | 450,922 |
| NIH | Cancer Treatment Research | Targeted Inhibition in Leukemi | | | | R01CA237016 | 93.395 | - | 450,959 | 450,959 |
| NIH | Cancer Biology Research | New activities of the human DE | | University of Kentucky | | R01CA239605 | 93.396 | 27,280 | 471,863 | 499,143 |
| NIH | Cancer Treatment Research | Co-targeting S6 and TAM kinas | University of Cincinnati | | 12653-002 | R01CA239657 | 93.395 | - | 23,274 | 23,274 |
| NIH | Cancer Biology Research | Defining genetic and metabolic | University of Cincinnati | | 012828-002 | R01CA239697 | 93.396 | - | 164,336 | 164,336 |
| NIH | Cancer Biology Research | Patho-Genetic Analysis of Inva | | Massachusetts General Hospital | | R01CA240317 | 93.396 | 111,161 | 227,931 | 513,777 |
| | | | | University of Utah | | | | 174,685 | - | |
| NIH | Cancer Biology Research | The Role of HIF1A-DNMT3A axis | University of Minnesota | | H0085223701 | R01CA248019 | 93.396 | - | 31,066 | 31,066 |
| NIH | Cancer Treatment Research | Mechanism of Therapy in high-r | | | | R01CA250516 | 93.395 | - | 670,287 | 670,287 |
| NIH | Cancer Biology Research | Modeling myebdysplasia | | Johns Hopkins University | | R01CA253981 | 93.396 | 86,980 | 293,935 | 461,849 |
| | | | | Yale University | | | | 80,934 | - | |
| NIH | Cancer Treatment Research | Therapeutic resistance and agg | University of Cincinnati | | 013734-00002 | R01CA255331 | 93.395 | - | 14,626 | 14,626 |
| NIH | Cancer Biology Research | Dissecting innate immune signa | | | | R01CA271455 | 93.396 | - | 58,337 | 58,337 |
| NIH | Drug Abuse and Addiction Research Programs | Role of Siglec-1 in HIV Intera | | University of Cincinnati | | R01DA051895 | 93.279 | 15,439 | 491,921 | 507,360 |
| NIH | Research Related to Deafness and Communication Disorders | Prevention of Ototoxicity with | | Oregon Health & Science University | | R01DC017867 | 93.173 | 260,962 | 341,639 | 617,058 |
| | | | | Washington University | | | | 14,457 | | |
| NIH | Research Related to Deafness and Communication Disorders | Pediatric dysphonia: Multidisc | University of South Florida | | 1219-1068-00-B | R01DC018008 | 93.173 | - | 53,540 | 53,540 |
| NIH | Research Related to Deafness and Communication Disorders | Technology-assisted language i | | Children's Hospital Colorado | | R01DC018550 | 93.173 | 4,001 | 592,752 | 717,693 |
| | | | | University of Colorado | | | | 120,940 | - | |
| NIH | Research Related to Deafness and Communication Disorders | Earliest predictors of languag | | University of Cincinnati | | R01DC018734 | 93.173 | 32,792 | 863,800 | 896,592 |
| NIH | Research Related to Deafness and Communication Disorders | Neuroimaging Reveals Treatment | University of Cincinnati | | 013916-00002 | R01DC019337 | 93.173 | - | 39,271 | 39,271 |
| NIH | Oral Diseases and Disorders Research | Developing Topical Fluoride He | University of Washington | | UWSC10797 | R01DE026741 | 93.121 | - | 64,925 | 64,925 |
| NIH | Oral Diseases and Disorders Research | Mandible Development | | | | R01DE027046 | 93.121 | - | 687,908 | 687,908 |
| NIH | Oral Diseases and Disorders Research | Stottmann R01 Subaward from Na | Nationwide Children's Hospital | | 700262-0622 | R01DE027091 | 93.121 | - | 32,373 | 32,373 |
| NIH | Oral Diseases and Disorders Research | Regulation of Craniofacial Dev | | | | R01DE029417 | 93.121 | - | 564,874 | 564,874 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Immunologic Dysfunction in Bil | | | | R01DK064008 | 93.847 | - | 417,529 | 417,529 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Adolescent Bariatric Surgery: | | Sanford Research North | | R01DK080020 | 93.847 | 46,581 | 533,600 | 619,134 |
| | | | | The CDM Group, Inc | | | | 38,953 | - | |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Inhibition of an Apical cAMP/c | | St Jude Children's Research Hospital | | R01DK080834 | 93.847 | 13,484 | 49,022 | 62,506 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Biological Basis of Phenotypes | | | | R01DK083781 | 93.847 | - | 673,117 | 673,117 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Genetic basis of virus induced | | University of Cincinnati | | R01DK091566 | 93.847 | 9,619 | 442,242 | 451,861 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Control of hepatic T cell resp | | | | R01DK095001 | 93.847 | - | 348,960 | 348,960 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Immunopathogenesis of non-alco | | | | R01DK099222 | 93.847 | - | 674,694 | 674,694 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | The Mechanism Regulating Renal Progen | | | | R01DK106225 | 93.847 | - | 34,235 | 34,235 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Mechanisms of genetic risk at 2p23 in Eos | | | | R01DK107502 | 93.847 | - | 110,628 | 110,628 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Role of Hepatic RNA Silencing in Insulin Re | | | | R01DK107530 | 93.847 | - | 19,272 | 19,272 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Building a functional biliary system from hep | | | | R01DK107553 | 93.847 | - | 283,558 | 283,558 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Nonlinear Ultrasound: an Imaging Biom | University of Michigan | | 3004067897 | 7 R01DK109032 | 93.847 | - | 43,864 | 43,864 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Advancing Treatment for Pancreatitis | University of Minnesota | | N005115002 | R01DK109124 | 93.847 | - | 6,294 | 6,294 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Mapping Disease Pathways for B | University of Pittsburgh | | CNVA00054687 (1295 | 5 R01DK109365 | 93.847 | - | 14,473 | 14,473 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Level and timing of diabetic hyperglycemia | | MedStar Health Research Institute, Inc. | | R01DK109956 | 93.847 | 28,268 | 546,394 | 604,620 |
| | | | | Tufts Medical Center, Inc | | | | 29,958 | - | |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Fibrin(ogen) control of metabo | University of North Carolina | | 5116413 | R01DK112778 | 93.847 | - | 17,459 | 17,459 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Targeting IRAK1/4 in Myelodysplastic Syn | | | | R01DK113639 | 93.847 | - | 146,404 | 146,404 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Epigenomic control of antimicrobial immun | | University of Cincinnati | | R01DK114123 | 93.847 | 30,968 | 317,415 | 348,383 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Host integration of commensal | | | | R01DK116868 | 93.847 | - | 273,009 | 273,009 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Type 2 cytokines and innate ly | | | | R01DK117119 | 93.847 | - | 54,493 | 54,493 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Molecular targets in cholestas | | | | R01DK117266 | 93.847 | - | 334,445 | 334,445 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Manipulating DNA Damage-respon | | | | R01DK117632 | 93.847 | - | 351,897 | 351,897 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Biomarkers for Urinary Tract I | University of Pittsburgh | | AWD00000120 (1325 | | 93.847 | - | 15,062 | 15,062 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Surgical or Medical Treatment | | University of Colorado | | R01DK119450 | 93.847 | 92,820 | 298,010 | 390,830 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | The role of SPRY2 in the colon | Children's Hospital Los Angeles | | RGF011923-A | R01DK119694 | 93.847 | - | 606 | 606 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Molecular regulation of hepati | | | | R01DK120765 | 93.847 | - | 320,053 | 320,053 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Hox Genes and Lineage Infideli | | | | R01DK120842 | 93.847 | - | 704,752 | 704,752 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Retinoic acid gene regulatory | | | | R01DK120847 | 93.847 | - | 261,831 | 261,831 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Regulation of functionally dis | | | | R01DK121062 | 93.847 | - | 536,227 | 536,227 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Diabetes Journey: From systema | | University of Florida | | R01DK121295 | 93.847 | 151,577 | 251,277 | 402,854 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Molecular mechanisms for bone | Northwestern University Medical School | | 60052734 CCHMC | R01DK121354 | 93.847 | - | 16,835 | 16,835 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Sox Proteins Modulate Genomic | | | | R01DK123092 | 93.847 | - | 391,883 | 391,883 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Role of extracellular vesicle | | Vanderbilt University | | R01DK123181 | 93.847 | 26,737 | 665,848 | 692,585 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Regulation of Niche Cell Diffe | Case Western University | | RES516540 | R01DK123299 | 93.847 | - | 16,867 | 16,867 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Mitochondria mediated intercel | | | | R01DK124115 | 93.847 | - | 391,244 | 391,244 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Microbiota-mediated fibrotic r | University of North Carolina | | 5117429 | R01DK124617 | 93.847 | - | 12,679 | 12,679 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Host and viral determinants of | Children's Hospital of Philadelphia | | 25460-GRT-0000414 | | 93.847 | - | 336,301 | 336,301 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Gene regulatory networks in th | | | | R01DK125577 | 93.847 | - | 390,214 | 390,214 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Determinants of inception of i | Massachusetts General Hospital | | 239459 | R01DK127171 | 93.847 | - | 66,618 | 66,618 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Limited Competition for the Cl | Wake Forest University Health Sciences | 11-1-1-1-1-1 | 241-100710-553791 | R01DK127208 | 93.847 | - | 19,404 | 19,404 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Changing Health And Lifestyle | | University of Delaware | | R01DK128525 | 93.847 | 802 | 140,865 | 141,667 |
| NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Hedgehog gene regulatory netwo Structure, function, and modul | The University of Chicago | | AWD102456SUB0000 | R01DK131052 | 93.847 93.847 | - | 140,946 19.860 | 140,946 19.860 |
| NH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Structure, function, and modul Precise Infliximab Exposure an | The oniversity of chicago | | V4AD 10542020R0000 | R01DK131542 R01DK132408 | 93.847 | - | 19,860 17,236 | 19,860 17,236 |
| NH | Diabetes, Digestive, and Kidney Diseases Extramural Research Discovery and Applied Research for Tech Innovations to Improve Human Hea | | Children's National Medical Center | | 30004680-03 | R01DK132408 R01EB025179 | 93.847 | - | 17,236 | 17,236 |
| T-meri | Discovery and Applied research for recit inflovations to improve Human. Hes | activity of the particle is to post for Ittipio | Cimpletto Manorial Medical Cellief | | J-3004000-03 | ILDUZJ 118 | 93.200 | - | 121,900 | 127,900 |

| NIH | Discovery and Applied Research for Tech Innovations to Improve Human Heal | | | | | R01EB029944 | 93.286 | - | 589,652 | 589,652 |
|------------|----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------------|---------------------------------|----------------------------|------------------|------------------|--------------------|----------------------|
| NIH | Discovery and Applied Research for Tech Innovations to Improve Human Heal | thQuantification of Liver Fibros | | New York University School of Medicine University of Michigan | | R01EB030582 | 93.286 | 28,584 26.839 | 429,661 | 520,712 |
| | | | | University of Wisconsin System | | | | 35,628 | - | |
| NIH | Discovery and Applied Research for Tech Innovations to Improve Human Heal | IthMRI-Compatible Robot for Real- | Children's National Medical Center | | 30006761-01 | R01EB031084 | 93.286 | - | 87,742 | 87,742 |
| NIH | Environmental Health | Developmental Effects of Manga | University of Kentucky | | 5R01ES026446 | R01ES026446 | 93.113 | - | 66,786 | 66,786 |
| NIH | Environmental Health | Prenatal Exposure to Endocrine | Pennsylvania State University | | S000447-NIH | R01ES026903 | 93.113 | - | 7,131 | 7,131 |
| NIH | Environmental Health | Internalizing Behaviors and Neuroimaging | | University of Cincinnati | | R01ES027224 | 93.113 | 8,192 | 302,330 | 314,743 |
| | | | | University of Pennsylvania | | | | 4,221 | - | |
| NIH | Environmental Health | Contribution of Thirdhand Smoke to | | San Diego State Univ. | | R01ES027815 | 93.113 | 150,067 | 133,866 | 304,063 |
| NIH | Environmental Health | Impact of pre- and postnatal c | University of Pennsylvania | University of Cincinnati | 580431 | R01ES028277 | 93.113 | 20,130 | 328,258 | 328,258 |
| NH | Environmental Health | Longitudinal Study of Endocrin | University of Cincinnati | | 011720-002 | R01ES029133 | 93.113 | - | 37,364 | 37.364 |
| NIH | Environmental Health | Endocrine disrupting chemical | Johns Hopkins University | | 2005393998 | R01ES030078 | 93.113 | - | 294,962 | 294,962 |
| NIH | Environmental Health | Effects of DDE exposure on adi | University of Southern California | | 129965417 | R01ES030364 | 93.113 | - | 13,922 | 13,922 |
| NIH | Environmental Health | ADVOCATE: Prevalence and Clini | | San Diego State Univ. | | R01ES030743 | 93.113 | 324,355 | 429,301 | 778,610 |
| | | | | University of Cincinnati | | | | 24,954 | | |
| NIH NIH | Environmental Health Environmental Health | Epigenetics, Air Pollution, an Longitudinal Impact of Air Pol | University of Cincinnati | Brown University | 013074-00003 | R01ES031054 R01ES031621 | 93.113 93.113 | 17,709 | 174,547 941,440 | 174,547 1,009,283 |
| NIT | Environmental realin | Eoriginal Impact of All Pol | | University of Cincinnati | | R0 (E3031621 | 93.113 | 50.134 | 941,440 | 1,009,203 |
| NIH | Environmental Health | Gene-pesticide interactions an | | Chirolotty of Calculates | | R01ES032270 | 93.113 | - | 461,678 | 461,678 |
| NIH | Environmental Health | Gestational PFAS Mixture Expos | Brown University | | 1R01ES032836-01 | R01ES032836 | 93.113 | - | 32,736 | 32,736 |
| NIH | Vision Research | Regulation of vascular dev in the eye | | Cleveland Clinic Foundation | | R01EY027077 | 93.867 | 210,808 | 20,749 | 231,557 |
| NIH | Vision Research | Gene Therapy of Corneal Dystro | University of Cincinnati | | 012501-002 | R01EY029427 | 93.867 | - | 16,404 | 16,404 |
| NIH | Vision Research | Predicting uveitis onset in ch | | Children's Hospital Boston | | R01EY030521 | 93.867 | 1,279 | 340,341 | 367,968 |
| | | | | Children's Hospital of Philadelphia | | | | 955 109 | - | |
| | | | | University of California University of Cincinnati | | | | 11.330 | - | |
| | | | | Wake Forest Univ School of Medicine | | | | 13,954 | _ | |
| NIH | Vision Research | RNA Nanoparticles for Ocular D | University of Cincinnati | | 013457-003 | R01EY031452 | 93.867 | - | 12,837 | 12,837 |
| NIH | Vision Research | Light regulated vascular devel | • | | | R01EY032029 | 93.867 | - | 456,879 | 456,879 |
| NIH | Vision Research | Mechanisms of intrinsic light | | Georgia Tech Research Corporation | | R01EY032752 | 93.867 | 9,214 | 312,893 | 415,652 |
| NIH | Vision Research | | | University of Alabama at Birmingham | | | | 60,966 | - | |
| NIH | Vision Research Riomedical Research and Research Training | | | Washington University | | | | 32,579 | - | |
| NIH NIH | Biomedical Research and Research Training Biomedical Research and Research Training | Biochemical and Computational Analysis Mechanisms of Homeodomain Tran | | University of Cincinnati | | R01GM055479 R01GM079428 | 93.859 93.859 | 107.597 | 467,819 385,352 | 467,819 492,949 |
| NIH | Biomedical Research and Research Training | Studies of Metal-Dependent Intercellular | | University of Colorado | | R01GM094363 | 93.859 | 49,033 | 236,619 | 285,652 |
| NIH | Biomedical Research and Research Training | Age-Dependent Mechanism Of Me | | | | R01GM115973 | 93.859 | - | 526,890 | 526,890 |
| NIH | Biomedical Research and Research Training | Epigenetic Reg of Gene Express during | University of California-Davis | | A21-3093-S001 | R01GM122776 | 93.859 | - | 12,531 | 12,531 |
| NIH | Biomedical Research and Research Training | Role of STAT3 in sepsis-induced adipose | | | | R01GM126551 | 93.859 | - | 346,717 | 346,717 |
| NIH | Biomedical Research and Research Training | Role of Vpu, Tetherin, and Sig | | | | R01GM132068 | 93.859 | - | 8,376 | 8,376 |
| NIH NIH | Biomedical Research and Research Training Child Health and Human Development Extramural Research | Functional characterization of Prenatal Genetic Diagnosis by | Columbia University Medical Center | The Ohio State University | 1(GG014633-01) | R01GM134731 R01HD055651 | 93.859 93.865 | 43,162 | 247,082 88,011 | 290,244 88.011 |
| NH | Child Health and Human Development Extramural Research | Molecular signaling in uterine receptivity | Columbia Oniversity Medical Certer | | 1(GG014033-01) | R01HD068524 | 93.865 | - | 355.350 | 355,350 |
| NH | Child Health and Human Development Extramural Research | Long-Term Outcomes of Interven | Oklahoma State University | | 1-571918-CHMC | R01HD074579 | 93.865 | - | 13.721 | 13.721 |
| NIH | Child Health and Human Development Extramural Research | A Cognitive Test Battery for | University of California-Davis | | A20-1951-S006 | R01HD076189 | 93.865 | - | 111,880 | 111,880 |
| NIH | Child Health and Human Development Extramural Research | Bone Mineral Accretion in Young Children | | Children's Hospital of Philadelphia | | R01HD076321 | 93.865 | 16,130 | 50,359 | 66,489 |
| NIH | Child Health and Human Development Extramural Research | Improving ADHD Teen Driving by Targeting | | Saint Louis University | | R01HD084430 | 93.865 | 2,240 | 191,296 | 193,536 |
| NIH | Child Health and Human Development Extramural Research | The role of executive functions in reading | | Kennedy Krieger Institute, Inc. | | R01HD086011 | 93.865 | 17,681 | 36,291 | 93,728 |
| NIH | Child Health and Human Development Extramural Research | Decision-Making for Patients Born with dif | University of Michigan | Technion Research & Development | 000 440 5000 | R01HD086583 | 93.865 | 39,756 | 67.417 | 67.417 |
| NIH NIH | Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research | PED Screen: Pediatric Sepsis EHR Rea | Northwestern University Medical School | | 3004425008 60046347 CCHMC | R01HD085383 | 93.865 | | 25.490 | 25.490 |
| NIH | Child Health and Human Development Extramural Research | Premature Infants Receiving Co | Sharp HealthCare Foundation | | #R012021 Cincinnati | R01HD088646 | 93.865 | _ | 10,554 | 10,554 |
| NIH | Child Health and Human Development Extramural Research | Identifying Pharmacogenomic Predictors of | | Duke University | | R01HD089928 | 93.865 | 59,346 | 79,791 | 139,137 |
| NIH | Child Health and Human Development Extramural Research | FA DDR Pathway in Germline Integrity | | | | R01HD089932 | 93.865 | - | 175,612 | 175,612 |
| NIH | Child Health and Human Development Extramural Research | VIRTUUS Children's Study-Valid | Children's Hospital of Philadelphia | | 3200880522 | R01HD091185 | 93.865 | - | 6,319 | 6,319 |
| NIH | Child Health and Human Development Extramural Research | The Effect of Emergency Depart | Medical College of Wisconsin | | R01HD091302 | R01HD091302 | 93.865 | - | 42,031 | 42,031 |
| NIH NIH | Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research | Development and Testing of a P Harnessing "omics": A Systems Biology app | Nationwide Children's Hospital | | 700171-0719-00 | R01HD091347 R01HD091527 | 93.865 93.865 | - | 21,551 1,038 | 21,551 1.038 |
| NIH | Child Health and Human Development Extramural Research | Vocational Fit Assessment and | Colorado State University | | R01HD092474 | R01HD092474 | 93.865 | - | 76,798 | 76,798 |
| NIH | Child Health and Human Development Extramural Research | Disorders/Differences of Sex Development | University of Michigan | | SUBK00008039 | R01HD093450 | 93.865 | = | 42,576 | 42,576 |
| NIH | Child Health and Human Development Extramural Research | CES1 Genetic Variation Influen | University of Florida | | SUB00001726 | R01HD093612 | 93.865 | - | 104,301 | 104,301 |
| NIH | Child Health and Human Development Extramural Research | A multicenter collaborative d | Children's National Medical Center | | 30004927-01 | R01HD093622 | 93.865 | - | 50,800 | 50,800 |
| NIH | Child Health and Human Development Extramural Research | Early Childhood Communication | University of California-Davis | | A19-0460-S002 | R01HD093654 | 93.865 | - | 110,612 | 110,612 |
| NIH NIH | Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research | High-Intensity Interval Traini Cognitive Outcome Measures in | University of Cincinnati | Colorado State University | 011445-02 | R01HD093694 R01HD093754 | 93.865 93.865 | 604.119 | 11,424 532,417 | 11,424 1.136.536 |
| NIH NIH | Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research | Thrombotic microangiopathy (TM | | The Hospital for Sick Children | | R01HD093754 R01HD093773 | 93.865 | 16.157 | 532,417 467,179 | 496.280 |
| | | | | University of Cincinnati. | | | | 12,944 | | ,200 |
| NIH | Child Health and Human Development Extramural Research | Improving the Detection of ST | Children's National Medical Center | | 30004942-05 | R01HD094213 | 93.865 | - | 87,834 | 87,834 |
| NIH | Child Health and Human Development Extramural Research | Exploring vascular-mesenchymal | | | | R01HD094698 | 93.865 | - | 341,734 | 341,734 |
| NIH | Child Health and Human Development Extramural Research | Dosing and Pilot Efficacy of 2 | | Connecticut Childrens Medical Center | | R01HD094862 | 93.865 | 97,198 | 398,701 | 680,273 |
| | | | | Nationwide Childrens Hospital | | | | 57,742 | - | |
| | | | | The Broad Institute Inc. | | | | 54,770 71.862 | - | |
| NIH | Child Health and Human Development Extramural Research | Study of Attitudes and Factors | Boston University Medical Campus | University of Cincinnati | 4500003864 | R01HD095060 | 93.865 | 1,862 | 980 | 980 |
| NIH | Child Health and Human Development Extramural Research | Stress Hydrocortisone In Pedia | Children's Hospital Boston | | GENFD00001702903 | R01HD096901 | 93.865 | - | 119,822 | 119,822 |
| NIH | Child Health and Human Development Extramural Research | Deciphering the pathophysiolog | • | | | R01HD098280 | 93.865 | - | 588,519 | 588,519 |
| NIH | Child Health and Human Development Extramural Research | Discovery of Molecular Targets | UCLA School of Public Health | | 1651 G WA732 | R01HD098389 | 93.865 | - | 109,392 | 109,392 |
| NIH | Child Health and Human Development Extramural Research | Executive Function Outcome Mea | Colorado State University | | G-45002-02 | R01HD099150 | 93.865 | - | 127,218 | 127,218 |
| NIH | Child Health and Human Development Extramural Research | Improving the Effectiveness an | | University of Cincinnati | | R01HD099775 | 93.865 | 259,001 | 215,620 | 474,621 |
| NIH | Child Health and Human Development Extramural Research | Genomics of bone and body comp | Children's Hospital of Philadelphia | | GRT-00000601 | R01HD100406 | 93.865 | - | 26,589 | 26,589 |
| NIH NIH | Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research | Enhancing Nursing Care Reliabi Development and persistence of | Ohio State University North Carolina State University | | 60077379 2020-2189-01 | R01HD100455 R01HD101406 | 93.865 93.865 | = | 52,758 18.081 | 52,758 18.081 |
| NIH NIH | Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research | Development and persistence of Skeletal Health and Bone Marro | North Carolina State University Children's Hospital Boston | | 2020-2189-01 GENFD0002013062 | R01HD101406 R01HD101421 | 93.865 | - | 18,081 328,464 | 18,081 328,464 |
| NIH | Child Health and Human Development Extramural Research | Pragmatic Pediatric Trial of B | Children's Hospital of Philadelphia | | GRT-00000762 | R01HD101528 | 93.865 | = | 61,242 | 61,242 |
| NIH | Child Health and Human Development Extramural Research | Integrating genomic studies of | | Univ of California | | R01HD101669 | 93.865 | 18,060 | 311,513 | 329,573 |
| NIH | Child Health and Human Development Extramural Research | An Injury Plausibility Assessm | Lurie Children's Hospital of Chicago | | 901615-CCHMC | R01HD102428 | 93.865 | - | 5,901 | 5,901 |
| | | | | | | | | | | |

| NIH | Child Health and Human Development Extramural Research | Endocannabinoid Signaling duri | | | | R01HD103475 | 93.865 | - | 425,082 | 425,082 |
|------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-----------------------------------------|--------------------------------------|------------------------|----------------------------|------------------|------------------|--------------------|--------------------|
| NIH | Child Health and Human Development Extramural Research | Integration of spatiotemporal | | | | R01HD103623 | 93.865 | - | 239,473 | 239,473 |
| NIH | Child Health and Human Development Extramural Research | Automated Risk Assessment for | | University of Pittsburgh | | R01HD103630 | 93.865 | 53,140 | 365,629 | 418,769 |
| NIH | Child Health and Human Development Extramural Research | Leveraging the electronic heal | | | | R01HD103654 | 93.865 | - | 233,314 | 233,314 |
| NIH | Child Health and Human Development Extramural Research | Using Dogs to Promote Therapeu | | Miami University | | R01HD106416 | 93.865 | 10,981 | 255,357 | 266,338 |
| NIH | Human Genome Research | Engaging adolescents in decis | | | | R01HG010166 | 93.172 | - | 739,883 | 739,883 |
| NIH | Human Genome Research | Virus-driven human gene misreg | | Brigham and Women's Hospital | | R01HG010730 | 93.172 | 137,050 | 590,909 | 756,325 |
| | | | | University of Cincinnati | | | | 28,366 | - | |
| NIH | Human Genome Research | Epigenome-wide variations and | | | | R01HG011411 | 93.172 | - | 190,913 | 190,913 |
| NIH | Cardiovascular Diseases Research | Molecular pathways controlling | | | | R01HL060562 | 93.837 | - | 438,917 | 438,917 |
| NIH | Cardiovascular Diseases Research | Autophagy and mTORC1 signaling | University of Cincinnati | | 011762-002 | R01HL073394 | 93.837 | - | 1,200 | 1,200 |
| NIH | Blood Diseases and Resources Research | Role of FA Proteins in Hematopoiesis | | | | R01HL076712 | 93.839 | - | 235,105 | 235,105 |
| NIH | Lung Diseases Research | Pathogenesis-Based Diagnostics | | | | R01HL085453 | 93.838 | - | 423,305 | 423,305 |
| NIH | Cardiovascular Diseases Research | Thrombospondin 4 regulates ada | | | | R01HL105924 | 93.837 | - | 634,438 | 634,438 |
| NIH | Cardiovascular Diseases Research | Venous Malformations (VM): A M | | | | R01HL117952 | 93.837 | - | 463,439 | 463,439 |
| NIH | Lung Diseases Research | Pulmonary Macrophage Transplan | | University of Washington | R01HL118342 | R01HL118342 | 93.838 | 86,793 | 285,835 | 372,628 |
| NIH | Lung Diseases Research | Pediatric Respiratory Illness | Kaiser Foundation Research Institute | | RNG211577-CCHMC | R01HL121067 | 93.838 | - | 11,301 | 11,301 |
| NIH | Blood Diseases and Resources Research | Mechanisms of granulocyte home | | | | R01HL122661 | 93.839 | - | 597,719 | 597,719 |
| NIH | Cardiovascular Diseases Research | Using MRI to visualize regiona | Duke University | University of Cincinnati | A034671 | R01HL126771 | 93.837 | 24,295 | 115,507 | 139,802 |
| NIH | National Center on Sleep Disorders Research | Upper Airway Structure and Fun | Albert Einstein College of Medicine | | 311427 | R01HL130468 | 93.233 | - | 724 | 724 |
| NIH | Lung Diseases Research | UTE MRI to monitor CF lung disease | | | | R01HL131012 | 93.838 | - | 104,038 | 104,038 |
| NIH | Cardiovascular Diseases Research | Functional Impact of Col18a1/Endostatin | Johns Hopkins School of Medicine | | JHU;R01HL132153 | R01HL132153 | 93.837 | - | 210 | 210 |
| NIH | Cardiovascular Diseases Research | Hippo Signaling in Heart Development and | | | | R01HL132211 | 93.837 | - | 331,461 | 331,461 |
| NIH | Cardiovascular Diseases Research | Unraveling ancestry and environmental exp | | University of Cincinnati | | R01HL132344 | 93.837 | 8,396 | 930,980 | 939,376 |
| NIH | Cardiovascular Diseases Research | Molecular examination of mitoc | | Univ of CalifDavis-Mmrrc | | R01HL132831 | 93.837 | 207,197 | 548,301 | 755,498 |
| NIH | Blood Diseases and Resources Research | Chronic thrombus ablation with | The University of Chicago | | FP066598 | R01HL133334 | 93.839 | - | 19,560 | 19,560 |
| NIH | Cardiovascular Diseases Research | Targeting pathologic G-protein signaling in | | | | R01HL133695 | 93.837 | - | 222,753 | 222,753 |
| NIH | Lung Diseases Research | WT1 Regulation of Pulmonary Fibrosis | | University of Cincinnati | | R01HL134801 | 93.838 | 9,755 | 284,342 | 323,246 |
| NIH | Lung Diseases Research | | | University of Michigan | | | | 29,149 | - | |
| NIH | Cardiovascular Diseases Research | Regulatory mechanisms of adult cardiomyo | | | | R01HL135848 | 93.837 | - | 155,645 | 155,645 |
| NIH | Blood Diseases and Resources Research Cardinyascular Diseases Research | Cellular crosstalk in the hematopoietic Molecular mechanisms of atrial develop | | | | R01HL136529 R01HL137766 | 93.839 | - | 268,800 | 268,800 |
| NIH NIH | Cardiovascular Diseases Research Cardiovascular Diseases Research | Molecular mechanisms of atnal develop Circadian Rhythms and Interna | The University of Massachusetts. Amhe | | 19-010568 A00 | R01HL137/66 R01HL138551 | 93.837 93.837 | - | 160,719 139,784 | 160,719 139,784 |
| NIH | | | The University of Massachusetts, Affine | r | 19-010568 AUU | R01HL138551 R01HL141174 | 93.837 | - | | 139,784 436.908 |
| NH NH | Lung Diseases Research | Transcriptional Regulation of Endothelial | | | | R01HL1411/4 R01HL141186 | 93.838 | - | 436,908 209.878 | |
| NIH | Cardiovascular Diseases Research Cardiovascular Diseases Research | Retinoic acid-dependent epigenetic and | | | | R01HL141186 R01HL141229 | 93.837 | - | 209,878 477.710 | 209,878 477,710 |
| NH | Lung Diseases Research | Cela1 in Lung Development and Disease | | Erasmus MC | | R01HL141286 | 93.838 | - | 412.009 | 477,710 |
| NIH NIH | Lung Diseases Research Blood Diseases and Resources Research | R01- Mapping environmental con Normal and Pathological Hematopoietic | | Erasmus MC | | R01HL141286 R01HL141418 | 93.838 | 26,393 | 412,009 | 438,402 |
| NH | Cardiovascular Diseases Research | Familial hypercholesterolemia | Columbia University Medical Center | | 7(GG012850-01) | R01HL141823 | 93.837 | - | 400,526 | 45,597 |
| NH | Lung Diseases Research | Mechanisms controlling early h | The Lundquist Institute | | | R01H 141856 | 93.838 | | 18.939 | 18.939 |
| NH | Cardiovascular Diseases Research | Predictive Molecular Markers o | The Euroquist Institute | | 1 BD-7 R0 1 RL 14 1030 | R01HL142210 | 93.837 | - | 183.712 | 183.712 |
| NIH | Cardiovascular Diseases Research | Cardiac fibroblasts in postnat | | | | R01HL142217 | 93.837 | | 707.861 | 707,861 |
| NIH | Lung Diseases Research | Development of neonatal innate | | | | R01HL142708 | 93.838 | | 379.012 | 379.012 |
| NIH | Lung Diseases Research | Validating Quantitative Magnet | | University of Cincinnati | | R01HL143011 | 93.838 | 7,465 | 699,874 | 707,339 |
| NIH | Cardiovascular Diseases Research | Mechanisms of Congenital Heart Valve Dis | | | | R01HL143881 | 93.837 | - | 323.094 | 323,094 |
| NIH | Cardiovascular Diseases Research | HDL compostion/function and ca | University of Washington | | UWSC10977 | R01HL144558 | 93.837 | - | 58,166 | 58,166 |
| NIH | Cardiovascular Diseases Research | Molecular mechanisms underlyin | | | | R01HL144774 | 93.837 | - | 399,108 | 399,108 |
| NIH | Cardiovascular Diseases Research | Characterizing the formation a | The University of Texas Southwestern | | GMO 190108 PO 0000 | R01HL144793 | 93.837 | - | 39,695 | 39,695 |
| NIH | Lung Diseases Research | The role of sex in the life cy | University of Cincinnati | | 012029-002 | R01HL146266 | 93.838 | - | 64,294 | 64,294 |
| NIH | Cardiovascular Diseases Research | MRI Phenotyping of Early BPD a | | University of Wisconsin System | | R01HL146689 | 93.837 | 51,721 | 834,124 | 885,845 |
| NIH | Lung Diseases Research | Sleep-Disordered Breathing in | University of Michigan | | SUBK00015153 | R01HL147261 | 93.838 | - | 29,267 | 29,267 |
| NIH | Lung Diseases Research | Investigating the Mechanisms o | | University of Cincinnati | | R01HL147351 | 93.838 | 1,359 | - | 16,193 |
| | | | | University of Tennessee | | | | 14,834 | - | |
| NIH | Blood Diseases and Resources Research | Small molecules targeting RhoA | | | | R01HL147536 | 93.839 | - | 468,159 | 468,159 |
| NIH | Cardiovascular Diseases Research | Impact of Well-Timed vs. Mis-t | | Rush University Medical Center | | R01HL147915 | 93.837 | 30,023 | 493,543 | 523,566 |
| NIH | Cardiovascular Diseases Research | Novel Methods to Grow the Impa | | | | R01HL147957 | 93.837 | - | 544,594 | 544,594 |
| NIH | Blood Diseases and Resources Research | Linking Endotypes and Outcomes | Children's Hospital of Philadelphia | | 3201710624 | R01HL148054 | 93.839 | - | 51,005 | 51,005 |
| NIH | Lung Diseases Research | Bedside Exclusion of Pulmonary | Indiana University | | 8492-CHMC | R01HL148247 | 93.838 | - | 36,212 | 36,212 |
| NIH | Lung Diseases Research | Bedside Exclusion of Pulmonary | Wayne State University | | WSU22071 | R01HL148247 | 93.838 | - | 27,982 | 27,982 |
| NIH | Cardiovascular Diseases Research | Ultrasound-Mediated Controlled | University of Cincinnati | | 012268-003 | R01HL148451 | 93.837 | - | 81,193 | 81,193 |
| NIH | Lung Diseases Research | Perinatal Dysbiosis, Lung Deve | | National Jewish Health | | R01HL149366 | 93.838 | 35,977 | 401,769 | 437,746 |
| NIH | Lung Diseases Research | Molecular Mechanisms Regulated | | University of Cincinnati | | R01HL149631 R01HL149743 | 93.838 | 39,277 | 508,808 | 548,085 |
| NIH NIH | Lung Diseases Research Child Health and Human Development Extramural Research | Role of GM-CSF in Alveolar Mac Endotypes in Children with Sev | University of Michigan | | SUBK00010627 | R01HL149743 R01HL149910 | 93.838 93.865 | - | 204,809 4.107 | 204,809 4,107 |
| | | | . , , | | | | | - | | |
| NIH NIH | Lung Diseases Research | Role of IGF Axis in Pulmonary | Johns Hopkins School of Medicine | | 2004833966 | R01HL150070 | 93.838 93.838 | - | 72,102 | 72,102 |
| NIH NIH | Lung Diseases Research | Imaging and Molecular Phenotyp | | Brigham and Women's Hospital | | R01HL151588 | | 0.000 | 456,282 | 456,282 |
| INIT | Cardiovascular Diseases Research | Accelerating research to advan | | Children's Hospital Boston | | R01HL151604 | 93.837 | 9,899 171.464 | 145,176 | 500,788 |
| | | | | Vanderbilt University Medical Center | | | | 174,249 | | |
| NIH | Blood Diseases and Resources Research | The role of mitochondria in he | | Johns Hopkins University | | R01HL151654 | 93.839 | 27.193 | 422,572 | 449.765 |
| NIH | Lung Diseases Research | A Role For EYA3 In Vascular RE | | , | | R01HL152094 | 93.838 | | 594.700 | 594,700 |
| NIH NIH | Lung Diseases Research Blood Diseases and Resources Research | The Role of Erythroblastic Isl | | The Feinstein Institute Medical Res | | R01HL152094 R01HL152099 | 93.838 | 221,409 | 405.847 | 627,256 |
| NH | Cardiovascular Diseases Research | MINDS Imaging Ancillary Study | University of Pittsburgh | Caroton module wedical res | AWD00002377 (13459 | | 93.837 | | 26,465 | 26,465 |
| NH | Lung Diseases Research | Development of novel therapeut | , | | | R01HL152973 | 93.838 | _ | 586.117 | 586.117 |
| NH | Lung Diseases Research | Uterine signaling networks in | | University of Cincinnati | | R01HL153045 | 93.838 | 268,004 | 356,336 | 624,340 |
| NIH | Blood Diseases and Resources Research | Mechanisms whereby IFN-gamma s | University of Pittsburgh | • | AWD00003978 | R01HL153106 | 93.839 | - | 39,220 | 39,220 |
| NIH | Lung Diseases Research | Penetrating the "Black box": | | The Ohio State University | | R01HL153108 | 93.838 | 2,843 | 316,901 | 319,744 |
| NIH | Cardiovascular Diseases Research | Spatial control of myeloid df | | • | | R01HL153229 | 93.837 | - | 227,826 | 227,826 |
| NH | Blood Diseases and Resources Research | MIDAS: Microangiopathy, Endoth | The Ohio State University Research Fro | i | 60078812 | R01HL153723 | 93.839 | - | 145,817 | 145,817 |
| NIH | Cardiovascular Diseases Research | Mechanisms underlying myxomato | | | | R01HL154522 | 93.837 | - | 348,704 | 348,704 |
| NIH | Cardiovascular Diseases Research | Hypertrophic Cardiomyopathy: U | Brigham & Women's Hospital | | 2020A015252 | R01HL155568 | 93.837 | - | 7,323 | 7,323 |
| NIH | Lung Diseases Research | Tissue niches for ILC3 develop | | | | R01HL155611 | 93.838 | - | 428,749 | 428,749 |
| NIH | Cardiovascular Diseases Research | Endothelial subpopulations in | | | | R01HL156270 | 93.837 | - | 359,862 | 359,862 |
| NIH | Cardiovascular Diseases Research | Innate immune response signali | | | | R01HL156852 | 93.837 | - | 196,300 | 196,300 |
| NIH | Lung Diseases Research | Epigenetic Regulation of the M | | | | R01HL156860 | 93.838 | - | 323,245 | 323,245 |
| NH | Cardiovascular Diseases Research | Pathogenesis and Treatment of | | | | R01HL156866 | 93.837 | - | 208,961 | 208,961 |
| | | | | | | | | | | |

| | Low Process | 0.00.00.00.00 | | | | R01HL157176 | 00.000 | 4.404 | 400.074 | 500.075 |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------|-----------------------------------------------------------|----------------------------------|-------------------------------|------------------|------------------|--------------------|--------------------|
| NIH | Lung Diseases Research Cardiovascular Diseases Research | Sox9 Regulation of Fibroblast Lipoprotein Interactions in th | | University of Cincinnati University of Cincinnati | | R01HL157176 R01HL157260 | 93.838 93.837 | 4,401 114.748 | 496,274 360.991 | 500,675 475,739 |
| | | | | | | | | | | |
| NIH | Lung Diseases Research | TRANSPIRE: A Prospective Cohor | | Baylor College of Medicine. Children's Hospital Boston | | R01HL157392 | 93.838 | 17,143 7,329 | 550,390 | 685,837 |
| | | | | Children's Hospital of Philadelphia | | | | 51,508 | - | |
| | | | | Fred Hutchinson Cancer Res Center | | | | 18.245 | | |
| | | | | Seattle Children's Hospital | | | | 8.513 | | |
| | | | | University of Minnesota | | | | 32,709 | - | |
| NIH | Cardiovascular Diseases Research | Effect of reproductive history | | , | | R01HL158100 | 93.837 | 28,707 | 189,296 | 218.003 |
| NH | Blood Diseases and Resources Research | Role of the local vascular mic | | | | R01HL158616 | 93.839 | - | 241.766 | 241,766 |
| NIH | Lung Diseases Research | Role of lung endothelial cells | | | | R01HL158659 | 93.838 | _ | 494,977 | 494,977 |
| NIH | Cardiovascular Diseases Research | Microprotein Regulation of Mt | | | | R01HL160569 | 93.837 | - | 194,595 | 194,595 |
| NIH | Blood Diseases and Resources Research | Hematopoietic Stem Cell engraf | | | | R01HL162649 | 93.839 | | 5,890 | 5,890 |
| NH | Medical Library Assistance | Personal Health Rec for Youth Emancipating | | | | R01LM012816 | 93.879 | | 13,244 | 13.244 |
| NH | Medical Library Assistance | A Framework for Automated and | | | | R01LM013222 | 93.879 | - | 229,700 | 229,700 |
| NIH | Medical Library Assistance | Situation Awareness to Improve | Children's Hospital of Philadelphia | | GRT-00001468 | R01LM013526 | 93.879 | _ | 42.191 | 42.191 |
| NH | Minority Health and Health Disparities Research | Linking pre-and post-natal | Cinaren o ricopitar er rimadepina | University of California | G111 00001400 | R01MD013006 | 93.307 | 31.331 | 609.682 | 641.013 |
| NIH | Mental Health Research Grants | Molecular Mechanisms Controlli | | University of Cincinnati | | R01MH090740 | 93.242 | 58,113 | 540,742 | 598,855 |
| NIH | Mental Health Research Grants | 1/2 Anomalous Motor System Phy | | | | R01MH095014 | 93.242 | - | 374,621 | 374,621 |
| NIH | Mental Health Research Grants | 4/7-Collaborative genomic stud | | | | R01MH115962 | 93.242 | - | 120,333 | 120,333 |
| NIH | Mental Health Research Grants | Nationwide dissemination of a | | American Academy of Pediatrics. | | R01MH118488 | 93.242 | 15,038 | 787,760 | 802,798 |
| NIH | Mental Health Research Grants | Patient and Provider perspecti | University of North Carolina | | 5113985 | R01MH118955 | 93.242 | - | 76,785 | 76,785 |
| NIH | Mental Health Research Grants | 1/3 Effectiveness Trial of the | Florida State University | | R000002935 | R01MH121627 | 93.242 | - | 49,880 | 49,880 |
| NIH | Mental Health Research Grants | Longitudinal Examination of SI | | | | R01MH122415 | 93.242 | - | 611,901 | 611,901 |
| NIH | Mental Health Research Grants | Molecular Dissection of Synapt | The University of Massachusetts, Amhe | r | TBD-R01MH122519 | R01MH122519 | 93.242 | - | 68,655 | 68,655 |
| NIH | Mental Health Research Grants | Neuron- and microglia-specific | University of Cincinnati | | 012928-002 | R01MH123545 | 93.242 | - | 19,922 | 19,922 |
| NIH | Mental Health Research Grants | Parsing Neurobiological Bases | | Purdue University | | R01MH123831 | 93.242 | 14,910 | 281,509 | 358,408 |
| | | | | University of Cincinnati | | | | 61,989 | - | |
| NIH NIH | Nursing Research Nursing Research | Self-Management in Adolescents Self-Management of Adolescent | Loyola University Chicago Children's Hospital of Philadelphia | | Loyola;R01NR016235 3201511123 | R01NR016235 R01NR017429 | 93.361 93.361 | - | 2,880 92,025 | 2,880 92,025 |
| NIH | Nursing Research | Peer Mentoring to Improve Self | Nationwide Children's Hospital | | 700160-0219-00 | R01NR017429 R01NR017533 | 93.361 | - | 199,815 | 199,815 |
| NH | Nursing Research | Fostering medication adherence | Nationwide Children's Hospital | CHOC Children's Hospital | 700100-0219-00 | R01NR017794 | 93.361 | 88.053 | 279.559 | 646,211 |
| NIFT | Nuising Research | Postering medication adherence | | Medical University South Carolina | | R01NR017794 | 93.301 | 137.693 | 279,559 | 646,Z11 |
| | | | | Nationwide Childrens Hospital | | | | 82,018 | | |
| | | | | North Carolina State University | | | | 7,589 | | |
| | | | | Research Inst. at Nationwide Hos | | | | 16,178 | - | |
| | | | | University of Florida | | | | 35,121 | - | |
| NIH | Nursing Research | Randomized Controlled Trial of | | University of Virginia | | R01NR019426 | 93.361 | 193,848 | 361.626 | 555.474 |
| NIH | Nursing Research | Identification of causal facto | University of Cincinnati | | 013249-002 | R01NR019531 | 93.361 | - | 37,712 | 37,712 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Mitogenic Activities in Neurofibromatosis | | | | R01NS028440 | 93.853 | - | 364,129 | 364,129 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Comparison of Hemorrhagic and | University of Cincinnati | | 2R01NS030678-26 | R01NS030678 | 93.853 | - | 229,177 | 229,177 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Ultrasound-assisted thrombolysis for stroke | University of Cincinnati | | 009291-010 | R01NS047603 | 93.853 | - | 8,638 | 8,638 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Molecular, cellular and physiological mech | | University of Florida | | R01NS054794 | 93.853 | 150,912 | 549,271 | 700,183 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Identification and reversal of | | | | R01NS065020 | 93.853 | - | 377,709 | 377,709 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Brain Mechanisms Supporting Individual Diff | | | | R01NS085391 | 93.853 | - | 43,327 | 43,327 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | MicroRNA-mediated silencing of the Kv4.2 | | | | R01NS092705 | 93.853 | - | 74,719 | 74,719 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Early Prediction of Cerebral Palsy in Premat | | | | R01NS096037 | 93.853 | - | 5,399 | 5,399 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Genetic and environmental influences on rec | | Phoenix Children's Hospital | | R01NS096053 | 93.853 | 631 | 173,663 | 196,311 |
| | | | | University of CA University of Exeter | | | | 14,584 7,433 | - | |
| NIH | 5.4IB. B | | | University of Exeter | | D0.41/0007000 | 00.050 | 7,433 | - | 00.000 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders Extramural Res Programs in the Neurosciences & Neurological Disorders | miR-155 and RUNX function in neurofibro Binding of Epstein Barr Virus EBNA2 unfi | | Stanford University | | R01NS097233 R01NS099068 | 93.853 93.853 | 9,400 | 39,922 351,848 | 39,922 361,248 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Mechanisms of Biguanide Sensit | | Starriord University | | R01NS099162 | 93.853 | 5,400 | 230.094 | 230.094 |
| NH | Extramural Res Programs in the Neurosciences & Neurological Disorders | ICH Recovery Grant | University of Cincinnati | | 011078-003 | R01NS100417 | 93.853 | - | 27,220 | 27.220 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Distinct Mechanisms of Cognitive Behav | , | | | R01NS101321 | 93.853 | _ | 493.670 | 493.670 |
| NH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Assessing Population-based Rad | University of Cincinnati | | 011815-003 | R01NS103824 | 93.853 | _ | 108.046 | 108.046 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Progranulin: A Novel Gene in Gaucher Dis | New York University | | 17-A0-00-008041-01 | R01NS103931 | 93.853 | - | 110,502 | 110,502 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | A novel smart patch for the f | University of Cincinnati | | 012058-002 | R01NS103992 | 93.853 | - | 257,646 | 257,646 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | The Vascular effects of Infect | Univ of California, San Francisco | | 11258sc | R01NS104094 | 93.853 | - | 9,367 | 9,367 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Sensitization of developing se | | | | R01NS105715 | 93.853 | - | 247,365 | 247,365 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Targeting the Hippo signaling | University of Houston | | R200017 | R01NS105787 | 93.853 | - | 22,493 | 22,493 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Mechanisms linking hemostatic | | | | R01NS107258 | 93.853 | - | 465,119 | 465,119 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Functional analysis of the mic | | | | R01NS107453 | 93.853 | - | 366,535 | 366,535 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Creatine Transporter Deficienc | University of Virginia | | GB10578.160162 | R01NS108763 | 93.853 | - | 59,192 | 59,192 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Headache Assessment of Childre | The Trustees of Columbia University | | PECARN Headache | R01NS110826 | 93.853 | - | 94,341 | 94,341 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Neonatal Seizure Registry Deve | UCSF Human Research Program | | 11997sc | R01NS111166 | 93.853 | - | 28,143 | 28,143 |
| NIH NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders Extramural Res Programs in the Neurosciences & Neurological Disorders | Spinal circuitry for ventilato | | | | R01NS112255 R01NS113965 | 93.853 93.853 | - | 310,795 786,644 | 310,795 786.644 |
| NIH NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders Extramural Res Programs in the Neurosciences & Neurological Disorders | Mechanisms of muscle afferent Bystander gene deletions in ca | | University of Cincinnati | | R01NS113965 R01NS114074 | 93.853 | 29.434 | 786,644 283.266 | 786,644 312,700 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders Extramural Res Programs in the Neurosciences & Neurological Disorders | Uncovering treatment targets f | University of Minnesota | OGrany Or Genderable | 1R01NS115438-01A1 | | 93.853 | 20,404 | 283,266 554,592 | 554,592 |
| NH | Extramural Res Programs in the Neurosciences & Neurological Disorders | CNS in congenital DM1: pathoge | Similar of millipaora | | INOTIONOUTAL | R01NS115662 | 93.853 | - | 301,356 | 301,356 |
| NH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Diagnostic validity and safety | Johns Hopkins University | | R01NS115929-01 | R01NS115929 | 93.853 | - | 218,830 | 218,830 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Circuit defects underlying in | Univ of California Los Angeles | | 1580 G YB180 | R01NS117597 | 93.853 | - | 179,948 | 179,948 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | ROSE-LAWN | University of Cincinnati | | 013382-002 | R01NS120493 | 93.853 | - | 23,105 | 23,105 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Identification of novel pathwa | | | | R01NS120892 | 93.853 | - | 194,771 | 194,771 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Anti-epileptogenic role of mTO | Ntl Inst of Neuro Disorders & Stroke | | R01NS121042 | R01NS121042 | 93.853 | - | 4,941 | 4,941 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Roles of Gsx factors in basal | | | | R01NS124660 | 93.853 | - | 183,049 | 183,049 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Understanding the Impact of Yo | | | | R01NS125316 | 93.853 | - | 92,188 | 92,188 |
| NIH | Drug Abuse and Addiction Research Programs | Automated Substance Use Detect | | | | R03DA054256 | 93.279 | - | 7,924 | 7,924 |
| NIH | Oral Diseases and Disorders Research | Tracing the origins of craniof | | | | R03DE030200 | 93.121 | - | 48,420 | 48,420 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Durability of Epethelial Defec | | | | R03DK124751 | 93.847 | - | 133,085 | 133,085 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Diabetes Timing and Types and | | | | R03DK131156 | 93.847 | - | 28,984 | 28,984 |
| NIH | National Center for Advancing Translational Sciences | Urinary Lipidomic profile in F | T | | TH. 110.5 | R03TR003916 | 93.350 | - | 39,889 | 39,889 |
| NIH NIH | Aging Research | A Novel Research Infrastructur | Tulane University | | TUL-HSC-556566-18 | /1 R21AG057983 R21Al139829 | 93.866 | - | 8,976 135.266 | 8,976 135,266 |
| NIH NIH | Allergy, Immunology and Transplantation Research Allergy, Immunology and Transplantation Research | Obesity, Metabolic Syndrome an Single cell analysis of transp | | | | R21Al139829 R21Al142264 | 93.855 93.855 | - | 135,266 | 135,266 23.851 |
| NIH | Allergy, Immunology and Transplantation Research Allergy, Immunology and Transplantation Research | Single cell analysis of transp Copper tolerance and homeostas | | University of Cincinnati | | R21AI142264 R21AI143467 | 93.855 | 97,687 | 52,643 | 150,330 |
| 1 441 | g.,nonoogy and manopianiation (topograf) | | | Jrony or Ouronaldit. | | | _ 3.000 | 31,001 | 02,010 | |

| NIH | Allergy, Immunology and Transplantation Research | Genetics of organ-specific lup | | University of Cincinnati | | R21Al145304 | 93.855 | 11,229 | 175,757 | 186,986 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NIH | Allergy, Immunology and Transplantation Research | Preserving T cell / antigen pr | | | | R21Al148612 | 93.855 | - | 186,372 | 186,372 |
| NIH | Allergy, Immunology and Transplantation Research | Immune Responses in the Mother | Mayo Clinic | | CHI-289276 | R21Al151208 | 93.855 | - | 3,764 | 3,764 |
| NIH | Allergy, Immunology and Transplantation Research | Preconceptual paternal environ | * * | Univ of CalifDavis-Mmrc | | R21Al152100 | 93.855 | 16,886 | 235,780 | 252,666 |
| NIH | Allergy, Immunology and Transplantation Research | Reconstituting the oligogenic | | University of Cincinnati | | R21Al152575 | 93.855 | 1.945 | 229.954 | 231,899 |
| NIH | Allergy, Immunology and Transplantation Research | Preconceptual paternal allerge | | , | | R21Al156185 | 93.855 | | 212.053 | 212.053 |
| NIH | Allergy, Immunology and Transplantation Research | Genetic ancestry differences i | | | | R21Al157363 | 93.855 | | 105.363 | 105,363 |
| NIH | Allergy, Immunology and Transplantation Research | Immunopathogenesis of Histopla | University of Cincinnati | | 0.13543-00003 | R21Al160722 | 93.855 | - | 15.405 | 15,405 |
| NIH | Allergy, Immunology and Transplantation Research | Biomarkers of Replication and | University of Cincinnati | | 013716-00002 | R21Al165171 | 93.855 | - | 8,058 | 8,058 |
| | | | University of Cincinnati | | 013716-00002 | | | - | | |
| NIH | Cancer Cause and Prevention Research | Increasing HPV Vaccination Rat | | | | R21CA238170 | 93.393 | - | 115,122 | 115,122 |
| NIH | Cancer Detection and Diagnosis Research | Redefining hemophagocytic lymp | | | | R21CA256390 | 93.394 | - | 94,131 | 94,131 |
| NIH | Cancer Biology Research | Infectious pressures on cell c | | | | R21CA257984 | 93.396 | - | 182,868 | 182,868 |
| NIH | Research Related to Deafness and Communication Disorders | Multimodal Neuroimaging Distin | University of Cincinnati | | 1R21DC017393-01A1 | | 93.173 | - | 27,714 | 27,714 |
| NIH | Research Related to Deafness and Communication Disorders | Investigating the contribution | | | | R21DC020242 | 93.173 | - | 11,955 | 11,955 |
| NIH | Oral Diseases and Disorders Research | Function and Regulation of Sem | | | | R21DE030193 | 93.121 | - | 211,281 | 211,281 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Early MRI Prediction of Respon | | | | R21DK114657 | 93.847 | - | 6,351 | 6,351 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Epigenetic and functional dete | | | | R21DK123691 | 93.847 | - | 14,731 | 14,731 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Individualized Structured Meal | University of Cincinnati | | 013507-00002 | R21DK125033 | 93.847 | - | 49,869 | 49,869 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Pilot and Feasibility Clinical | | | | R21DK128635 | 93.847 | - | 197,885 | 197,885 |
| NIH | Discovery and Applied Research for Tech Innovations to Improve Human Hea | althDevelopment of Hybrid Tracheas | University of Cincinnati | | 011164-004 | R21EB025378 | 93.286 | - | 17,341 | 17,341 |
| NIH | Environmental Health | Developing and Evaluating Nove | | University of Kentucky | | R21ES030092 | 93.113 | 60,776 | 172,519 | 233,295 |
| NH | Environmental Health | Innovative Personal Monitoring | RTI International | | 1-340-0217531-66041 | R21ES030142 | 93.113 | - | 97.000 | 97.000 |
| NIH | Family Smoking Prevention and Tobacco Control Act Regulatory Research | Distinguishing Exposure to Sec | University of Cincinnati | | 013228-003 | R21ES032161 | 93.077 | _ | 7,715 | 7,715 |
| NIH | Biomedical Research and Research Training | Death-Seq, a Method for Genome | Onvoidity of Ontonina | | 0 10220 000 | R21GM135634 | 93.859 | | 224,522 | 224,522 |
| NIH | Biomedical Research and Research Training | A Synthetic Approach for Bacte | University of Cincinnati | | 0.13094-002 | R21GM137321 | 93.859 | _ | 12.846 | 12.846 |
| NIH | Child Health and Human Development Extramural Research | Human-animal interaction to pr | | | | R21HD095132 | 93.865 | _ | 12,646 | 12,646 |
| NIH | Child Health and Human Development Extramural Research | Neonatal PBPK-PD Modeling of M | | | | R21HD095418 | 93.865 | - | 11.179 | 11.179 |
| NH | Child Health and Human Development Extramural Research | Driving Skills of Adolescents | | | | R21HD096014 | 93.865 | - | 81.332 | 81,332 |
| | | | | | | | | - | | |
| NIH NIH | Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research | ROR Plus: Randomized Trial of Brain organoid modeling of Gau | | | | R21HD102702 R21HD102788 | 93.865 93.865 | - | 135,450 234,843 | 135,450 234,843 |
| | | | | | | | | - | | |
| NIH | Blood Diseases and Resources Research | Defining human hematopoietic c | | | | R21HL150678 | 93.839 | - | 146,939 | 146,939 |
| NIH | Cardiovascular Diseases Research | Finding the contribution of th | | | | R21HL162572 | 93.837 | - | 162,794 | 162,794 |
| NIH | Nursing Research | Improving Drug Adherence Using | | Nationwide Childrens Hospital | | R21NR017633 | 93.361 | 2,885 | - | 2,885 |
| NIH | Nursing Research | Reducing Health Disparities th | University of Cincinnati | | 013513-002 | R21NR019126 | 93.361 | - | 98,931 | 98,931 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Neuromagnetic High Frequency O | | | | R21NS104459 | 93.853 | - | 3,062 | 3,062 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Using a ketogenic diet to trea | | | | R21NS111217 | 93.853 | - | 65,043 | 65,043 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Assessing the contribution of | | | | R21NS121644 | 93.853 | - | 20,054 | 20,054 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | A new human iPSC model of ALS: | | The University of Arizona | | R21NS122169 | 93.853 | 107,955 | 116,437 | 224,392 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Distinguishing TLE and TLE us | | | | R21NS123630 | 93.853 | - | 43,170 | 43,170 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Genetic approaches to address | | | | R21NS123974 | 93.853 | - | 20,356 | 20,356 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Impact of Lztr1 mutations on o | | | | R21NS125347 | 93.853 | - | 59,853 | 59,853 |
| NH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Cell type-specific functions o | | | | R21NS126740 | 93.853 | - | 16.864 | 16.864 |
| NH | Research Infrastructure Programs | Establish a novel mouse model | | | | R21OD031906 | 93.351 | - | 243,034 | 243,034 |
| NIH | Research Infrastructure Programs | Development of a mouse model o | | | | R21OD031907 | 93.351 | _ | 355 | 355 |
| NIH | International Research and Research Training | An implementation toolkit for | Global Health Uganda | | GHU-02-2021-01 | R21TW011554 | 93.989 | _ | 19.989 | 19,989 |
| NIH | Child Health and Human Development Extramural Research | Pediatric Injury: Modules to Manage | University of Utah | | 1046978 | R24HD096350 | 93.865 | _ | 231,979 | 231,979 |
| NIH | Biomedical Research and Research Training | Growing Community Change Resea | University of Cincinnati | | 011577-004 | R25GM129234 | 93.859 | _ | 1,595 | 1,595 |
| NIH | Biomedical Research and Research Training | WE ENGAGE via Data & Stories to Improve | Onvoidity of Ontonina | Miami University | 011011 004 | R25GM129808 | 93.859 | 123.085 | 98,846 | 254,350 |
| TAIL I | biomedical Nesearch and Nesearch Hairing | WE ENGAGE VIA DAIA & Stolles & Implove | | University of Cincinnati | | 1423GW128000 | 93.639 | 32.419 | 80,040 | 254,550 |
| NIH | Aging Research | Mechanisms in Lamin A function | | University of Carcillati | | R33AG054770 | 93.866 | 32,415 | 606.410 | 606.410 |
| NIH | Aging Research | Sub to Tulane -Transfer from R | Tulane University | | TUL-HSC-556566 | R33AG05778 | 93.866 | - | 484.518 | 484,518 |
| | 5 5 | | Tulane University | | TUL-HSC-556566 | | | - | | |
| NIH | Environmental Health | Assessing Personal Exposure to Ultrafine P | | | | R33ES024713 | | - | | 103,328 |
| NIH | National Center on Sleep Disorders Research | | | | | | 93.113 | | 103,328 | |
| | | Positive airway pressure for t | Children's Hospital of Philadelphia | | GRT-00001521 | R33HL151253 | 93.233 | - | 139,191 | 139,191 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Targeting complement 5a-mediat | | | | R33NS112407 | 93.233 93.853 | - | 139,191 448,529 | 448,529 |
| NIH | Research and Training in Complementary and Alternative Medicine | Targeting complement 5a-mediat Feasibility and acceptability | Children's Hospital of Philadelphia The Research Instit at Nationwide Hosp | | 700266-0622-00 | R33NS112407 R34AT011218 | 93.233 93.853 93.213 | | 139,191 448,529 54,018 | 448,529 54,018 |
| NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs | Targeting complement 5a-mediat Feasibility and acceptability 4/5 HEAL Consortium: Establish | The Research Instit at Nationwide Hosp | University of Cincinnati | 700266-0622-00 | R33NS112407 R34AT011218 R34DA050268 | 93.233 93.853 93.213 93.279 | - - 20,844 | 139,191 448,529 54,018 227,859 | 448,529 54,018 248,703 |
| NIH | Research and Training in Complementary and Alternative Medicine | Targeting complement 5a-mediat Feasibility and acceptability | | University of Cincinnati | | R33NS112407 R34AT011218 R34DA050268 | 93.233 93.853 93.213 | - - - 20,844 - | 139,191 448,529 54,018 | 448,529 54,018 248,703 80,804 |
| NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs | Targeting complement 5a-mediat Feasibility and acceptability 4/5 HEAL Consortium: Establish | The Research Instit at Nationwide Hosp | | 700266-0622-00 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH112648 | 93.233 93.853 93.213 93.279 | - - - 20,844 - - | 139,191 448,529 54,018 227,859 | 448,529 54,018 248,703 80,804 4,002 |
| NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research | Targeting complement 5a-mediat Feasibility and acceptability 4/5 HEAL Consortium: Establish Procalcitonin to Reduce Antibi | The Research Instit at Nationwide Hosp | University of California | 700266-0622-00 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 | 93.233 93.853 93.213 93.279 93.838 | - - 8,823 | 139,191 448,529 54,018 227,859 80,804 | 448,529 54,018 248,703 80,804 |
| NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants | Targeling complement Sa-mediat Feasibility and acceptability 4/5 HEAL Construin: Establish Procalcitonin to Reduce Antibi Improving Medication Continuity among Ad Emotion coaching skills as an | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital | | 700266-0622-00 A21-0001-S001-CCHM | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH112648 R34MH115897 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 | - | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 | 448,529 54,018 248,703 80,804 4,002 159,055 |
| NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants | Tangeting complement 5a-medist Feasability and acceptability 4/5 HEAL Consortium: Establish Procatition in Reduce Artibil Improving Mactication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc | The Research Instit at Nationwide Hosp | University of California University of Georgia | 700266-0622-00 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH112648 R34MH115897 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 | - - 8,823 27,602 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 | 448,529 54,018 248,703 80,804 4,002 159,055 |
| NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Orni Diseases and Disorders Research | Targeling complement Sa-mediat Feasibility and acceptability 4/5 HEAL Construin: Establish Procalcitonin to Reduce Antibi Improving Medication Continuity among Ad Emotion coaching skills as an | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital | University of California University of Georgia Nationwide Childrens Hospital | 700266-0622-00 A21-0001-S001-CCHM | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH112648 R34MH115897 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 | - - 8,823 27,602 - 15,040 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 | 448,529 54,018 248,703 80,804 4,002 159,055 |
| NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research | Tangeting complement 5a-medist Feasability and acceptability 4/5 HEAL Consortium: Establish Procatition in Reduce Artibil Improving Mactication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH112648 R34MH115897 R34MH117206 R35DE027557 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 | - - 8,823 27,602 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 | 448,529 54,018 248,703 80,804 4,002 159,055 |
| NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Orni Diseases and Disorders Research | Tangeting complement 5a-medist Feasability and acceptability 4/5 HEAL Consortium: Establish Procatition in Reduce Artibil Improving Mactication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital | University of California University of Georgia Nationwide Childrens Hospital | 700266-0622-00 A21-0001-S001-CCHM | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH112648 R34MH115897 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 | - - 8,823 27,602 - 15,040 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 | 448,529 54,018 248,703 80,804 4,002 159,055 |
| NIH NIH NIH NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Environmental Health | Targeting complement Sa-medist Feasibility and acceptability 41.5 HEAL Construm: Establish Procalcitonin to Reduce Antibi Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Natonwide Childrens Hospital The Jackson Laboratory | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH115847 R34MH115897 R34MH117206 R35DE027557 R35ES030435 R35GM119458 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.242 93.121 | - - 8,823 27,602 - 15,040 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 |
| NIH NIH NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Crial Diseases and Disorders Research Environmental Health | Tangeting complement Sa-medist Feasability and acceptability 4/5 HEAL Consortum: Establish Procatchorin to Reduce Antibi Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherenca in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Nationwide Childrens Hospital | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH112648 R34MH112648 R34MH117206 R35DE027557 | 93.233 93.853 93.213 93.279 93.838 93.342 93.242 93.242 93.121 | - - 8,823 27,602 - 15,040 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 |
| NIH NIH NIH NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Environmental Health | Targeting complement Sa-medist Feasibility and acceptability 41.5 HEAL Construm: Establish Procalcitonin to Reduce Antibi Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Natonwide Childrens Hospital The Jackson Laboratory | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH115847 R34MH115897 R34MH117206 R35DE027557 R35ES030435 R35GM119458 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 | 8,823 27,602 - 15,040 2,172 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 |
| NIH NIH NIH NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Environmental Health | Targeting complement Sa-medist Feasibility and acceptability 41.5 HEAL Construm: Establish Procalcitonin to Reduce Antibi Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH115847 R34MH115897 R34MH117206 R35DE027557 R35ES030435 R35GM119458 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 | - 8,823 27,602 - - 15,040 2,172 - - - 500 500 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 |
| NIH NIH NIH NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Environmental Health | Targeting complement Sa-medist Feasibility and acceptability 41.5 HEAL Construm: Establish Procalcitonin to Reduce Antibi Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH115847 R34MH115897 R34MH117206 R35DE027557 R35ES030435 R35GM119458 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 | - 8,823 27,602 - 15,040 2,172 - - 500 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 |
| NIH NIH NIH NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Environmental Health | Targeting complement Sa-medist Feasibility and acceptability 41.5 HEAL Construm: Establish Procalcitonin to Reduce Antibi Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH115847 R34MH115897 R34MH117206 R35DE027557 R35ES030435 R35GM119458 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 | - 8,823 27,602 - 15,040 2,172 500 500 7,500 2,022 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 |
| NIH NIH NIH NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Environmental Health | Targeting complement Sa-medist Feasibility and acceptability 41.5 HEAL Construm: Establish Procalcitonin to Reduce Antibi Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Natonwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Alron Children's Hospital of Philadelphia | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH115847 R34MH115897 R34MH117206 R35DE027557 R35ES030435 R35GM119458 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 | - 8,823 27,602 - 15,040 2,172 - - - 500 500 7,500 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 |
| NIH NIH NIH NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Environmental Health | Targeting complement Sa-medist Feasibility and acceptability 41.5 HEAL Construm: Establish Procalcitonin to Reduce Antibi Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH115847 R34MH115897 R34MH117206 R35DE027557 R35ES030435 R35GM119458 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 | - 8,823 27,602 - 15,040 2,172 - 500 500 7,500 2,022 1,000 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 |
| NIH NIH NIH NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Environmental Health | Targeting complement Sa-medist Feasibility and acceptability 41.5 HEAL Construm: Establish Procalcitonin to Reduce Antibi Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH115847 R34MH115897 R34MH117206 R35DE027557 R35ES030435 R35GM119458 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 |
| NIH NIH NIH NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disordern Research Oral Diseases and Disordern Research Environmental Health Biomedical Research and Research Taining Biomedical Research and Research Taining | Tangeting complement Sa-medat Feasability and acceptability 4/5 HEAL Consortium: Establish Procalcition to Reduce Antibil Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog Sepsis from Bedside to Bench to Bedside | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Natonwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34DA050268 R34HL153474 R34MH115847 R34MH115897 R34MH117206 R35DE027557 R35ES030435 R35GM119458 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 93.859 | 8,823 27,802 - 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 | 139,191 449,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 426,191 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 460,037 |
| NIH NIH NIH NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Environmental Health | Tangeting complement 5a-mediat Feasability and acceptability 4/5 HEAL Consortium: Establish Procatition in Reduce Artifibi Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog Sepsis from Bedside to Bench to Bedside | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34AD450268 R34AL950268 R34H1158474 R34MH112648 R34MH112648 R35DE027557 R35ES030435 R35GM119458 R35GM126943 | 93 233 93 853 93 213 93 279 93 838 93 242 93 242 93 121 93 113 93 859 93 859 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139.191 448.529 54.018 227.859 80.804 4.002 122.630 - 28.071 997.424 - 36.762 381.001 426.191 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 460,037 |
| NIH NIH NIH NIH NIH NIH NIH NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Environmental Health Biomedical Research and Research Training Biomedical Research and Research Training Biomedical Research and Research Training Biomedical Research and Research Training | Tangeting complement Sa-medist Feasability and acceptability 4/5 HEAL Consortium: Establish Procalization in Draduce Antibi Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog Sepsis from Bedside to Bench to Bedside Regulatory Mechanisms Governin How CHAF18 maintains cell stat | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34MS102628 R34MS158474 R34MS112648 R34MS112648 R35MS117206 R35DE027557 R35ES030435 R35GM140808 R35GM128943 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 93.859 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 2,80,71 997,424 36,762 381,001 426,191 523,715 300,968 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 460,037 |
| NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Environmental Health Biomedical Research and Research Taining | Tangeting complement Sa-medist Feasability and acceptability 4/5 HEAL Consortium: Establish Procaticion in Reduce Artibil Improving Madestain Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Obl Macrophage regulation of the spermatog Sepsis from Bedside to Bench to Bedside Regulatory Mechanisms Governi How CHAF18 maintains call stat Decoding imale immune signaling in normal | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0622-00 A21-0001-S001-CCHM RES514545 | R33NS112407 R34AT011218 R34AT011218 R34L0450208 R34L1158174 R34MH112648 R34MH112648 R34MH117206 R350E027557 R35ES030436 R35GM19458 R35GM126943 | 93.233 93.853 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 93.859 93.859 93.859 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139.191 448.529 54.018 277,899 80.804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 426,191 523,715 300,968 606,539 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,836 36,762 381,001 460,037 |
| NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Crist Diseases and Disorders Research Environmental Health Bismedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research and Research Taining | Tangeting complement Sa-medist Feasability and acceptability 4/5 HEAL Consortium: Establish Procalcitorin to Reduce Artifibi Improving Macteation Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog Sepsis from Bedside to Bench to Bedside Regulatory Mechanisms Governi How CHAF Its maintains cell stat Decoding Imate Immune signaling in normal Pathogenic Robo of Foot1 Hipps | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University Icahn School of Medicine at Mount Shail | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0822-00 A21-0001-S001-CCHM RES514545 0255-0602-4609 | R33NS112407 R34AT011218 R34AD450268 R34AH.158474 R34AMH112648 R34AMH112648 R35DE027557 R35ES030435 R35GM14988 R35GM129943 R35GM129943 | 93.233 93.853 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 93.859 93.859 93.859 93.859 93.859 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139,191 446,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 426,191 523,715 300,968 606,539 388,300 | 448,529 54,018 248,703 80,864 4,002 159,055 28,071 1,014,636 36,762 381,001 460,037 |
| NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disordern Research Crail Diseases and Disordern Research Crail Diseases and Disordern Research Environmental Health Blomedical Research and Research Taining Blomedical Research and Research Research Cannor Biology Research Human Genome Research | Tangeting complement 5a-medat Feasability and escopiability 4/5 HEAL Consortium: Establish Procalcition in Reduce Artibil Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog Sepsis from Bedside to Bench to Bedside Regulatory Mechanisms Governin How CHAF16 maintains cell stat Decoding insale immune signaling in normal Pathogenic Role of Foult Hepa SciDAP-a next generation data | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University Icahn School of Medicine at Mount Shail | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0622-00 A21-0001-5001-CCHM RESS14545 0255-0602-4609 | R33NS112407 R34AT011218 R34AT011218 R34AT011218 R34AT011218 R34AH112648 R34MH112648 R34MH112648 R35DE027557 R35E3030435 R35GM126943 R35GM140806 R35GM1 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.121 93.113 93.859 93.859 93.859 93.859 93.859 93.859 93.859 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139,191 448,529 54,018 227,859 80,804 4,002 122,530 - 28,071 997,424 36,762 381,001 426,191 523,715 300,968 606,539 386,360 120,781 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 460,037 |
| NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disordern Research Oral Diseases and Disordern Research Crial Diseases and Disordern Research Environmental Health Biomedical Research and Research Taining Biomedical Research and Research Limit Research Limit Genome Research Lancer Biology Research Lancer Biology Research Luman Genome Research Mental Health Research Grants | Tangeting complement 5a-mediat Feasability and acceptability 4/5 HEAL Consortium: Establish Procatition in Reduce Artibil Improving Mactication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog Sepais from Bedside to Bench to Bedside Regulatory Mechanisms Governi How CHAF18 maintains cell state Decoding instale immune signating in normal Pathogenic Role of Foott Hepa SciDAP-a next generation data Validation of a salvary miRNA | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University Isahn School of Medicine at Mount Shail | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0622-00 A21-0001-S001-CCHM RESS14545 0255-0602-4609 | R33NS112407 R34AT011218 R34AT011218 R34AD450268 R34H115847 R34MH112648 R34MH112648 R35DE027557 R35E5030435 R35GM129943 R35GM129943 R35GM129943 R35GM129943 R35GM129943 R35GM129943 R35GM129943 | 93 233 93.853 93.279 93.888 93.242 93.242 93.121 93.113 93.859 93.859 93.859 93.859 93.859 93.859 93.899 93.396 93.172 93.242 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139.191 448.529 54.018 227,859 80,804 4,002 122,630 - 28,071 997,424 38,762 381,001 426,191 523,715 300,968 606,539 389,380 120,781 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 460,037 523,715 300,968 606,539 388,380 120,781 |
| NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Crist Diseases and Disorders Research Environmental Health Biomedical Research and Research Taining Biomedical Research Research Cannor Biology Research Human Genome Research Human Genome Research Mental Health Research Grants Arthrits, Musculoskelettal and Skin Diseases Research | Tangeting complement Sa-medist Feasability and acceptability 4/5 HEAL Consortum: Establish Procalcitorin to Reduce Artibis Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog Sepsis from Bedside to Bench to Bedside Regulatory Mechanisms Governi How CHAF1B maintains cell stat Decoding imals immuse signaling in normal Pathogenic Role of Foot! Hypa SiGIAP: a next generation data Validation of a salvary mRNA Development of a urinary borna | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University Icahn School of Medicine at Mount Shail Datinum LLC Quadrant Biosciences Ethos Research and Development, LLC | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0622-00 A21-0001-S001-CCHM RES514545 0255-0602-4609 1R41HG011219-0141 1293481880000 R43AR077338 | R33NS112407 R34AT011218 R34AD450268 R34H415687 R34MH112648 R34MH112648 R35DE027557 R35ES030435 R35GM14988 R35GM129943 R35GM149806 R35GM129943 R35GM140806 R35GM140806 R35GM140807 R34GM15077 R34GM174077 R34GM1747 R34GM1738 | 93.233 93.853 93.273 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 93.859 93.859 93.859 93.859 93.859 93.839 93.839 93.839 93.839 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 426,191 533,715 300,968 606,539 398,380 120,781 20,460 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 460,037 |
| NIH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Environmental Health Biomedical Research and Research Taining Biomedical Research and Research Lauran Genome Research Mental Health Research Mental Health Research Mental Health Research Mental Health Research Althritis, Musculoskeletal and Skin Diseases Research Althritis, Musculoskeletal and Skin Diseases Research | Tangeting complement Sa-mediat Feasability and acceptability 4/5 HEAL Consortium: Establish Procaticion in Reduce Artibil Improving Madestain Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Obl Macrophage regulation of the spermatog Sepsia from Bedaide to Bench to Bedaide Regulatory Mechanisms Governi How CHAF1B maintains call stat Decoding imate immune signaling in normal Pathogenic Role of Foot! Hepa ScIDAP: a next generation dat Validation of a salivary miRNA Development of a urinary borna Low-Cost, Rapid Molecular (Big | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University Icahn School of Medicine at Mount Shail Datinum LLC Quadrant Biosciences Ethos Research and Development, LLC Novel Microdevices | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0622-00 A21-0001-S001-CCHM RESS14545 0255-0602-4609 1RA1HG011219-01A1 1293481860000 R43-NG77338 1RA44135616-101 | R33NS112407 R34AT011218 R34AT011218 R34AD050208 R34HL158474 R34MH112648 R34MH112648 R35MH112648 R35MH112648 R35MH12648 R35MH19458 R35GM126943 R35GM126943 R35GM126943 R35GM126957 R37CA225807 R37CA225807 R37CA225807 R37CA225807 R42MH11347 R43AR077338 | 93.233 93.853 92.213 93.279 93.838 93.242 93.242 93.121 93.113 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139,191 448,529 54,018 277,859 80,804 4,002 122,630 - 28,071 967,424 36,762 381,001 426,191 523,715 300,968 606,539 386,360 120,761 20,460 17,718 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,836 36,762 381,001 460,037 |
| NEH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Crist Diseases and Disorders Research Environmental Health Bismedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research Research Biomedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research and Research Taining Biomedical Research and Research Mental Health Research Grants Arthritis, Musculoskeletal and Skin Diseases Research Allergy, Immunology and Transplantation Research Biomedical Research and Research Taining | Tangeting complement 5a-mediat Feasability and acceptability 4/5 HEAL Consordium: Establish Procability and acceptability Inproving Maclacian Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog Sepsis from Bedside to Bench to Bedside Regulatory Mechanisms Governi How CHAF1B maintains coll stat Decoding inantal immune signaing in normal Pathogenic Role of Foxl1 Heps SiGIAP-1 a next generation data Validation of a salwary mRNA Development of a urinary borna Low-Cost, Rapid Molecular Edg Pontol-Clare Prognostic Toxl | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University Icahn School of Medicine at Mount Shail Datinum LLC Quadrant Biosciences Ethos Research and Development, LLC | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0622-00 A21-0001-S001-CCHM RES514545 0255-0602-4609 1R41HG011219-0141 1293481880000 R43AR077338 | R33NS112407 R34AT011218 R34AT011218 R34AD050208 R34AL158474 R34MH112648 R34MH11266 R350E027557 R35ES030435 R35GM1968 R35GM126943 R35GM126943 R35GM126967 R35GM12697 R35GM126 | 93.233 93.853 93.279 93.838 93.242 93.242 93.121 93.113 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139,191 445,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 426,191 523,715 300,968 606,539 308,360 120,781 20,460 117,718 66,036 80,689 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 460,037 |
| Paid Nation Nati | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disordern Research Oral Diseases and Disordern Research Crail Diseases and Disordern Research Environmental Health Biomedical Research and Research Taining Biomedical Research and Research Alternative Control Research Human Genome Research Human Genome Research Mental Health Research Grants Arthritis, Musculoskeletal and Skin Diseases Research Allergy, Immunology and Transplantation Research Biomedical Research Research Taining Cannor Biology Research | Tangeting complement 5a-medat Feasability and escopiability 4/5 HEAL Consortium: Establish Procalcitonin to Reduce Artibil Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage requisition of the spematog Sepsis from Bedside to Bench to Bedside Regulatory Mechanisms Governi How CHAF-18 maintains cell stat Decoding innais immune signaling in normal Pathoganic Role of Food 1 Hepa SCIGAP: a next generation dat Validation of a salvary miRNA Development of a urinary birna Low-Cost, Rapid Molecular Dag Point-Id-Care Prognosist: Tod Therapeutic trisights through patient | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University Icahn School of Medicine at Mount Shail Datinum LLC Quadrant Biosciences Ethos Research and Development, LLC Novel Microdevices | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0622-00 A21-0001-S001-CCHM RESS14545 0255-0602-4609 1RA1HG011219-01A1 1293481860000 R43-NG77338 1RA44135616-101 | R33NS112407 R34AT011218 R34AT011218 R34AD36028 R34H1158174 R34MH112648 R34MH112648 R34MH112648 R34MH117206 R35DE027557 R35E303435 R35GM129943 R35GM129943 R35GM129943 R35GM129943 R35GM129943 R35GM129943 R35GM129943 R35GM129943 R35GM129943 R42MH111347 R37CA22807 R42MH111347 R43AR077338 R44A136161 R44GM125181 R44GM125181 R44GM125181 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.121 93.113 93.859 93.859 93.859 93.859 93.839 93.396 93.172 93.242 93.42 93.42 93.859 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139,191 448,529 54,018 227,859 80,804 4,002 122,530 - 28,071 997,424 36,762 381,001 426,191 523,715 300,988 606,539 388,360 120,781 20,460 80,889 3,395 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,836 36,762 381,001 460,037 |
| Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled Niled | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disordern Research Oral Diseases and Disordern Research Crain Diseases and Disordern Research Environmental Health Biomedical Research and Research Taining Biomedical Research Mental Health Research Grants Arthritis, Musculoskeletal and Six Diseases Research Altery, Immunology and Transplantation Research Biomedical Research and Research Taining Cancer Biology Research Biomedical Research and Research Taining Cancer Biology Research Aging Research | Tangeting complement 5a-mediat Feasability and acceptability 4/5 HEAL Consortium: Establish Procability and acceptability Inproving Mactication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog Sepsis from Bedside to Bench to Bedside Regulatory Mechanisms Governi How CHAF18 maintains cell state Decoding instale immune signating in normal Pathogenic Role of Foot! Heps SciDAP- a next generation data Validation of a salvary miRNA Development of a urinary borna Low-Cost, Rapid Molecular Edg Point-of-Care Prognostic Tod Therapeutic insights through patient Homeostasis and function of re | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University Icahn School of Medicine at Mount Shail Datinum LLC Quadrant Biosciences Ethos Research and Development, LLC Novel Microdevices | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0622-00 A21-0001-S001-CCHM RESS14545 0255-0602-4609 1RA1HG011219-01A1 1293481860000 R43-NG77338 1RA44135616-101 | R33NS112407 R34AT011218 R34AT011218 R34AD450268 R34LN158374 R34MH112648 R34MH112648 R35DE027557 R35E5030435 R35GM129943 | 93.233 93.853 93.279 93.888 93.242 93.242 93.221 93.121 93.113 93.859 93.859 93.859 93.899 93.396 93.172 93.242 93.242 93.346 93.846 93.855 93.859 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139.191 449.529 54.018 227,859 80.804 4,002 122,630 - 28,071 997,424 36,762 381,001 426,191 523,715 300,968 606,539 396,360 120,781 86,036 80,689 3,395 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 460,037 |
| NBH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Crain Diseases and Disorders Research Environmental Health Biomedical Research and Research Taining Biomedical Research Taining Biomedical Research Human Genome Research Human Genome Research Human Genome Research Alterits, Musculoskeletal and Six Diseases Research Alterits, Musculoskeletal and Six Diseases Research Allergy, Immunology and Transplantation Research Gance Biology Research Aging Research | Tangeting complement 5a-medat Feasability and acceptability 4/5 HEAL Consortium: Establish Procation in Reduce Antibil Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the threspectic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog Sepsis from Bedside to Bench to Bedside Regulatory Mechanisms Governi How CHAF18 maintains cell stat Decoding imate immune signaling in normal Pathogenic Role of Fort! Highs SciDAP-a next generation data Validation of a salvary miRNA Development of a urinary borna Low-Cost, Rapid Molecular Diag Point-of-Care Proposatic Tod Therapeutic insights through patient Homeostasis and function of re Regulation and Runction of me | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University Icahn School of Medicine at Mount Shail Datinum LLC Quadrant Biosciences Ethos Research and Development, LLC Novel Microdevices | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University Univ of California University of Florida Vanderbit University Medical Center | 700266-0622-00 A21-0001-S001-CCHM RESS14545 0255-0602-4609 1RA1HG011219-01A1 1293481860000 R43-NG77338 1RA44135616-101 | R33NS112407 R34AR11218 R34AR412628 R34AR4112648 R34AR4112648 R34AR4112648 R35DE027557 R35ES030435 R35GM140805 R35GM128943 R35GM128943 R35GM128943 R35GM128943 R35GM128943 R35GM128943 R35GM128943 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.121 93.113 93.859 93.859 93.859 93.839 93.172 93.242 93.177 93.242 93.46 93.855 93.866 93.866 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 14,324 - - - - - | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 426,191 523,715 300,968 606,539 389,380 120,781 20,460 17,718 86,036 80,689 3,395 4,038 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 460,037 |
| Niel Niel Niel Niel Niel Niel Niel Niel | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disordern Research Oral Diseases and Disordern Research Environmental Health Biomedical Research and Research Taining Biomedical Research and Research Cancer Biology Research Mental Health Research Grants Atthitis, Musculoskeletal and Skin Diseases Research Biomedical Research Research Biomedical Research Research Biomedical Research Research Research Aging Research Aging Research Aging Research Aging Research Aging Research Aging Research | Tangeting complement Sa-medat Feasability and acceptability 4/5 HEAL Consortium: Establish Procaticion in Reduce Artibil Improving Madestain Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the therapeutic potential of neur Early Warning Systems for Obl Macrophage regulation of the spermatog Sepais from Bedaide to Bench to Bedaide Regulatory Mechanisms Governn How CHAF1e maintains call stat Decoding imale immune signaling in normal Pathogenic Role of Foot! Hepa SciDAP: a next generation data Validation of a salivary miRNA Development of a urinary bicms Low-Cost, Rapid Melecular (Bg Point-Of-Care Prognostic Tod Therapeutic insights through patient Homeostasis and function of the Regulation and | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University Icahn School of Medicine at Mount Shail Datinum LLC Quadrant Biosciences Ethos Research and Development, LLC Novel Microdevices MBio Diagnostics, Inc. | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University. Univ of California University of Florida | 700266-0622-00 A21-0001-S001-CCHM RESS14545 0255-D602-4609 1R41HG011219-01A1 1293481880000 R43-R4077338 1R444136161-01 R444GM125418 | R33NS112407 R34AT011218 R34AT011218 R34AD050208 R34LN150374 R34MH112648 R34MH112648 R34MH112648 R35MH115897 R35ES030436 R35GM126943 R35GM14948 R35GM14948 R35GM14948 R35GM149491 R35GM149492 R35GM149492 R35GM149492 R35GM149492 R35GM149492 R35GM149492 | 93.233 93.853 93.279 93.838 93.242 93.242 93.242 93.121 93.113 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 93.859 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 4,500 | 139,191 448,529 54,018 227,899 80,804 4,002 122,630 - 28,071 967,424 36,762 381,001 426,191 523,715 300,968 606,539 398,360 120,761 20,460 17,718 86,006 80,689 3,395 4,038 224,506 76,813 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,836 36,762 381,001 460,037 523,715 300,968 606,539 388,360 17,718 86,036 80,689 3,395 4,038 224,506 80,7768 |
| NBH | Research and Training in Complementary and Alternative Medicine Drug Abuse and Addiction Research Programs Lung Diseases Research Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Mental Health Research Grants Oral Diseases and Disorders Research Oral Diseases and Disorders Research Crain Diseases and Disorders Research Environmental Health Biomedical Research and Research Taining Biomedical Research Taining Biomedical Research Human Genome Research Human Genome Research Human Genome Research Alterits, Musculoskeletal and Six Diseases Research Alterits, Musculoskeletal and Six Diseases Research Allergy, Immunology and Transplantation Research Gance Biology Research Aging Research | Tangeting complement 5a-medat Feasability and acceptability 4/5 HEAL Consortium: Establish Procation in Reduce Antibil Improving Medication Continuity among Ad Emotion coaching skills as an Improving Adherence in Adolesc Hamessing the threspectic potential of neur Early Warning Systems for Chil Macrophage regulation of the spermatog Sepsis from Bedside to Bench to Bedside Regulatory Mechanisms Governi How CHAF18 maintains cell stat Decoding imate immune signaling in normal Pathogenic Role of Fort! Highs SciDAP-a next generation data Validation of a salvary miRNA Development of a urinary borna Low-Cost, Rapid Molecular Diag Point-of-Care Proposatic Tod Therapeutic insights through patient Homeostasis and function of re Regulation and Runction of me | The Research Instit at Nationwide Hosp Ann & Robert H Lurie Children's Hospital Case Western University Icahn School of Medicine at Mount Shail Datinum LLC Quadrant Biosciences Ethos Research and Development, LLC Novel Microdevices | University of California University of Georgia Nationwide Childrens Hospital The Jackson Laboratory Children's Hosp & Clinics Minnesota Children's Hosp Med Center of Akron Children's Hospital of Philadelphia McMaster University Stanford University Univ of California University of Florida Vanderbit University Medical Center | 700266-0622-00 A21-0001-S001-CCHM RESS14545 0255-0602-4609 1RA1HG011219-01A1 1293481860000 R43-NG77338 1RA44135616-101 | R33NS112407 R34AR11218 R34AR412628 R34AR4112648 R34AR4112648 R34AR4112648 R35DE027557 R35ES030435 R35GM140805 R35GM128943 R35GM128943 R35GM128943 R35GM128943 R35GM128943 R35GM128943 R35GM128943 | 93.233 93.853 93.213 93.279 93.838 93.242 93.242 93.121 93.113 93.859 93.859 93.859 93.839 93.172 93.242 93.177 93.242 93.46 93.855 93.866 93.866 | 8,823 27,602 15,040 2,172 - - 500 500 7,500 2,022 1,000 3,500 14,324 - - - - - | 139,191 448,529 54,018 227,859 80,804 4,002 122,630 - 28,071 997,424 - 36,762 381,001 426,191 523,715 300,968 606,539 389,380 120,781 20,460 17,718 86,036 80,689 3,395 4,038 | 448,529 54,018 248,703 80,804 4,002 159,055 28,071 1,014,636 36,762 381,001 460,037 |

| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Cyst induction and growth in A | | | | R56DK129238 | 93.847 | - | 39,352 | 39,352 |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| NIH | Cardiovascular Diseases Research | Mechanisms of Eosinophil-Assoc | University of Cincinnati | | 013967-00002 | R56HL147898 | 93.837 | - | 19,302 | 19,302 |
| NIH | Cardiovascular Diseases Research | Chronome chanisms of Cardiometa | | | | R56HL158531 | 93.837 | - | 214,079 | 214,079 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Manipulation of microRNA for C | | Indiana University | | R56NS114124 | 93.853 | 15,850 | 274,206 | 290,056 |
| NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Improving delivery of therapeu | | | | R61AR076771 | 93.846 | - | 240,901 | 240,901 |
| NIH | Arthritis, Musculoskeletal and Skin Diseases Research | Electrical Coupling of Circula | | Salk Institute | | R61AR078060 | 93.846 | 30,606 | 292,984 | 323,590 |
| NIH | Child Health and Human Development Extramural Research | Evaluating Assessment and Medi | | Univ of CalifDavis-Mmrrc | | R61HD100934 | 93.865 | 227,909 | 241,924 | 469,833 |
| NIH | Trans-NIH Research Support | COVID-19 Network of Networks E | Rutgers | | 1813 | COVID-19 R61HD105619 | 93.310 | - | 18,804 | 18,804 |
| NIH | National Center on Sleep Disorders Research | Positive airway pressure for t | Children's Hospital of Philadelphia | | 3201930820 | R61HL151253 | 93.233 | - | 63,344 | 63,344 |
| NIH | Lung Diseases Research | Commercial Translation of Biom | | | | R61HL154105 | 93.838 | - | 345,504 | 345,504 |
| NIH | Lung Diseases Research | Human gene transfer and macrop | | University of South Florida | | R61HL156888 | 93.838 | 15,759 | 412,802 | 428,561 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | SPRINT: Signature for Pain Rec | Stanford University Medical Center | | R61NS114926 | R61NS114926 | 93.853 | - | 328,054 | 328,054 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Developing novel biomarkers of | Ann & Robert H Lurie Children's Hospita | ı | 901654-CHMC | R61NS122094 | 93.853 | - | 97,564 | 97,564 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | A generalizable framework for | | University of Pittsburgh | | RC2DK122376 | 93.847 | 149,107 | 609,517 | 996,392 |
| | | | | Yale University | | | | 237,768 | - | |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Systems Biology of Bone Marrow | Children's Hospital Boston | | GENFD0001792995 | RC2DK122533 | 93.847 | - | 12,994 | 12,994 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | APRISE-Dementia (Assessing Pop | University of Cincinnati | | 1 RF1 NS117643-01 | RF1NS117643 | 93.853 | - | 25,347 | 25,347 |
| NIH | Arthritis, Musculoskeletal and Skin Diseases Research | CINCINNATI TRAINING PROGRAM IN | | | | T32AR069512 | 93.846 | | 187,022 | 187,022 |
| NIH | Cancer Research Manpower | Training grant | University of Cincinnati | | 1017546 | T32CA117846 | 93.398 | _ | 102,260 | 102,260 |
| NIH | Cancer Research Manpower | T32 Training grant | University of Cincinnati | | 1017278 | T32CA236764 | 93.398 | | 160,220 | 160,220 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Research Training in Pediatric | • | | | T32DK007695 | 93.847 | - | 167,261 | 167,261 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Pediatric Gastroenterology and | | | | T32DK007727 | 93.847 | - | 554.416 | 554.416 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Research Training in Child Beh | | | | T32DK063929 | 93.847 | _ | 439.651 | 439.651 |
| NIH | Environmental Health | Training grant | University of Cincinnati | | 1016232 | T32ES007250 | 93.113 | _ | 62.074 | 62.074 |
| NIH | Environmental Health | Environmental Carcinogenesis a | University of Cincinnati | | 1017372 | T32ES007250 | 93.113 | - | 54,702 | 54.702 |
| NIH | Environmental Health | Training grant | University of Cincinnati | | 1016305 | T32ES010957 | 93.113 | _ | 74,327 | 74.327 |
| NIH | Biomedical Research and Research Training | Host Response to Trauma Resear | University of Cincinnati | | 1017224 | T32GM847828 | 93.859 | - | 76,048 | 76,048 |
| NIH | Child Health and Human Development Extramural Research | Enhancing Pediatric Treatment Adherence | | | | T32HD068223 | 93.865 | _ | 330,706 | 330,706 |
| NIH | Child Health and Human Development Extramural Research | T32 Cincinnati Pediatric Clini | | | | T32HD069054 | 93.865 | | 146,902 | 146,902 |
| NIH | Lung Diseases Research | Pulmonary Development and Dise | | | | T32HL007752 | 93.838 | _ | 323.896 | 323.896 |
| NIH | Cardiovascular Diseases Research | Understanding Cardiovasquar D | | | | T32HL125204 | 93.837 | - | 296.527 | 296.527 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Cerebrovascular Fellowship Tra | University of Cincinnati | | 013104-002 | T32NS047996 | 93.853 | | 10.446 | 10.446 |
| NH | Lung Diseases Research | Cincinnati Children's Summer M | Oniversity of Ciricinnati | | 0 13 104-002 | T35HL113229 | 93.838 | | 59,221 | 59,221 |
| NIH | Allergy, Immunology and Transplantation Research | Gene therapy for SCID-X1 with | Children's Hospital Boston | | GENFD0001865408 | U01Al125051 | 93.855 | | 2,807 | 2,807 |
| NIH | Allergy, Immunology and Transplantation Research | Controlling and Preventing Asthma Prog | Children's Hospital Boston | | GENFD0002045257 | U01Al126614 | 93.855 | | 299.841 | 299.841 |
| NIH | Allergy, Immunology and Transplantation Research | Gene Regulation as a Foundation for Auto | Cilidens respiral boston | Stanford University. | GLIVI DOUGZONGZGI | U01AI130830 | 93.855 | 215.638 | 649,520 | 1.161.409 |
| TAIL I | Allergy, illimunology and manapiantation research | Gene Negulation as a Foundation for Auto | | The Scripps Research Institute | | 00 IAI130000 | 83.003 | 168.309 | 049,520 | 1,101,405 |
| | | | | University of Colorado | | | | 36,480 | _ | |
| | | | | University of Nebraska Med Center | | | | 91.462 | | |
| NIH | Allergy, Immunology and Transplantation Research | COVID-19 Exosomes and the Immune Respon | Stanford University | University of Nebraska Wed Certier | 62502353-128779 | COVID-19 U01Al135950-03S1 | 93.855 | 81,402 | 91.681 | 91.681 |
| NIH | Allergy, Immunology and Transplantation Research | Impact of the Initial Influenz | Stanista Ginerally | University of Cincinnati | 02002000 120110 | U01Al144673 | 93.855 | 373,522 | 2,855,311 | 3,228,833 |
| NIH | Allergy, Immunology and Transplantation Research | COVID-19 Epidemiology and Immu | | University of Cincinnati | | COVID-19 U01Al144673-02S1 | 93.855 | 96,984 | 3,242,787 | 3,339,771 |
| NIH | Allergy, Immunology and Transplantation Research | Dynamic regulatory network mod | Icahn School of Medicine at Mount Sina | | 0255-E053-4609 | U01Al150748 | 93.855 | 30,304 | 351.161 | 351,161 |
| NIH | Allergy, Immunology and Transplantation Research | Atopic dermatitis: mechanisms | Icanni Scribbi di Medicine at Modifi Sila | 11 | 0233120334008 | U01AI152034 | 93.855 | | 220,694 | 220,694 |
| NIH | Allergy, Immunology and Transplantation Research | Genomics of Nephrotic Syndrome | Duke University | | 265416 / A034556 | U01Al152585 | 93.855 | | 130 | 130 |
| NIH | Allergy, Immunology and Transplantation Research | Randomized trial of viral spec | Duke Officerolly | | 2034107 7034030 | U01Al157620 | 93.855 | - | 497,311 | 497,311 |
| NIH | Allergy, Immunology and Transplantation Research | Multi-omics of the Frequent Ex | | | | U01Al159087 | 93.855 | | 368.268 | 368.268 |
| NIH | Allergy, Immunology and Transplantation Research | Advancing Transplantation Outc | Harvard Medical School | | GENFD0002098919 | U01Al163072 | 93.855 | | 13,856 | 13,856 |
| NH | | Itacitinib to reduce lung infl | Duke University | | A03-5348/1U01Al1630 | | 93.855 | - | 33,308 | 33,308 |
| NH | Allergy, Immunology and Transplantation Research | Mind Body Balance for Pediatri | Duke Officerolly | University of Colorado | A03-3340/100 IA11030 | U01AT010132 | 93.213 | 80.330 | 528.116 | 630.089 |
| NIH | Research and Training in Complementary and Alternative Medicine | Mind Body Balance for Pediatri | | University of Virginia | | 001A1010132 | 93.213 | 21.643 | 528,116 | 630,089 |
| NIH | Drug Abuse and Addiction Research Programs | First-In-Human Study of a Huma | University of Cincinnati | Oniversity of Virginia | 012264-003 | U01DA048525 | 93.279 | 21,043 | 72.714 | 72,714 |
| NIH | Drug Abuse and Addiction Research Programs | 4/6 HBCD Prenatal Experiences | University of Ciricinati | | 0 12204-003 | U01DA055342 | 93.279 | | 291.945 | 291,945 |
| NH | 3 | | D | | SITZMAN-20-03 | | | - | | |
| NIH | Oral Diseases and Disorders Research Diabetes, Digestive, and Kidney Diseases Extramural Research | Velopharyngeal insufficiency f TODAY2 Phase 2 (T2P2): Long-Term Post | Phoenix Children's Hospital George Washington University | | | | | | 24.002 | |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | | | | | U01DE029750 | 93.121 | - | 24,983 | 24,983 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | | | | 17-D05 | U01DK061230 | 93.847 | - | 5,066 | 5,066 |
| NH | | Non Alcoholic Steatohepatitis Clinical Center for Cholestati | Cleveland Clin Lerner Col of Med of CW | | | U01DK061230 U01DK061732 | 93.847 93.847 | - - - | 5,066 153,037 | 5,066 153,037 |
| 14011 | | Clinical Center for Cholestati | Cleveland Clin Lerner Col of Med of CW | | 17-D05 1324-SUB | U01DK061230 U01DK061732 U01DK062497 | 93.847 93.847 93.847 | - - - | 5,066 153,037 869,719 | 5,066 153,037 869,719 |
| NH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Clinical Center for Cholestati CKID IV (patient care and sala | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital | | 17-D05 1324-SUB 18-0007 | U01DK061230 U01DK061732 U01DK062497 U01DK066143 | 93.847 93.847 | - - - - - | 5,066 153,037 869,719 65,978 | 5,066 153,037 869,719 65,978 |
| NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research | Clinical Center for Cholestati | Cleveland Clin Lerner Col of Med of CW | | 17-D05 1324-SUB | U01DK061230 U01DK061732 U01DK062497 | 93.847 93.847 93.847 93.847 93.847 | - - - - - - | 5,066 153,037 869,719 65,978 14,912 | 5,066 153,037 869,719 65,978 14,912 |
| | Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research | Clinical Center for Cholestati CKID IV (patient care and sala CUREGN 2.0 - Midwest Pediatric Defining the intestinal stem c | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital | | 17-D05 1324-SUB 18-0007 | U01DK061230 U01DK061732 U01DK062497 U01DK066143 U01DK100866 | 93.847 93.847 93.847 93.847 | | 5,066 153,037 869,719 65,978 14,912 274,253 | 5,066 153,037 869,719 65,978 14,912 274,253 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research | Clinical Center for Cholestati CKID IV (patient care and sala CUREGN 2.0 - Midwest Pediatric | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital | | 17-D05 1324-SUB 18-0007 700198-0620-00 | U01DK061230 U01DK061732 U01DK062497 U01DK066143 U01DK10866 U01DK10866 U01DK1083117 U01DK108328 | 93.847 93.847 93.847 93.847 93.847 | - - - - - - - - | 5,066 153,037 869,719 65,978 14,912 | 5,066 153,037 869,719 65,978 14,912 |
| NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Clinical Center for Cholestati CKID IV (patient care and sala CUREGN 2.0 - Midwest Pediatric Defining the intestinal stem c Consortium for the Study of Ch | Cleveland Clin Lerner Col of Med of CN Children's Mercy Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health | | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 | U01DK061230 U01DK061732 U01DK062497 U01DK066143 U01DK100866 U01DK103117 | 93.847 93.847 93.847 93.847 93.847 93.847 | - - - - - - - - | 5,066 153,037 869,719 65,978 14,912 274,253 10,386 | 5,066 153,037 869,719 65,978 14,912 274,253 10,386 |
| NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Clinical Center for Cholestati CKID IV (gatient care and sale CUREGN 2.0 - Midwest Pediatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital University of Iowa | | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 | U01DK061230 U01DK061732 U01DK066497 U01DK066143 U01DK100666 U01DK100817 U01DK100817 U01DK1008128 U01DK122013 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 | | 5,066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 | 5,066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 |
| NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health | Clinical Center for Chobstatis CKID IV (patient care and sals CUREGN 2.0 - Midwest Prediatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture Prenatal inflammatory exposures and neo | Cleveland Clin Lerner Col of Med of CN Children's Mercy Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health | | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 | U010/R061230 U010/R061732 U010/R068497 U010/R066143 U010/R066143 U010/R0686 U010/R063117 U010/R06328 U010/R022013 U010/R022013 U010/R022016 U010/R062996 U0168029234 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 | - - - - - - - - - - - - - - - - - - - | 5,066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 | 5,066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 |
| NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Clinical Center for Cholestati CKID IV (gatient care and sale CUREGN 2.0 - Midwest Pediatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture | Cleveland Clin Lerner Col of Med of CN Children's Mercy Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health | Children's Hospilal Boston | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 | U01DK061230 U01DK061732 U01DK066143 U01DK066143 U01DK100866 U01DK1008117 U01DK10828 U01DK10823 U01DK122013 U01DK122013 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 | 82,197 312,482 | 5,066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 | 5,066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 |
| NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health | Clinical Center for Cholestali CKID IV (gatient care and sala CUREGN 2.0 - Midwest Pediatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture Prenetal inflammatory exposures and neo Polygenic Risk Scores for Heal | Cieveland Clin Lerner Col of Med of CW Children's Mency Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health Lurie Children's Hospital of Chicago | | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH | U010M61230 U01DM661230 U01DM662497 U01DM666143 U01DM606143 U01DM1008166 U01DM103117 U01DM108128 U01DM122013 U01DM122013 U01ES029234 U01HG011172 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.8113 93.172 | | 5,066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 789,517 | 5,066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 |
| NIH NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research | Clinical Center for Onoisstati CKID IV (patient care and saia CUREGN 2.0 - Midwest Pedatatic Defining the intestinal stem c Consortium for the Study of On Phosphate binder therapy and c Pedatatic Acute Liver Faiture Prenatal inflammatory exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dyslipidemia of Obesty | Cieveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes | Children's Hospilal Boston | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH | U0110K081230 U0110K081230 U0110K086143 U0110K08686 U0110K103117 U0110K103218 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K122013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K12013 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110K120 U0110 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 | | 5,065 153,037 866,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 789,517 | 5,066 153,037 889,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 |
| NIH NIH NIH NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research Cardiovascular Diseases Research Cardiovascular Diseases Research | Clinical Center for Cholestati CKID IV (patient care and sets UCREGN 2.0 - Midwest Pediatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture Prenatal inflammatory exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dyslipidemia of Obestly Impact of Treatment of Mild Sleep-Disorder | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital University of Ioxa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia | Children's Hospilal Boston | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH | U010M61230 U010M68133 U010M68497 U010M68643 U010M086613 U010M0866 U010M08117 U010M0823 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 | | 5,065 153,037 866,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 789,517 239 1,026 | 5,066 153,037 889,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 |
| NH NH NH NH NH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research Lung Diseases Research Lung Diseases Research | Clinical Center for Onoisstati CKID IV (patient care and saia CUREGN 2.0 - Midwest Pedatatic Defining the intestinal stem c Consortium for the Study of On Phosphate binder therapy and c Pedatatic Acute Liver Faiture Prenatal inflammatory exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dyslipidemia of Obesty | Cieveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes | Children's Hospital Boston University of Cincinnati | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH | U01DK061230 U01DK062497 U01DK062497 U01DK062497 U01DK06643 U01DK103017 U01DK103017 U01DK102013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | | 5,066 153,037 869,719 65,978 14,912 277,283 10,386 6,394 3,264 139,000 789,517 29 1,026 300,067 | 5,066 153,037 889)719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 336,067 |
| NIH NIH NIH NIH NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research Cardiovascular Diseases Research Cardiovascular Diseases Research | Clinical Center for Cholestatis CKID IV (patient care and sals CUREGN 2.0 - Midwest Prediatric Defining the intestinal store c Consortium for the Study of Ch Phosphate binder herapy and c Pediatric Acute Liver Faiture Prenatal inflammatory exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dyslipidemia of Obestly Impact of Treatment of Mid Sleep-Disorder ORBEX: Primary Prevention of Asthma | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital University of Ioxa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia | Children's Hospital Boston University of Cincinnati Brigham and Women's Hospital | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH | U010M61230 U010M68133 U010M68497 U010M68643 U010M086613 U010M0866 U010M08117 U010M0823 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 U010M22013 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 | 312,482 - - | 5,065 153,037 866,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 789,517 239 1,026 | 5,066 153,037 889,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 |
| NIH NIH NIH NIH NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research Lung Diseases Research Lung Diseases Research | Clinical Center for Cholestatis CKID IV (patient care and sals CUREGN 2.0 - Midwest Prediatric Defining the intestinal store c Consortium for the Study of Ch Phosphate binder herapy and c Pediatric Acute Liver Faiture Prenatal inflammatory exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dyslipidemia of Obestly Impact of Treatment of Mid Sleep-Disorder ORBEX: Primary Prevention of Asthma | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital University of Ioxa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia | Children's Hospital Boston University of Cincinnati | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH | U01DK061230 U01DK062497 U01DK062497 U01DK062497 U01DK06643 U01DK103017 U01DK103017 U01DK102013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 312,482 - - - 83,157 | 5,066 153,037 869,719 65,978 14,912 277,283 10,386 6,394 3,264 139,000 789,517 29 1,026 300,067 | 5,066 153,037 889)719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 336,067 |
| NIH NIH NIH NIH NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research Lung Diseases Research Lung Diseases Research | Clinical Center for Cholestatis CKID IV (patient care and sals CUREGN 2.0 - Midwest Prediatric Defining the intestinal store c Consortium for the Study of Ch Phosphate binder herapy and c Pediatric Acute Liver Faiture Prenatal inflammatory exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dyslipidemia of Obestly Impact of Treatment of Mid Sleep-Disorder ORBEX: Primary Prevention of Asthma | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital University of Ioxa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia | Children's Hospital Boston University of Cincinnati Brigham and Women's Hospital Children's Hospital Boston | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH | U01DK061230 U01DK062497 U01DK062497 U01DK062497 U01DK06643 U01DK103017 U01DK103017 U01DK102013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 312,482 - - - - 83,157 203,264 | 5,066 153,037 869,719 65,978 14,912 277,283 10,386 6,394 3,264 139,000 789,517 29 1,026 300,067 | 5,066 153,037 889)719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 336,067 |
| NIH NIH NIH NIH NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research Lung Diseases Research Lung Diseases Research | Clinical Center for Cholestatis CKID IV (patient care and sals CUREGN 2.0 - Midwest Prediatric Defining the intestinal store c Consortium for the Study of Ch Phosphate binder herapy and c Pediatric Acute Liver Faiture Prenatal inflammatory exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dyslipidemia of Obestly Impact of Treatment of Mid Sleep-Disorder ORBEX: Primary Prevention of Asthma | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital University of Ioxa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia | Children's Hospital Boston University of Cincinnati Brigham and Women's Hospital Children's Hospital Boston Children's Hospital Los Angeles | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH | U01DK061230 U01DK062497 U01DK062497 U01DK062497 U01DK06643 U01DK103017 U01DK103017 U01DK102013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 312,482 - - - - 83,157 203,264 600 | 5,066 153,037 869,719 65,978 14,912 277,283 10,386 6,394 3,264 139,000 789,517 29 1,026 300,067 | 5,066 153,037 889)719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 336,067 |
| NIH NIH NIH NIH NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research Lung Diseases Research Lung Diseases Research | Clinical Center for Cholestatis CKID IV (patient care and sals CUREGN 2.0 - Midwest Prediatric Defining the intestinal store c Consortium for the Study of Ch Phosphate binder herapy and c Pediatric Acute Liver Faiture Prenatal inflammatory exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dyslipidemia of Obestly Impact of Treatment of Mid Sleep-Disorder ORBEX: Primary Prevention of Asthma | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital University of Ioxa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia | Children's Hospital Boston University of Cincinnati Brigham and Women's Hospital Children's Hospital Boston Children's Hospital Dos Angeles Children's Hospital of Philadelphia | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH | U01DK061230 U01DK062497 U01DK062497 U01DK062497 U01DK06643 U01DK103017 U01DK103017 U01DK102013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 312,482 - - - 83,157 203,264 600 75,000 | 5,066 153,037 869,719 65,978 14,912 277,283 10,386 6,394 3,264 139,000 789,517 29 1,026 300,067 | 5,066 153,037 889)719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 336,067 |
| NIH NIH NIH NIH NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research Lung Diseases Research Lung Diseases Research | Clinical Center for Cholestatis CKID IV (patient care and sals CUREGN 2.0 - Midwest Prediatric Defining the intestinal store c Consortium for the Study of Ch Phosphate binder herapy and c Pediatric Acute Liver Faiture Prenatal inflammatory exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dyslipidemia of Obestly Impact of Treatment of Mid Sleep-Disorder ORBEX: Primary Prevention of Asthma | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital University of Ioxa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia | Children's Hospital Boston University of Cincinnati Brigham and Women's Hospital Children's Hospital Boston Children's Hospital Los Angeles Children's Hospital of Philadelphia Columbia University | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH | U01DK061230 U01DK062497 U01DK062497 U01DK062497 U01DK06643 U01DK103017 U01DK103017 U01DK102013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 312,482 - - - 83,157 203,264 600 75,000 20,159 | 5,066 153,037 869,719 65,978 14,912 277,283 10,386 6,394 3,264 139,000 789,517 29 1,026 300,067 | 5,086 153,037 889)719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 336,067 |
| NIH NIH NIH NIH NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research Lung Diseases Research Lung Diseases Research | Clinical Center for Cholestatis CKID IV (patient care and sals CUREGN 2.0 - Midwest Prediatric Defining the intestinal store c Consortium for the Study of Ch Phosphate binder herapy and c Pediatric Acute Liver Faiture Prenatal inflammatory exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dyslipidemia of Obestly Impact of Treatment of Mid Sleep-Disorder ORBEX: Primary Prevention of Asthma | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital University of Ioxa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia | Children's Hospital Boston University of Cincinnati Brigham and Women's Hospital Children's Hospital Boston Children's Hospital Los Angeles Children's Hospital Los Angeles Children's Hospital Los Angeles Columbia University | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH | U01DK061230 U01DK062497 U01DK062497 U01DK062497 U01DK06643 U01DK103017 U01DK103017 U01DK102013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 U01DK122013 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 312,482 - - 83,157 203,264 600 75,000 20,159 75,000 | 5,066 153,037 869,719 65,978 14,912 277,283 10,386 6,394 3,264 139,000 789,517 29 1,026 300,067 | 5,086 153,037 889)719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 336,067 |
| NIH NIH NIH NIH NIH NIH NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research | Clinical Center for Cholestati CKID IV (patient care and sala CUREGN 2.0 - Midwest Prediatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture Prenstal infammation exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dystipidemia of Obesty Impact of Treatment of Midd Sleep-Disorder ORBEX: Primary Prevention of Asthma Administrative Coordinating Ce Multicenter Interventional Lymphangiolebmy | Cleveland Clin Lerner Col of Med of CW Children's Mercy Hospital Nationwide Children's Hospital University of Ioxa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia | Children's Hospital Boston University of Cincinnati Brigham and Women's Hospital Children's Hospital Boston Children's Hospital Los Angelse Children's Hospital of Philadephia Columbia University Holland Blooview Kits Mount Sinal School of Medicine | 17-D05 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH | U010K081230 U010K082497 U010K082497 U010K08643 U010K08086 U010K108117 U010K108238 U010K122913 U010K122913 U010K122913 U010K022913 U010K022913 U010K022913 U010K022913 U010K022913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 83,157 203,264 600 75,000 20,159 75,000 43,720 77,304 | 5.066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 789,517 - 239 1,026 300,047 3,000,374 | 5,086 153,037 889,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 306,067 3,578,578 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Human Genome Research Cardiovascular Diseases Research Lung Diseases Research Cardiovascular Diseases Research Cardiovascular Diseases Research | Clinical Center for Cholestati CKID IV (patient care and sals CUREGN 2.0 - Midwest Pedatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture Prenatal inflammatory exposures and reco Polygenic Risk Scores for Heal Vascular Core for Dyslipidemia of Obesty Impact of Treatment of Mid Sieep-Disorder ORBEX: Primary Prevention of Ashma Administrative Coordinating Co | Cieveland Clin Lerner Col of Med of CW Children's Mency Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia University of Arizona | Children's Hospital Boston University of Cincinnati Brigham and Women's Hospital Children's Hospital Boston Children's Hospital Los Angelse Children's Hospital of Philadephia Columbia University Holland Blooview Kits Mount Sinal School of Medicine | 17-005 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH U01H-088270 U01H-125295 PO 438886 | U0110061230 U0110066123 U0110066143 U01100666143 U0110010866 U01100103117 U01100120338 U01100122013 U01100122013 U01100122013 U01100122013 U01100122013 U01100122013 U0110011172 U01140011172 U01140011172 U011410011010101 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.172 93.837 93.837 93.838 93.837 | 312,482 | 5,066 153,037 866,719 65,978 14,912 274,253 10,366 6,384 3,264 139,000 789,517 | 5,086 153,037 889,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 366,967 3,578,578 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research | Clinical Center for Cholestati CKID IV (patient care and sala CUREGN 2.0 - Midwest Prediatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture Prenstal infammation exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dystipidemia of Obesty Impact of Treatment of Midd Sleep-Disorder ORBEX: Primary Prevention of Asthma Administrative Coordinating Ce Multicenter Interventional Lymphangiolebmy | Cieveland Clin Lerner Col of Med of CW Children's Mency Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia University of Arizona | Children's Hospital Boston University of Cincirnati Brigharm and Women's Hospital Children's Hospital Boston Children's Hospital Boston Children's Hospital Los Angeles Children's Hospital Los Angeles Children's Hospital of Philadelphia Columbia University Holland Blooriew Kitis Mount Sinai School of Medicine University of Ueh | 17-005 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH U01H-088270 U01H-125295 PO 438886 | U010K081230 U010K082497 U010K082497 U010K08643 U010K08086 U010K108117 U010K108238 U010K122913 U010K122913 U010K122913 U010K022913 U010K022913 U010K022913 U010K022913 U010K022913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 83,157 203,264 600 75,000 20,159 75,000 43,720 77,304 | 5.066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 789,517 - 239 1,026 300,047 3,000,374 | 5,086 153,037 889,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 306,067 3,578,578 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research | Clinical Center for Cholestati CKID IV (patient care and sala CUREGN 2.0 - Midwest Prediatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture Prenstal infammation exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dystipidemia of Obesty Impact of Treatment of Midd Sleep-Disorder ORBEX: Primary Prevention of Asthma Administrative Coordinating Ce Multicenter Interventional Lymphangiolebmy | Cieveland Clin Lerner Col of Med of CW Children's Mency Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia University of Arizona | Children's Hospital Boston University of Cincinnati Brigham and Women's Hospital Children's Hospital Boston Children's Hospital Los Angelse Children's Hospital of Philadephia Columbia University Holland Bloonview Kids Mount Sinal School of Mediche University of Ush Aclaim Baylor College of Medicine. CEFA/Centre Hospitalier Monicole | 17-005 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH U01H-088270 U01H-125295 PO 438886 | U010K081230 U010K082497 U010K082497 U010K08643 U010K08086 U010K108117 U010K108238 U010K122913 U010K122913 U010K122913 U010K022913 U010K022913 U010K022913 U010K022913 U010K022913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 312,482 - - 83,157 200,284 600 75,000 20,159 75,000 43,720 77,304 - 8,442 29,074 67,696 | 5.066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 789,517 - 239 1,026 300,047 3,000,374 | 5,086 153,037 889,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 306,067 3,578,578 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research | Clinical Center for Cholestati CKID IV (patient care and sala CUREGN 2.0 - Midwest Prediatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture Prenstal infammation exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dystipidemia of Obesty Impact of Treatment of Midd Sleep-Disorder ORBEX: Primary Prevention of Asthma Administrative Coordinating Ce Multicenter Interventional Lymphangiolebmy | Cieveland Clin Lerner Col of Med of CW Children's Mency Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia University of Arizona | Children's Hospital Boston University of Cincinnati Brigham and Women's Hospital Children's Hospital Boston Children's Hospital Boston Children's Hospital Ios Angeles Children's Hospital Ios Angeles Children's Hospital Ios Angeles Children's Hospital of Philadelphia Children's Hospital of Mediche University of University Holland Bloonview Kits Mount Sinai School of Mediche University of Uni | 17-005 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH U01H-088270 U01H-125295 PO 438886 | U010K081230 U010K082497 U010K082497 U010K08643 U010K08086 U010K108117 U010K108238 U010K122913 U010K122913 U010K122913 U010K022913 U010K022913 U010K022913 U010K022913 U010K022913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 312.482 - - 83.157 200.264 600 75.000 20.159 75.000 43.720 77.304 - 8.442 20.074 | 5.066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 789,517 - 239 1,026 300,047 3,000,374 | 5,086 153,037 889,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 306,067 3,578,578 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research | Clinical Center for Cholestati CKID IV (patient care and sala CUREGN 2.0 - Midwest Prediatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture Prenstal infammation exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dystipidemia of Obesty Impact of Treatment of Midd Sleep-Disorder ORBEX: Primary Prevention of Asthma Administrative Coordinating Ce Multicenter Interventional Lymphangiolebmy | Cieveland Clin Lerner Col of Med of CW Children's Mency Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia University of Arizona | Children's Hospital Boston University of Cincimat Brigham and Women's Hospital Children's Hospital Boston Children's Hospital Boston Children's Hospital Los Angeles Children's Hospital Los Angeles Children's Hospital Los Angeles Children's Hospital Finitedephia Columbia University Mount Sinai School of Medicine University of Usah Adaim Baylor College of Medicine. CEFA/Contre Hospitaller Mohlob Hospital Pediatrico David Bernardno Mbale Regional Referral Hospital | 17-005 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH U01H-088270 U01H-125295 PO 438886 | U010K081230 U010K082497 U010K082497 U010K08643 U010K08086 U010K108117 U010K108238 U010K122913 U010K122913 U010K122913 U010K022913 U010K022913 U010K022913 U010K022913 U010K022913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 312,482 - - 83,157 200,264 600 75,000 20,159 75,000 43,720 77,304 - - 8,442 29,074 67,696 110,356 88,389 | 5.066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 789,517 - 239 1,026 300,047 3,000,374 | 5,086 153,037 889,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 306,067 3,578,578 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research | Clinical Center for Cholestati CKID IV (patient care and sala CUREGN 2.0 - Midwest Prediatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture Prenstal infammation exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dystipidemia of Obesty Impact of Treatment of Midd Sleep-Disorder ORBEX: Primary Prevention of Asthma Administrative Coordinating Ce Multicenter Interventional Lymphangiolebmy | Cieveland Clin Lerner Col of Med of CW Children's Mency Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia University of Arizona | Children's Hospital Boston University of Cincinnati Brigham and Women's Hospital Children's Hospital Boston Children's Hospital Boston Children's Hospital Os Angeles Children's Hospital of Philadethia Columbia University Holland Bloonview Kids Mount Sinal School of Mediche University of Useh Adaim Baylor College of Medicine. CEFA/Carther Hospitalier Monkole Hospital Pediatrico David Bernardno Mbale Regional Referral Hospital The Chancellor, Masters and Scholars | 17-005 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH U01H-088270 U01H-125295 PO 438886 | U010K081230 U010K082497 U010K082497 U010K08643 U010K08086 U010K108117 U010K108238 U010K122913 U010K122913 U010K122913 U010K022913 U010K022913 U010K022913 U010K022913 U010K022913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 312,482 | 5.066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 789,517 - 239 1,026 300,047 3,000,374 | 5,086 153,037 889,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 306,067 3,578,578 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Environmental Health Human Genome Research Cardiovascular Diseases Research | Clinical Center for Cholestati CKID IV (patient care and sala CUREGN 2.0 - Midwest Prediatric Defining the intestinal stem c Consortium for the Study of Ch Phosphate binder therapy and c Pediatric Acute Liver Faiture Prenstal infammation exposures and neo Polygenic Risk Scores for Heal Vascular Core for Dystipidemia of Obesty Impact of Treatment of Midd Sleep-Disorder ORBEX: Primary Prevention of Asthma Administrative Coordinating Ce Multicenter Interventional Lymphangiolebmy | Cieveland Clin Lerner Col of Med of CW Children's Mency Hospital Nationwide Children's Hospital University of Iowa UCLA School of Public Health Lurie Children's Hospital of Chicago New England Research Institutes Children's Hospital of Philadelphia University of Arizona | Children's Hospital Boston University of Cincimat Brigham and Women's Hospital Children's Hospital Boston Children's Hospital Boston Children's Hospital Los Angeles Children's Hospital Los Angeles Children's Hospital Los Angeles Children's Hospital Finitedephia Columbia University Mount Sinai School of Medicine University of Usah Adaim Baylor College of Medicine. CEFA/Contre Hospitaller Mohlob Hospital Pediatrico David Bernardno Mbale Regional Referral Hospital | 17-005 1324-SUB 18-0007 700198-0620-00 W001038585 1652 G YA029 901628-OCH U01H-088270 U01H-125295 PO 438886 | U010K081230 U010K082497 U010K082497 U010K08643 U010K08086 U010K108117 U010K108238 U010K122913 U010K122913 U010K122913 U010K022913 U010K022913 U010K022913 U010K022913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K02913 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K029 U010K | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.113 93.172 93.837 93.837 93.837 | 312,482 - - 83,157 200,264 600 75,000 20,159 75,000 43,720 77,304 - - 8,442 29,074 67,696 110,356 88,389 | 5.066 153,037 869,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 789,517 - 239 1,026 300,047 3,000,374 | 5,086 153,037 889,719 65,978 14,912 274,253 10,386 6,384 3,264 139,000 1,184,196 239 1,026 306,067 3,578,578 |

| NIH | Lung Diseases Research | Editing Alveolar Progenitor Cells for Correct | | Battelle Memorial Institute | | U01HL134745 | 93.838 | 35,864 353,959 | 361,685 | 1,344,702 |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------|-------------------------------------|------------------|-----------------------------|---------------------|---------------------|
| | | | | Boston University Johns Hopkins University National Jewish Health | | | | 353,959 10,500 11,110 | - - - | |
| | | | | Univ of Pennsylvania | | | | 527,621 | - | |
| NIH | Blood Diseases and Resources Research | Darbepoetin Trial to Improve R | University of Utah | Washington University | 10053175-02 | U01HL136318 | 93.839 | 43,963 | 29.055 | 29.055 |
| NIH | Blood Diseases and Resources Research | Sickle Cell Improvement, Enhan | Medical College of Wisconsin | | U01HL143477 | U01HL143477 | 93.839 | - | 7,352 | 7,352 |
| NIH | Lung Diseases Research | LungMan Phase II - Building a | | Cedars-Sinai Medical Center Massachusetts General Hospital | | U01HL148856 | 93.838 | 9,875 103,781 | 744,427 | 859,437 |
| NIH | Cardiovascular Diseases Research | LungMap Phase II - Building a Lung Map submission with UC Sa | University of California San Diego | The Broad Institute Inc. | 125063615 | U01HL148867 | 93.837 | 1,354 | 44.226 | 44.226 |
| NIH | Blood Diseases and Resources Research | Sickle Cell Improvement: ENhan | Medical College of Wisconsin | | U01HL159850 | U01HL159850 | 93.839 | - | 44,335 | 44,335 |
| NIH | Lung Diseases Research | Eliminating Monitor Overuse (E | Children's Hospital of Philadelphia | | GRT-00001474 | U01HL159880 | 93.838 | - | 34,743 | 34,743 |
| NIH NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders Extramural Res Programs in the Neurosciences & Neurological Disorders | Neuronext NN107 Preventing Epilepsy Using Vigabatrin | University of Cincinnati University of Alabama-Birmingham | | 009175-018 U01NS092595 | U01NS077311 U01NS092595 | 93.853 93.853 | - | 5,204 13,452 | 5,204 13.452 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | High-dose Erythropoietin for Asphyxia | University of California | | 10018sc | U01NS092764 | 93.853 | - | 32,669 | 32,669 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Perinatal Arterial Stroke: A M | University of Cincinnati | | 011961-136901 | U01NS106655 | 93.853 | - | 17,395 | 17,395 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Pediatric Dose Optimization fo | Baylor College of Medicine | | 0001625 | U01NS114042 | 93.853 | - | 62,777 | 62,777 |
| NIH NIH | National Center for Advancing Translational Sciences National Center for Advancing Translational Sciences | STeroids to REduce Systemic inflammation Disseminating Curative Biological Therap | Duke University Children's Hospital Boston | | 203-8371 U01TR001814 | U01TR001803 U01TR001814 | 93.350 93.350 | - | 6,761 94.640 | 6,761 94,640 |
| NIH | National Center for Advancing Translational Sciences | Precision Medicine in the Diag | Tufts Medical Center | | 5016131-SERV | U01TR002271 | 93.350 | = | 127,907 | 127,907 |
| NIH | National Center for Advancing Translational Sciences | Instrumenting the Delivery Sys | Children's Hospital Boston | | GENFD0001706578 | U01TR002623 | 93.350 | - | 208,060 | 208,060 |
| NIH NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Cancer Treatment Research | INSPPIRE: A Longitudinal Cohor Dasqupta COG from PHI | University of lowa Public Health Institute | | S02042-02 AR04476 | U02DK108334 U10CA180886 | 93.847 93.395 | - | 100,639 7,834 | 100,639 7.834 |
| NIH | Cancer Treatment Research | COMMITTEE LEADERSHIP: NIH Nati | Public Health Institute | | AR03217 | U10CA180886 | 93.395 | - | 50,058 | 50,058 |
| NIH | Cancer Treatment Research | O'Brien PHI-COG Study Chair AA | Public Health Institute | | AR03402 | U10CA180886 | 93.395 | - | 31,303 | 31,303 |
| NIH | Cancer Treatment Research | Norris PHI-COG Associate Medic | Public Health Institute | | AR03186 | U10CA180886 | 93.395 | - | 41,731 | 41,731 |
| NIH | Cancer Treatment Research | Study Chair | Public Health Institute | | AR03451 | U10CA180886 | 93.395 | - | 10,435 | 10,435 |
| NIH NIH | Cancer Treatment Research Cancer Treatment Research | Study Chair AREN 1721 2021 COG NCTN Workload Intensity General | Public Health Institute Children's Hospital of Philadelphia | | AR03450 2U10CA180886 | U10CA180886 U10CA180886 | 93.395 93.395 | - | 10,435 8,614 | 10,435 8.614 |
| NIH | Cancer Treatment Research | PHI-COG PCR Work Order 2021 | Public Health Institute | | Norris R. PH/NIH | U10CA180886 | 93.395 | - | 4,524 | 4,524 |
| NIH | Cancer Treatment Research | PHI-COG NCTN Work Order 2021 | Public Health Institute | | U10CA180886 | U10CA180886 | 93.395 | - | 36,999 | 36,999 |
| NIH | Cancer Treatment Research Cancer Treatment Research | NCTN Renal Committee Retreat | Public Health Institute | | AR04978 | U10CA180886 | 93.395 | - | 8,000 | 8,000 |
| NIH NIH | Cancer Treatment Research Cancer Treatment Research | AHEP 1531 (PHI managed) BIQSFP ACNS Integral@U10CA1 | Public Health Institute Public Health Institute | | AR04543/U10CA1808 AR03753 | U10CA180886 U10CA180886 | 93.395 93.395 | - | 29,293 137,719 | 29,293 137,719 |
| NIH | Cancer Treatment Research | Biomarker, Imaging and Quality | Public Health Institute | | AR04810 | U10CA180886 | 93.395 | - | 8,099 | 8,099 |
| NIH | Cancer Treatment Research | COG NCTN Network Group Operati | Children's Hospital of Philadelphia | | 20115662 - RSUB | U10CA180886 | 93.395 | - | 11,046 | 11,046 |
| NIH NIH | Cancer Treatment Research Cancer Treatment Research | COG NCTN Network Group Operati | Children's Hospital of Philadelphia | | AR03425 | U10CA180886 | 93.395 93.395 | - | 15,665 | 15,665 31,982 |
| NIH | Cancer Treatment Research Cancer Treatment Research | COG NCTN Network Group Operati COG NCTN Network Group Operati | Children's Hospital of Philadelphia Public Health Institute | | U10CA180886 renews AR04579 | U10CA180886 | 93.395 | - | 31,982 11,749 | 31,982 11,749 |
| NIH | Cancer Treatment Research | COG NCTN Network Group Operati | Public Health Institute | | AR04575 | U10CA180886 | 93.395 | - | 12,062 | 12,062 |
| NIH | Cancer Treatment Research | Study Chair | Public Health Institute | | AR03426 | U10CA180886 | 93.395 | - | 20,869 | 20,869 |
| NIH | Cancer Treatment Research | Study Chair | Public Health Institute | | AR03413 | U10CA180886 | 93.395 | - | 31,302 | 31,302 |
| NIH NIH | Vision Research Cardiovascular Diseases Research | Phase 1 Trial of Bevacizumab Treatment for Fontan Udenafil Exercise Longitudinal | Jaeb Center for Health Res Fdn., Inc. New England Research Institutes | | U10EY011751 U10HL068270 | U10EY011751 U10HL068270 | 93.867 93.837 | - | 31,221 2,497 | 31,221 2,497 |
| NIH | Allergy, Immunology and Transplantation Research | Epithelial Genes in Allergic I | New England Nessaldi Illahas | | 01012000270 | U19Al070235 | 93.855 | - | 1,318,221 | 1,318,221 |
| NIH | Allergy, Immunology and Transplantation Research | COVID-19 Epithelial Genes in Allergic I | | | | COVID-19 U19Al070235-14S1 | 93.855 | - | 20,880 | 20,880 |
| NIH NIH | Allergy, Immunology and Transplantation Research Cancer Treatment Research | Airway Inflammation and airway monitoring | University of California San Diego | | 83115022 (PO S9001 111287260-7914878 | 6 U19Al070535 U24CA055727 | 93.855 93.395 | - | 146,159 364,580 | 146,159 364,580 |
| NIH | Cancer Treatment Research Diabetes, Digestive, and Kidney Diseases Extramural Research | Childhood Cancer Survivor Study Investigating the role of VPS4 | St Jude's Children's Hospital University of Utah | | 11128/260-/9148/8 | U24CA05727 U24DK126127 | 93.395 | - | 28,158 | 28,158 |
| NIH | Child Health and Human Development Extramural Research | Neonatal Research Network Capitation | RTI International | | NRN: 0216392 | U24HD095254 | 93.865 | - | 476,169 | 476,169 |
| NIH | Child Health and Human Development Extramural Research | dGTEX BPC Participation | The Nat'l Disease Research Interchange | 1 | 141143/1U24HD10653 | | 93.865 | - | 38,236 | 38,236 |
| NIH NIH | Cardiovascular Diseases Research Cardiovascular Diseases Research | Translating gene/pulmonary mac Fontan Udenafil Exercise Longitudinal | University of Maryland (Baltimore) New England Research Institutes | | 1701192 U24HL135691 | U24HL134763 U24HL135691 | 93.837 93.837 | - | 175,648 8,960 | 175,648 8,960 |
| NIH | Cardiovascular Diseases Research | Liver stiffness in Patients wi | New England Research Institutes | | 0001315 | U24HL135691 | 93.837 | - | 29,186 | 29,186 |
| NIH | Cardiovascular Diseases Research | Single Institutional Review Bo | New England Research Institutes | | NERI, Cnota, James | U24HL135691 | 93.837 | - | 242,867 | 242,867 |
| NIH | Cardiovascular Diseases Research | Dyslipidemia of Obesity Intervention in Teen | New England Research Institutes | | U24HL135691 | U24HL135691 | 93.837 | - | 17,147 | 17,147 |
| NIH NIH | Cardiovascular Diseases Research Cardiovascular Diseases Research | Use of Oxandrolone to Promote COVID-19 PHN COVID/MUSIC Study Subcontr | New England Research Institutes New England Research Institutes | | U24HL135691 U24HL135691 | U24HL135691 COVID-19 U24HL135691 | 93.837 93.837 | - | 1,808 35.875 | 1,808 35.875 |
| NIH | Lung Diseases Research | The LungMAP Data Coordination | Ten England Nooddon malaeb | Research Triangle Institute | 02412100001 | U24HL148865 | 93.838 | 139.734 | 1,169,847 | 2.163.107 |
| | • | • | | The Broad Institute Inc. | | | | 284,488 | - | |
| | | | | University of California Santa Cruz | | | | 319,038 | - | |
| | | | | University of California, San Diego University of Rochester | | | | 100,000 100,000 | - | |
| | | | | University of Pennsylvania | | | | 50,000 | - | |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Electrical Stimulation of Indu | University of Cincinnati | | 011609-00009 | U24NS107200 | 93.853 | - | 182,123 | 182,123 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research Trans-NIH Research Support | Obtain healthy reference tissu | University of Cincinnati | | 012507-002 | U2CDK114886 | 93.847 | - | 20,166 | 20,166 |
| NIH NIH | Trans-NIH Research Support National Center for Advancing Translational Sciences | Decentralized and Reproducible Data Management and Coordinati | Duke University | University of Cincinnati | Duke, Brokamp | U2COD023375 U2CTR002818 | 93.310 93.350 | - 1,145 | 15,044 5,317,274 | 15,044 5,318,419 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Clinical, Imaging, and Mucosal | Connecticut Children's Medical Center | , | 21-181065-02 | U34DK126638 | 93.847 | | 6,416 | 6,416 |
| NIH | Allergy, Immunology and Transplantation Research | PRIMARY IMMUNE DEFICIENCY TREA | The Univ of California, San Francisco | | 8404sc | U54Al082973 | 93.855 | - | 624 | 624 |
| NIH | Allergy, Immunology and Transplantation Research | Consortium of Eosinophilic Gas | | Ann & Robert H Lurie Children's Hosp Arkansas Children's Hospital | | U54Al117804 | 93.855 | 64,218 26.705 | 804,751 | 1,517,848 |
| | | | | Baylor College of Medicine. | | | | 26,705 19.980 | - | |
| | | | | Children's Hospital of Philadelphia | | | | 65,867 | - | |
| | | | | Indiana University | | | | 89,304 | - | |
| | | | | Mount Sinai School of Medicine Northwestern University | | | | 23,433 80.074 | - | |
| | | | | Tufts Medical Center, Inc | | | | 4,145 | - | |
| | | | | Univ of Pennsylvania | | | | 72,634 | - | |
| | | | | University of CA | | | | 28,521 | - | |
| | | | | University of Colorado University of North Carolina-Chapel Hill | | | | 103,726 56,335 | - | |
| | | | | University of Utah | | | | 64,168 | - | |
| | | | | Vanderbilt University Medical Center | | | | 13,987 | - | |
| NIH | Allergy, Immunology and Transplantation Research | COVID-19 Consortium of Eosinophilic Gas | | University of Colorado | | COVID-19 U54AI117804-06S1 | 93.855 | 55,934 | 34,862 | 90,796 |

| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Cincinnati Cooperative Center | 1.1 | | 000 40 405 75 | U54DK126108 | 93.847 | - | 610,162 | 610,162 |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------------------|----------------|--------------------|--------------------|----------------|
| NIH | Discovery & Applied Research for Tech Innovations to Improve Human Health | Center for Point-of-Care Techn | Johns Hopkins University | | 2004018575 | U54EB007958 | 93.286 | - | 170,131 | 170,131 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Rett Syndrome, MECP2 Duplication, | International Rett Syndrome Foundation | | U54HD061222 | U54HD061222 | 93.853 | | 16,507 | 16,507 |
| NIH | Child Health and Human Development Extramural Research | Translational medicine and mec | | Univ of Oklahoma Health Sciences Univ of Texas Southwestern | | U54HD104461 | 93.865 | 11,285 413,771 | 736,052 | 1,398,260 |
| | | | | Univ or Texas Sournwestern University of California, Riverside | | | | 115,262 | - | |
| | | | | University of California, Riverside University of Cincinnati | | | | 115,262 | - | |
| NIH | 54 | Brain Vascular Malformation Co | HOOF II | University of Circumati | 11552sc | U54NS065705 | 93.853 | 121,090 | 240 | 240 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders Extramural Res Programs in the Neurosciences & Neurological Disorders | Brain Vascular Malformation Co Developmental Synaptopathies A | UCSF Human Research Program Children's Hospital Boston | | | U54NS065705 U54NS092090 | 93.853 | - | 240 119,667 | 240 119,667 |
| NIH | | | Children's Hospital Boston | | 81199.CCHMC.01.PTE | | 93.853 | - | 57.416 | 57,416 |
| NIH | Extramural Res Programs in the Neurosciences & Neurological Disorders | Developmental Synaptopathies A Norris PHI-COG NCORP PCR Work | Public Health Institute | | 81199.CCHMC.01.P1E | UG4NS092090 UG1CA189955 | 93.853 | - | 7,416 | 7,416 |
| NIH | Drug Abuse and Addiction Research Programs | Ohio Valley Node-Network (OVNN | University of Cincinnati | | 013764-00024 | UG1DA013732 | 93.279 | - | 59,036 | 59,036 |
| NIH | Vision Research | Adalimumab in Juvenile Idiopat | The Univ of California, San Francisco | | 11309sc_FEX | UG1DAD13732 UG1EY029658 | 93.279 | - | 59,036 | 5,556 |
| NIH | Vision Research Child Health and Human Development Extramural Research | NICHD Cooperative Multicenter Neonatal | The Univ of California, San Francisco | | 11309SC_FEX | UG1EY029658 UG1HD027853 | 93.865 | - | 264,954 | 264,954 |
| NIH | Cardiovascular Diseases Research | Pediatric Heart Network Prairieland Cons | New England Research Institutes | Indiana University | U24HL135691 | UG1HL135678 | 93.805 | 132.307 | 264,954 | 376.847 |
| NIH | Oral Diseases and Disorders Research | Reduction of bloodstream infec | New England Research manues | Indiana Oniversity | U24FL 133091 | UG3DE030401 | 93.037 | 132,307 | 243,015 | 243,015 |
| NIH | Lung Diseases Research | Hydrocortisone for BPD Respira | Children's Hospital of Philadelphia | | 3200930822 | UG3HL137872 | 93.838 | - | 50.728 | 50.728 |
| NIH | Lung Diseases Research | AZinthromycin Therapy in Presc | University of Arizona | | AZ-SWED | UG3HL137672 UG3HL147016 | 93.838 | - | 19.132 | 19,132 |
| NIH | Cardiovascular Diseases Research | Multicenter Clinical Trial of | University of Maryland (Baltimore) | | 901632-CCHMC | UG3HL148318 | 93.837 | | 15 021 | 15,021 |
| NIH | Trans-NIH Research Support | NYU Pediatric Obesity, Metabolism | NYU Sponsored Programs Administratio | | UG30D023305 | UG30D023305 | 93.310 | | 40.357 | 40,357 |
| NIH | Allergy, Immunology and Transplantation Research | Extension of clinical data str | NTO Oponisoreu Flogranis Auministratio | | 00300023300 | UH2Al145837 | 93.855 | - | 224,586 | 224,586 |
| NIH | Disheter Diseasing and Mideau Diseases Entremond December | Modeling diabetes using an int | | Cleveland State University | | UH3DK119982 | 93.847 | 291,553 | 1,021,462 | 1,497,667 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Modeling diabetes using an Int | | University of Illinois at Chicago | | UH3DK119982 | 93.847 | 291,553 184.652 | 1,021,462 | 1,497,567 |
| NIH | Trans-NIH Research Support | | Massachusetts General Hospital | University of fillinois at Cricago | 233284 | UH3OD023253 | 93.310 | 104,032 | 255 | 255 |
| NIH | Trans-NiH Research Support Trans-NiH Research Support | Airway microbiome and age 6y a Children's Respiratory Research | University of Wisconsin-Madison | | 233284 UG30D023282 | UH3OD023282 | 93.310 | - | 1 050 410 | 1,050,410 |
| NIH | Trans-NIH Research Support | Developmental Impact of NICU E | Albert Einstein College of Medicine | | 312044 | UH3OD023320 | 93.310 | - | 204.462 | 204.462 |
| NIH | ** | Preclinical characterization o | Albert Einstein College of Medicine | Cedars-Sinai Medical Center | 312044 | UH3TR002612 | 93.310 | 1,366 | 120 786 | 122 152 |
| NIH | National Center for Advancing Translational Sciences National Center for Advancing Translational Sciences | Center for Clinical and Transl | University of Cincinnati | Cedars-Sinai Medical Center | 012847-00008 | UL1TR001425 | 93.350 | 1,300 | 2,362,381 | 2,362,381 |
| NIH | Allergy, Immunology and Transplantation Research | Inner City Asthma Consortium 3 | University of Wisconsin-Madison | | 839K182 | UM1AI114271 | 93.855 | _ | 98 634 | 98,634 |
| NIH | Allergy, Immunology and Transplantation Research | Inner City Asthma Consortium (| Univ of Wisconsin | | 0000000189 | UM1Al114271 | 93.855 | _ | 11,759 | 11,759 |
| NIH | Allergy, Immunology and Transplantation Research | Vaccine and Treatment Evaluati | Only of Waconsti | Nationwide Childrens Hospital | 000000109 | UM1AI148372 | 93.855 | 18,212 | 676.520 | 694 732 |
| NIH | Allergy, Immunology and Transplantation Research | COVID-19 A Phase III Randomized, Double | | Traditional Conditions (Conditional Conditional Condit | | COVID-19 UM1AI148372-01S1 | 93.855 | 10,212 | 2.188.831 | 2,188,831 |
| NIH | Allergy, Immunology and Transplantation Research | COVID-19 A Phase III Randomized, Double | | | | COVID-19 UM1AI148372-02S2/03S2 | | _ | 681.012 | 681,012 |
| NIH | Allergy, Immunology and Transplantation Research | COVID-19 A Phase III Randomized, Double | | | | COVID-19 UM1AI148372-02S3/03S3 | | - | 618.221 | 618.221 |
| NIH | Allergy, Immunology and Transplantation Research | COVID-19 Phase 1, Open-Label, Randomize | | | | COVID-19 UM1AI148372-03S1 | 93.855 | _ | 345 745 | 345,745 |
| NIH | Allergy, Immunology and Transplantation Research | COVID-19 Phase 1, Open-Label, Randomize | | | | COVID-19 UM1AI148372-03S4/02S4 | 93.855 | - | 277.305 | 277.305 |
| NIH | Allergy, Immunology and Transplantation Research | Infectious Diseases Clinical R | Emory University | | A414395 | UM1AI148684 | 93.855 | - | 87,016 | 87,016 |
| NIH | Allergy, Immunology and Transplantation Research | Childhood Asthma in Urban Sett | Univ of Wisconsin | | 0000001464 | UM1AI160040 | 93.855 | _ | 431.468 | 431,468 |
| NIH | Cancer Treatment Research | The Pediatric Brain Tumor Cons | St Jude's Children's Hospital | | 110068220-7998047 | UM1CA081457 | 93.395 | - | 116.777 | 116,777 |
| NIH | Cancer Treatment Research | PEP-CTN institutional support | Children's Hospital of Philadelphia | | sub2401 | UM1CA228823 | 93.395 | - | 37,795 | 37,795 |
| NIH | Cancer Treatment Research | Norris PHI-COG PEP-CTN WLI Cor | Public Health Institute | | AR06748 | UM1CA228823 | 93.395 | - | 16,120 | 16,120 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Teen Longitudinal Assessment of Bariatric | University of Colorado | | FY 18.896.002 | UM1DK072493 | 93.847 | - | 76,088 | 76,088 |
| NIH | Diabetes, Digestive, and Kidney Diseases Extramural Research | Teen Longitudinal Assessment of Bariatric | University of Cincinnati | | 010577-009 | UM1DK095710 | 93.847 | - | 384,790 | 384,790 |
| NIH | Allergy, Immunology and Transplantation Research | New Horizons in the Prevention | Johns Hopkins University | University of Cincinnati | 2004813187 | UM2AI130836 | 93.855 | 134,403 | 527,060 | 661,463 |
| SAMHSA | A Substance Abuse & Mental Health Svcs Projects of Reg & Nat Significance | Implementation of Screening, B | | University of Cincinnati | | H79TI084035 | 93.243 | 17,861 | 474,882 | 492,743 |
| NIH | , , , , , , , , , , , , , , , , , , , , | Mouse and Guinea Pig Models for Cylome | | Pennington Biomedical Res Center | | HHSN272201700017I | 93.RD | 114,178 | 622,726 | 736,904 |
| NIH | | Vaccine and Treatment Eval VTEU | | | | HHSN272201300016I | 93.RD | - | 58,218 | 58,218 |
| NIH | | Vaccine and Treat Eval Units (VTEU) | | | | HHSN272201300016I | 93.RD | _ | 127,788 | 127,788 |
| NIH | | Vaccine and Treat Eval Units (VTEU) | | | | HHSN272201300016I | 93.RD | _ | 19,089 | 19,089 |
| NIH | | Vaccine and Treat Eval Units (VTEU) | | | | HHSN272201300016I | 93.RD | _ | 908.181 | 908.181 |
| NIH | | CISA Clinical Vaccine Safety Eval - | | | | 200-2012-53661 | 93.RD | _ | 181.524 | 181.524 |
| NIH | | Apnea in Hospitalized Preterm Infants | | Emory University | | 200-2012-53661 | 93.RD | 26,637 | 87,407 | 114,044 |
| NIH | | A Multicenter Prospective Study of Human | Children's Hospital of Philadelphia | Emory onliverous | HHSN272201600014C | HHSN272201600014C | 93.RD | 20,037 | 69,548 | 69,548 |
| NIH | | A Phase II Multi-Center, Prospective, Ran | Northwestern University Medical School | | | HHSN272201600014C | 93.RD 93.RD | - | 247 217 | 247,217 |
| NIH | | Safety of Recombinant Influenz | NOTHINGSTERN ORINGISHY MEDICAL SCHOOL | University of Cincinnati | 11113NZ7ZZU1000U16U | 200-2012-53661-0010 | 93.RD 93.RD | 1,833 | 247,217 126,141 | 127,974 |
| NIH | | Vaccine and Treatment Evaluati | | Oniversity of Officialitati. | | 200-2012-63661-0010 HHSN272201300016I | 93.RD 93.RD | 1,033 | 120,141 | 127,974 |
| | | | | | | | | - | , | |
| NIH | | RTOP FY2020 A1B1C1D10123-HHSN2 | | | | HHSN272201300016I | 93.RD 93.RD | - | 274,971 | 274,971 |
| NIH | | A Prospective Observational St | | | | 200-2012-53661 | | - | 235,898 | 235,898 |
| NIH | | Safety of Simultaneous versus | | | | 200-2012-53661 | 93.RD | - | 164,982 | 164,982 |
| | | | | | | Dept of Health and Human | Sony Total | 19,307,213 | 177,315,653 | 196,622,866 |
| | | | | | | Dept of nearth and Human | Serv IUMI | 19,307,213 | 111,310003 | 130,022,066 |
| HUD | Healthy Homes Technical Studies Grants | Role of measured and observed | Heisensite of Cineirosti | | 011199 | OHHHU0037-17 | 14.906 | | 3.309 | 3,309 |
| HUD | Lead Technical Studies Grants | Analysis of Benefits of Abatem | University of Cincinnati National Center for Healthy Housing, Inc. | | MDLTS000818 HUD | | 14.906 | - | 3,309 | 21.022 |
| HUD | Lead rediffical Studies Statis | Analysis of Delibilits of Ababili | reasonal Celler for nealing nousing, inc | | MPETOUDOTO HUD | Dept of Housing and Urb | | | 21,022 | 21,022 |
| | | | | | | Dept of nousing and Ort | ALL DEV TOTAL | - | 24,331 | 24,331 |

Dept of Housing and Urban Dev

| Office of Personnel Management | OPM OPM OPM OPM OPM OPM | Intergovemmental Personnel Act (IPA) Mobility Program | Role of a common leptin recept IPA Cheplety for Kaufman VA Me Mechanisms of liver failure VAIIPA - Mechanisms of liver f Richards VA Merit Kaufman Mechanisms of liver f Tripathi VA Merit Kaufman Tripathi VA Merit Kaufman | |
|--------------------------------|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| | CMS | Medical Assistance Program | Pediatric Behavioral Health Cl | Ohio State University |
| Department of Transportation | NHTSA | National Priority Safety Programs | Occupant Protection Regional C | Ohio Department of Health (ODH |
| | CMS | Accountable Health Communities | Greater Cincinnati Accountable Health | The Health Collaborative |
| Dept of Health and Human Serv | CDC | Public Health Emergency Preparedness | Poison Center Bioterrorism Pre | Nationwide Children's Hospital |
| Dept of Health and Human Serv | CDC | Environmental Public Health and Emergency Response | Center for Disease Control and | Ohio Department of Health (ODH) |
| Dept of Health and Human Serv | CDC | Strengthening Public Health Systems and Services through National Partnershi | COVID-19 The Task Force for Global Heal | The Task Force for Global Health, Inc |
| Dept of Health and Human Serv | CDC | Strengthening Public Health Systems and Services through National Partnershi | COVID-19 Support for Early Childhood St COVID19 | Assoc of Univ Center on Disabilities |
| Dept of Health and Human Serv | CDC | Strengthening Public Health Systems and Services through National Partnershi | COVID-19 Addressing COVID-19 vaccine ac | Assoc of Univ Center on Disabilities |
| Dept of Health and Human Serv | CDC | Strengthening Public Health Systems and Services through National Partnershi | COVID-19 Enhance Support for Early Chil COVID19 | Assoc of Univ Center on Disabilities |
| Dept of Health and Human Serv | CDC | Preventive Health and Health Services Block Grant | Child Injury Prevention Grant COVID-19 Provider Relief Fund and American Rescue | Stark County Combined General Health |
| Dept of Health and Human Serv | HRSA | Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution | Plan (ARP) Rural Distribution | |
| Dept of Health and Human Serv | SAMHSA | | Opioid Response Grants | |
| Dept of Health and Human Serv | HRSA | Block Grants for Prevention and Treatment of Substance Abuse | Substance Abuse Prevention and Treatment | |

| | IPA -Filippi | 27.011 | - | 8,529 | 8,529 |
|-------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|---------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| | IPA-Chepelev | 27.011 | - | 4,762 | 4,76 |
| | IPA-Kapil | 27.011 | - | 73,903 | 73,903 |
| | IPA-Polaki | 27.011 | - | 63,543 | 63,54 |
| | IPA-Richards | 27.011 | - | 61,418 | 61,41 |
| | IPA-Sharma | 27.011 | - | 64,028 | 64,02 |
| | IPA-Tripathi | 27.011 | - | 73,108 | 73,10 |
| | Office of Personnel Man | agement Total | - | 349,291 | 349,29 |
| | Research and Develo | pment Tota | 19,444,397 | 181,977,806 | 201,422,203 |
| 2205OH5ADM | G-2223-05-0063 ODM202211 | 93.778 | - | 33,195 | 33,195 |
| Medical Assista | ance Program/Medicaid Clu | ster Total | - | 33,195 | 33,195 |
| | | | | | |
| 03130014BB0118 | | 20.616 | - | 58,300 | 58,300 |
| 03130014BB0118 | Highway Safety Clu | | - | 58,300 58,300 | |
| | | | - | | 58,300 |
| 1P1CMS331598-01-00 | | ster Total | <u>-</u> - - | 58,300 | 58,300 |
| 1P1CMS331598-01-00 720441-0620-00 | 1P1CMS331598 | 93.650 | - - - - | 58,300 45,788 | 58,300 45,788 |
| 1P1CMS331598-01-00 720441-0620-00 Contract No. 47013 | 1P1CMS331598 ODH Prime Contract 34225 | 93.650 93.069 | - - - - | 58,300 45,788 99,459 | 58,30 0 45,78 99,45 20,14 |
| 1P1CMS331598-01-00 720441-0620-00 Contract No. 47013 Fask Force (COVID-19 | 1P1CMS331598 ODH Prime Contract 34225 NUE1EH001385 | 93.650 93.069 93.070 | - - - - - | 58,300 45,788 99,459 20,145 | 58,300 45,78 99,45 20,14 16,67 |
| 1P1CMS331598-01-00 720441-0620-00 Contract No. 47013 Fask Force (COVID-19 07-128-4913 | 1P1CMS331598 ODH Prime Contract 34225 NUE1EH001385 COVID-19 NU380T000316 | 93.650 93.069 93.070 93.421 | - - - - - - | 58,300 45,788 99,459 20,145 16,671 | 58,300 45,788 99,456 20,148 16,67' 52,352 |
| 1P1CMS331598-01-00 720441-0620-00 Contract No. 47013 Task Force (COVID-19 07-128-4913 05-21-8815 | 1P1CMS331598 ODH Prime Contract 34225 NUE1EH001385 COVID-19 NU38OT000280-02-02 | 93.650 93.069 93.070 93.421 93.421 | - - - - - - - | 58,300 45,788 99,459 20,145 16,671 52,352 | 58,300 45,788 99,456 20,148 16,67 52,352 18,038 |
| IP1CMS331598-01-00 720441-0620-00 Contract No. 47013 Fask Force (COVID-19 07-128-4913 15-21-8815 29-8814-22 | 1P1CMS331598 ODH Prime Contract 34225 NUE1EH001385 COVID-19 NU3807000280-02-02 COVID-19 NU3807000280-03-05 | 93.650 93.069 93.070 93.421 93.421 93.421 | | 58,300 45,788 99,459 20,145 16,671 52,352 18,035 | 58,300 45,781 99,451 16,67' 52,35; 18,033 46,49; |
| 1P1CMS331598-01-00 720441-0620-00 Contract No. 47013 Task Force (COVID-19 07-128-4913 05-21-8815 29-8814-22 | 1P1CMS331598 ODH Prime Contract 34225 NUE1EP001385 COVID-19 NU380T000280-02-02 COVID-19 NU380T000280-03-05 COVID-19 NU380T000280-04-02 | 93.650 93.069 93.070 93.421 93.421 93.421 93.421 | | 58,300 45,788 99,459 20,145 16,671 52,352 18,035 46,493 | 58,300 45,781 99,455 20,144 16,67 52,35; 18,031 46,491 8,000 |
| 1P1CMS331598-01-00 720441-0620-00 Contract No. 47013 | 1PICMS331598 ODH Prime Contract 34225 NULE1EH001385 COVID-19 NUJ807T00316 COVID-19 NUJ807T00036-02-02 COVID-19 NUJ807T000280-02-02 COVID-19 NUJ807T000280-03-05 COVID-19 NUJ807T000280-03-06 COVID-19 NUJ807T000280-04-02 07610014I(0321 | 93.650 93.069 93.070 93.421 93.421 93.421 93.421 93.421 93.991 | | 58,300 45,788 99,459 20,145 16,671 52,352 18,035 46,493 8,000 | 58,300 58,300 45,788 99,458 20,146 16,671 52,352 18,035 46,493 8,000 50,000,000 |

Grand Total \$ 19,444,397 \$ 232,805,980 \$ 252,250,377

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2022

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation — The accompanying Supplemental Schedule of Expenditures of Federal Awards (the "Schedule") includes the federal grant activity of Cincinnati Children's under programs of the federal government for the year ended June 30, 2022 and is presented on the accrual basis of accounting. This is consistent with the basis of accounting used in the preparation of the basic consolidated financial statements. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Guidance*. Because the Schedule presents only a selected portion of the operations of Cincinnati Children's, it is not intended to and does not present the financial position, changes in net assets or cash flows of Cincinnati Children's.

Net Asset Balances — Negative amounts represent grants with deficit balances which were closed during fiscal 2022.

2. DE MINIMIS COST RATE

Cincinnati Children's did not elect to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

3. SCOPE OF AUDIT

All federal grant operations of Cincinnati Children's are included in the scope of Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance)*. Single audits under the Uniform Guidance are performed in accordance with the provisions of the Office of Management and Budget (OMB)'s Compliance Supplement for Single Audits of Higher Learning Institutions and other Non-Profit Institutions (the "Compliance Supplement"). The Department of Health and Human Services has been designated as Cincinnati Children's cognizant agency for the Single audit.

4. PROVIDER RELIEF FUND TAX IDENTIFCATION NUMBER

Cincinnati Children's received COVID-19 Provider Relief funds under the 31-0833936 tax identification number only.

Deloitte.

Deloitte & Touche LLP

50 W 5th Street Suite 200 Cincinnati, OH 45202-3789

Tel: +513 784 7100 Fax: +513 784 7204 www.deloitte.com

REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

INDEPENDENT AUDITOR'S REPORT

To the Board of Trustees of Children's Hospital Medical Center and Affiliates Cincinnati, Ohio

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Children's Hospital Medical Center and Affiliates (the "Company"), which comprise the Company's consolidated statement of financial position as of June 30, 2022, and the related consolidated statements of activities, and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated September 30, 2022.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Company's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we do not express an opinion on the effectiveness of the Company's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Company's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

September 30, 2022

Deloitte > Touche LLP



Deloitte & Touche LLP

50 W 5th Street Suite 200 Cincinnati, OH 45202-3789 USA

Tel: +513 784 7100 Fax: +513 784 7204 www.deloitte.com

REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE

INDEPENDENT AUDITOR'S REPORT

To the Board of Trustees Children's Hospital Medical Center and Affiliates Cincinnati, Ohio

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Children's Hospital Medical Center and Affiliates (the "Company's") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Company's major federal programs for the year ended June 30, 2022. The Company's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Company complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2022.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Company's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Company's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Company's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Company's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, Government Auditing Standards, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Company's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Company's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not

identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of the Company as of and for the year ended June 30, 2022, and have issued our report thereon dated September 30, 2022, which contained an unmodified opinion on those financial statements. Our audit was performed for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the financial statements as a whole.

Deloitte ? Touche LIP

November 1, 2022

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED JUNE 30, 2022

PART I. SUMMARY OF AUDITOR'S RESULTS

| Financial Statements: | | | |
|--------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------|--------------------|
| Type of auditor's report issued | : | Unmodified | |
| Internal control over financial i | reporting: | | |
| Material weakness(es) identif | ied? | Yes | XNo |
| Significant deficiency(ies) ide | entified? | Yes | None X reported |
| Noncompliance material to fina | ancial statements noted? | Yes | XNo |
| Federal Awards: | | | |
| Internal control over major pro | grams: | | |
| Material weakness(es) identif | ied? | Yes | <u>X</u> No |
| Significant deficiency(ies) ide | entified? | | 2.7 |
| | | Yes | None X reported |
| Type of auditor's report issued programs: | on compliance for major | Unmodified | |
| Any audit findings disclosed thaccordance with 2 CFR 200.516 | nat are required to be reported in (a)? | Yes | XNo |
| Identification of Major Program | ns: | | |
| ALN Number | Name of Fede | eral Program or Cluster | |
| Various | Research and Development* | | |
| 93.498 | COVID-19-Provider Relief Fund | 1 | |
| 73.170 | And American Rescue Plan | | |
| | (ARP) Rural Distribution | | |
| | as determined that its entire research a ent grant activity should be considered | | |
| | stinguish between Type A and Type B program tested as a single Type A pro | | \$ 3,000,000 |
| Auditee qualified as low-risk | c auditee? | X Yes | No |

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED JUNE 30, 2022

PART II. FINDINGS RELATED TO THE FINANCIAL STATEMENTS

None

PART III. FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

None